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ABSTRACT

Coronaviruses (CoV) are well known human pathogens. Severe Acute
Respiratory Syndrome coronavirus (SARS-CoV) and Middle Ease Respiratory Syndrome
coronavirus (MERS-CoV) pose a severe threat to humans because of high mortality.
Despite the risk of coronavirus emerging in the human population there are no antiviral
drugs or vaccines to combat coronavirus infection. The focus of my dissertation was to
study the multifunctionality of papain-like proteases (PLPs) encoded within coronavirus
genomes to facilitate the development of antiviral drugs and vaccines. The viral PLPs are
critical for processing the amino-terminal end of the replicase during virus replication and
are attractive targets for antiviral therapies. In my research, I analyzed the activities of
PLPs from multiple coronaviruses to determine if those proteases can be targets for broad
spectrum therapeutics.
I determined that SARS-CoV PLpro is an effective target of small molecule
inhibitors by evaluating their efficacy and ability to inhibit SARS-CoV replication in cell
culture. Further, I determined that the predicted PLpro domain from MERS-CoV is a
multifunctional enzyme with protease, deubiquitinase, interferon antagonism and
deISGylating activities. Despite low sequence identity, this multifunctionality of PLPs
seems to be conserved among many coronaviruses since I demonstrated protease and

xv

deubiquitinase activity of PLP2s from HCoV-OC43, HCoV-229E, HCoV-HKU1, and
FIPV.
To evaluate the role of PLP during virus replication and pathogenesis I utilized a
mouse model system mouse hepatitis virus (MHV). I determined that similar to other
PLPs, MHV PLP2 is a multifunctional enzyme. Further, I used two approaches to
investigate the role of the PLP in virus pathogenesis. First, I performed deletion analysis
and mutagenesis of the ubiquitin-like (UBL) domain of the PLP2 and showed, for the
first time, that the UBL domain is important for PLP2 stability and virus pathogenesis.
The UBL mutant virus is attenuated in mice and protects the mice from the disease upon
challenge with wild-type virus suggesting that this virus is a vaccine candidate. Secondly,
based on the MHV PLP2 crystal structure and modeling of the PLP2 with an ubiquitin
moiety, I identified residues on PLP2 that likely interact with ubiquitin. I tested multiple
mutants of predicted PLP2-ubiquitin interaction sites and found several residues that are
important for both protease and deubiquitinase function. Taken together my data suggest
that PLP multifunctionality is conserved among coronaviruses and that it is a valuable
target for vaccines and antiviral drugs development for existing and emerging
coronaviruses.

xvi

CHAPTER I
INTRODUCTION

CORONAVIRUSES IN HUMAN DISEASE
Coronaviruses are positive sense RNA viruses that infect humans and other
animals. Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East
Respiratory Syndrome coronavirus (MERS-CoV) pose a severe threat to humans because
of high mortality (Peiris, Guan, & Yuen, 2004; Zaki, van Boheemen, Bestebroer,
Osterhaus, & Fouchier, 2012). As of April 14, 2014, there have been 228 confirmed
cases and 92 deaths of MERS (http://www.who.int/2014_03_20_mers/en/). MERS
disease is characterized primarily by respiratory symptoms but several patients also
developed renal failure (Drosten et al., 2013; Zaki et al., 2012). In most cases reported
thus far, immunosuppression or other types of medical disorders have been associated
with more severe disease (Assiri et al., 2013). The sequence of the RNA genome of
MERS-CoV is most similar to bat coronaviruses HKU4 and HKU5 (van Boheemen et al.,
2012); however, the origin of MERS-CoV is not known. A recent report showed that
dromedary camels have high levels of neutralizing serum antibodies against MERS-CoV,
suggesting a possible zoonotic source (Alagaili et al., 2014; Reusken et al., 2013).
Moreover, MERS-CoV sequences with 99% nucleotide similarity to human MERS-CoV
have been detected in dromedary camels (Chu et al., 2014). Further analysis of the
1
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polymorphism signatures of virus sequences from infected camels suggested crossspecies transmission of MERS-CoV (Memmish et al., 2014). In addition, analysis of fecal
samples from bats identified the Egyptian tomb bat as a potential source of infection
(Memish et al., 2013), but more work is needed to identify the animal reservoir(s) for
MERS-CoV. Limited human-to-human transmission of MERS-CoV has been reported,
which considering the high mortality, raises a concern that the virus has a potential to
become a threat to public health similar to SARS-CoV (Assiri et al., 2013; Guery et al.,
2013). The SARS-CoV pandemic from 2002-2003 with 10% mortality rate (Drosten,
Preiser, Gunther, Schmitz, & Doerr, 2003; Drosten, Gunther, et al., 2003; Peiris et al.,
2003), was controlled by public health measures of identification and isolation of
infected, symptomatic individuals and their contacts which broke the chain of human-tohuman transmission (Zhong, 2004). A SARS-CoV-like virus is endemic in Chinese
horseshoe bats, but changes in the sequence of the spike glycoprotein are required for this
virus to efficiently infect humans (Lau et al., 2005; Rockx et al., 2007). For MERS-CoV,
it is unclear if the virus can jump directly from bats to humans, if there are any mutations
in the viral genome that facilitate infection or disease in humans, and if there are both
symptomatic and asymptomatic cases, which would make any potential epidemic more
difficult to control by public health measures alone.
Additional endemic human coronaviruses that cause respiratory tract disease
include: HCoV-229E and HCoV-OC43, which cause common colds; HCoV-NL63,
which has been associated with croup in children; and HCoV-HKU1, associated with
lower respiratory tract infection and pneumonia in the elderly. Coronaviruses are also
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important pathogens of livestock and pets including transmissible gastroenteritis virus
(TGEV) (pigs), porcine epidemic diarrhea virus (PEDV) (pigs); Feline Infectious
Peritonitis Virus (FIPV) feline coronavirus (cats); bovine coronavirus (cows); infectious
bronchitis virus (chickens); and canine coronavirus (dogs). Interestingly, we now
recognize that bats harbor diverse strains of coronaviruses, and these bat viruses may be
the ancestors of the “species-specific” viruses (Lau et al., 2013). The identification of a
common therapeutic target in the genomes of coronaviruses may allow for the
development of a broad spectrum antiviral therapy to combat existing and potentially
emerging coronaviruses.
Despite the threat of coronaviruses emerging in the human population and the fact
that coronavirus infections in domestic animals lead to significant economic losses, there
are no FDA approved antiviral drugs or vaccines to combat coronavirus infection.
Coronaviruses, similar to other viruses, have evolved multiple ways to delay and evade
the induction of protective immune responses in the host upon infection. By
understanding the mechanisms by which coronaviruses antagonize the innate immune
response, we might be able to rationally design specific antiviral therapeutics.

CORONAVIRUSES STRUCTURE AND REPLICATION
Coronaviruses are enveloped, positive strand RNA viruses belonging to the order
Nidovirales (De Groot et al., 2012). The viral particle is about 120-160 nm in diameter.
The spike glycoproteins project out from the virus surface which looks like the crown

4

Figure 1. MHV life cycle. Upon entry virus RNA is translated into polyprotein. Viral
replicase is processed and produced proteins assemble on double membrane vesicles
which are required for the replication of viral RNA and production of the nested set of
subgenomic RNA. Upon translation of structural genes the virions bud from the ER and
through the Trans Golgi network translocate to the plasma membrane where the progeny
virus is released.

5

surrounding the viral particle (corona is a Latin for crown). Coronaviruses are the biggest
RNA viruses genome wise ranging in size from 28 to 32 kilobases. Coronaviruses enter
the host cell via interaction of the spike glycoprotein and cell surface receptor. All
coronaviruses replicate in the cytoplasm of infected cells through the action of the viral
replicase complex. The coronavirus replicase is produced upon translation of the
incoming RNA genome. The genomic RNA has a 5’-methyl cap and polyadenylated tail
that resembles cellular mRNA and can be directly translated by cellular translation
machinery in the cytoplasm. Two thirds of the genome encodes replicase and the rest of
the genome encodes structural and accessory genes. The replicase gene contains two
open reading frames, ORF1a and ORF1b, which are connected by a frame shift region
allowing for translation of the ORF1ab polyprotein. The replicase polyproteins,
designated pp1a and pp1ab, are processed into non-structural proteins (nsps) by two or
three, depending on the coronavirus, viral proteases. The papain-like proteases (PLPs)
are responsible for the cleavage of the amino-terminal portion of the polyprotein and 3Clike proteinase (3CLpro or Mpro) are required for polyprotein processing and virus
replication. The detailed description of PLPs activity is presented in sections below.
Proteolytic processing allows for the generation of 16 non-structural proteins that
assemble on cellular membranes forming double membrane vesicles (DMVs) (Gosert,
Kanjanahaluethai, Egger, Bienz, & Baker, 2002; Knoops et al., 2008). The DMVs are
derived from cellular membranes and are the sites of viral RNA synthesis. Replication
and “hiding” from cellular Pattern Recognition Receptors on DMVs is one of the
hypotheses for the lack of induction of interferon response early during virus replication.

6

The replication cycle is completed upon translation of the structural genes when the viral
particles assemble and bud from the endoplasmic reticulum. Following, viral particles
traffic via Trans Golgi network to the plasma membrane, where the progeny virus is
released (Figure 1) (Masters, 2006).

MULTIFUNCTIONAL CORONAVIRUS PAPAIN-LIKE PROTEASES
Packing a lot of information into a small space is a challenge for all microbes and
analysis of viral genomes reveals interesting strategies of genetic economy. Positive
strand RNA viruses employ genetic economy by encoding polyproteins that are
processed by viral proteases during replication. This strategy minimizes genome size by
allowing for the expression of multiple protein products from a single open reading
frame. An additional twist to this genetic economy is that the viral protease itself may be
multifunctional, i.e. the protease may act on both viral and host cell proteins. Hepatitis C
virus encodes a polyprotein that is processed by the viral protease, NS3/4a, that also
cleaves host cell mitochondrial associated viral sensor (MAVS), thus inactivating the
innate immune response to viral infection (Li, Sun, Seth, Pineda, & Chen, 2005).
Poliovirus 2A protease processes the viral polyprotein and host cell factor eIF4G, which
shifts the ribosomes from cap-dependent to cap-independent translation, whereas 3C
protease cleaves poly(A)-binding protein to facilitate the complete host translation
shutoff (Gradi, Svitkin, Imataka, & Sonenberg, 1998; Kuyumcu-Martinez, Van Eden,
Younan, & Lloyd, 2004). In the section below, I will discuss coronaviruses and
arteriviruses, two families of positive strand RNA viruses in the order Nidovirales, and
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review recent findings illuminating the multifunctionality of the papain-like proteases
(PLPs) encoded in the replicase polyproteins. For these viruses, PLPs play a critical role
in processing the amino-terminal portion of the replicase polyprotein and are attractive
targets for antiviral drug development. In addition, structural studies have revealed a
striking similarity of the viral PLPs to cellular deubiquitinating enzymes (DUBs), which
are involved in the regulation of the innate immune response to viral infection. This
raises the question of the multifunctional potential of Nidovirus PLPs and their role in
antagonism of the innate immune response to viral replication (summarized in Table 1).

CORONAVIRUS PAPAIN-LIKE PROTEASES AND THEIR ROLE IN VIRUS
REPLICATION
The PLPs are responsible for the cleavage of the amino-terminal portion of the
polyprotein during coronavirus replication. Coronavirus PLP activity was identified by in
vitro transcription/translation studies of genomic RNA and the recognition that the
polyprotein product was processed by an encoded protease domain (Denison & Perlman,
1986). Site-directed mutagenesis and deletion studies revealed that, for the model
coronavirus mouse hepatitis virus (MHV), there are two PLP domains with PLP1
processing the polyprotein between nsp1/nsp2 and nsp2/nsp3 (Baker et al., 1989, 1993;
Denison et al., 1992; Teng, Piñón, & Weiss, 1999). Further expression studies of MHV
ORF1a revealed that the PLP2 domain processes the polyprotein at the nsp3/nsp4 site
using a recognition site of LXGG (Kanjanahaluethai & Baker, 2000). Similar studies of
other coronaviruses revealed the existence of either one or two PLP domains that were

8

Table 1. Coronavirus and Arterivirus papain-like proteases characteristics. Table
published in Mielech, Chen, Mesecar, & Baker, 2014.

9

required for processing the amino-terminal region of the replicase polyprotein (Figure 2).
SARS-CoV encodes only one PLP domain termed PLpro within nsp3 which cleaves the
replicase polyprotein at the junctions between nsp1/nsp2, nsp2/nsp3, and nsp3/nsp4
through recognition of a LXGG motif (Harcourt et al., 2004). For the recently emerged
MERS-CoV the cleavage sites recognized by the PLpro are predicted and await
experimental validation (van Boheemen et al., 2012). However, Kilianski and coworkers showed that MERS-CoV PLpro can recognize a LXGG motif similarly to
SARS-CoV PLpro (Kilianski, Mielech, Deng, & Baker, 2013). It has been shown that
when two PLP domains are encoded within the coronavirus replicase polyprotein, the
PLP2 has similar characteristics to SARS-CoV PLpro and recognizes the LXGG motif
(Figure 2). Coronavirus PLP2 domains are known to or predicted to cleave between nsp3
and nsp4, whereas the cleavage between nsp1/nsp2 and nsp2/nsp3 is usually mediated by
the PLP1 domain. Interestingly, gamma- and deltacoronaviruses encode one PLpro
domain within nsp2 that is predicted to cleave between nsp1/nsp2 and nsp2/nsp3.

FROM VIRAL PROTEASE TO VIRAL DEUBIQUITINASE
The multifunctionality of coronavirus PLPs was first proposed by Sulea and coworkers from their study of molecular modeling of the SARS-CoV PLpro domain (Sulea,
Lindner, Purisima, & Menard, 2005). In their study, the authors predicted PLpro
deubiquitinating (DUB) activity based on the observations that PLpro could be modeled
onto the structure of the herpesvirus-associated ubiquitin-specific protease
(HAUSP/USP18), which was a known cellular DUB.

10

Figure 2. Coronavirus and Arterivirus Papain-like Proteases. Schematic depiction of
the N-terminal region of the replicase polyprotein of selected coronaviruses (A) and
arteiviruses (B). The papain-like protease domains, termed PLpro, PLP1 or PLP2 for
CoV, or Pα, Pβ or PLP2 for arteriviruses are depicted with correspondingly colored
arrowheads indicating predicted or confirmed cleavage sites. Figure published in
Mielech, Chen, Mesecar, & Baker, 2014.
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DUBs are enzymes that can remove ubiquitin modifications from target proteins.
Ubiquitination is a post translational modification of proteins that allows for the addition
of ubiquitin molecules to a specific lysine residue within the target protein in an ATPdependent reaction. This system is mediated by three enzymes: an E1 ubiquitinactivating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase.
These enzymes might add one (monoubiquitination) or several (polyubiquitination)
ubiquitin moieties to a target protein. The ubiquitin molecules in the polyubiquitin chain
can be covalently linked via any of the seven lysine residues present within ubiquitin.
Several types of polyubiquitination have been characterized [reviewed in (Komander &
Rape, 2012)]. The form of ubiquitin linkage determines the fate of the modified protein
and influences its function. Three types of polyubiquitination are known to be involved in
the regulation of the innate immune signaling pathways: Lys48-linked Ub (K-48-Ub),
Lys63-linked Ub (K-63-Ub), and linear polyubiquitination. K-63 linked ubiquitin and
linear ubiquitin modifications are associated with activation of proteins in certain innate
immune signaling cascades. In contrast, K-48 linked polyubiquitination is a signal that
directs proteins for proteosomal degradation. Removal of ubiquitin from cellular targets
is mediated by cellular enzymes called deubiquitinases (DUBs) (Komander, Clague, &
Urbe, 2009). DUBs recognize the RLRGG motif that links ubiquitin chains and remove
ubiquitin conjugates from cellular proteins.
The SARS-CoV PLpro DUB activity predicted by Sulea and co-workers was
tested in vitro and in transfected cells by several groups. Using purified enzyme, two
groups showed SARS-CoV PLpro DUB activity in vitro and that catalytic activity of the
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protein is required for DUB activity. They showed that the mutation of the predicted
catalytic cysteine or aspartic acid residue to alanine leads to a loss of DUB activity
(Barretto et al., 2005; Lindner et al., 2005). Further studies revealed that PLpro is capable
of processing both K-48-linked diubiquitin and heptaubiquitin, as well as K-63-linked
heptaubiquitin chains in vitro (Lindner et al., 2007). These in vitro studies were the first
to demonstrate the multifunctional nature of the coronavirus PLPs.
Structural studies have contributed to a detailed understanding of SARS-CoV
PLpro (Ratia et al., 2006). The structure of SARS-CoV PLpro displays a thumb-palmfingers architecture resembling cellular ubiquitin specific proteases (USPs) (Figure 3A)
(Ratia et al., 2006). Structural superposition of SARS-CoV PLpro with USP14 resulted in
a pairwise root-mean-square-deviation (RMSD) of 3.6 Å over 198 aligned backbone Cα,
although the sequence identity between these two proteins is only around 10%. The
active site of SARS-CoV PLpro consists of a canonical Cys-His-Asp catalytic triad,
which is in a similar position to that of USP14 (Figure 3A). In contrast to some USPs,
including USP14 and HAUSP, whose fingers domains consist of a Cys4-type-like zinc
ribbon without zinc (Hu et al., 2005), the fingers domain of SARS-CoV PLpro contains a
zinc finger with four cysteines tetrahedrally coordinating a zinc atom (Ratia et al., 2006).
Moreover, the zinc-binding ability seems to be essential for SARS-CoV PLpro activity,
as supported by mutagenesis studies (Barretto et al., 2005). Such dependence on zinc
seems to be conserved among coronaviral PLPs as zinc binding has also been observed
for other PLPs, including TGEV PLP1 and HCoV-229E PLP1 (Herold, Siddell, &
Gorbalenya, 1999; Wojdyla et al., 2010).
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Figure 3. Structures of SARS-CoV PLpro compared to USP14 and EAV PLP2
compared to yeast OTU1. (A) Structural superposition of SARS-CoV PLpro (magenta,
PDB code 2FE8) to USP14 (cyan, PDB code 2AYO). The zinc atom from the zinc finger
of SARS-CoV PLpro is shown as a gray sphere. (B) Close-up view of the active site in
SARS-CoV PLpro with the catalytic triad residues shown as sticks. Numbering of the
residues is based on (Ratia et al., 2006) (C) Structural overlay of EAV PLP2 (blue, PDB
code 4IUM) with yeast OTU1 (yellow, PDB code 3BY4) bound to ubiquitin. The
ubiquitin molecules have been omitted for clarity. The zinc atom from the zinc finger of
EAV PLP2 is shown in gray sphere. (D) Close-up view of the active site in EAV PLP2.
Numbering of the residues is based on (van Kasteren et al., 2013). Asn263 in EAV PLP2
catalytic triad has two alternative conformations. Images were generated using PyMOL.
Figure published in Mielech, Chen, Mesecar, & Baker, 2014.
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The structure of the PLP1 domain of TEGV is similar to SARS-CoV PLpro and
several cellular USPs including USP 2, 7, 8, 14, and 21 (Wojdyla et al., 2010). Purified
TGEV PLP1 has DUB activity in vitro. In addition, the authors showed that TEGV PLP1
has a slight preference for cleavage of K-48-linked over K-63-linked polyubiquitin
chains. The role of DUB activity of TEGV PLP1 in cell culture or infected animals
remains to be determined.
HCoV-NL63 PLP2 that has only 22% homology to SARS-CoV PLpro has also
been shown to act as a DUB in vitro and in cell culture. Expression of PLP2, but not
PLP2 catalytic mutant (C1678A) leads to a decrease in the level of ubiquitinated proteins
in transfected cells. In addition, purified PLP2 can process both K-48-linked and K-63linked hexaubiquitin chains (Chen et al., 2007; Clementz et al., 2010).
Similarly to HCoV-NL63, PEDV encodes two PLPs in the genome; however,
only PLP2 has been shown to have the ability to deconjugate ubiquitin from cellular
substrates (Xing et al., 2013). Moreover, the authors showed that alanine mutants of the
active site residues (cysteine, histidine, or aspartic acid) led to the loss of DUB activity in
PEDV PLP2-transfected cells. In addition, the authors showed that PEDV PLP2 can
efficiently remove both K-48-linked and K-63-linked polyubiquitin conjugates from
cellular proteins. Specifically, the authors showed that PLP2 can remove K-63-linked
polyubiquitin chains from RIG-I and STING, two molecules important for induction of
innate immunity. These results suggest a possible mechanism by which coronavirus
PLP2 DUB activity can block induction of interferon β (IFNβ) (Xing et al., 2013).
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DUB activity of MHV PLP2 has also been reported. Frieman and co-workers showed that
MHV can deubiquitinate multiple cellular proteins conjugated with ubiquitin in infected
cells (Frieman, Ratia, Johnston, Mesecar, & Baric, 2009). In addition, Zheng and coworkers showed that MHV PLP2 is capable of processing both K-48-linked and K-63linked polyubiquitin chains from cellular substrates (Zheng, Chen, Guo, Cheng, & Tang,
2008). Further, Wang and co-workers determined that MHV PLP2 can deubiquitinate K63-linked TBK1, a kinase required to activate transcription factor IRF3, which activates
expression of proinflammatory cytokines such as IFNβ (Wang, Chen, Zheng, Cheng, &
Tang, 2011). These results suggest that MHV PLP2 DUB activity may have a role in
blocking the induction of the antiviral state.
Of note, the PLpro domain from the recently emerged, highly pathogenic MERSCoV has been characterized as a protease, DUB and inhibitor of innate immune
responses, including IFNβ (Kilianski, Mielech, Deng, & Baker, 2013; Mielech et al.,
2014; Yang et al., 2013). Further work is required to determine if the DUB activity
detected during the overexpression of the PLpro in transfected cells is also critical for
viral replication or pathogenesis.

FROM VIRAL PROTEASE TO DEISGYLATING ENZYME
The recognition that coronavirus PLPs had the ability to recognize the LXGG
motif and process both polyproteins and ubiquitin chains led to the hypothesis that PLP
domains might also process ubiquitin-like molecules such as interferon stimulated gene
15 (ISG15). ISG15 is an interferon stimulated di-ubiquitin-like molecule that can be
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linked to cellular targets via a mechanism termed ISGylation (Jeon, Yoo, & Chung,
2010). Similar to ubiquitination, ISGylation requires the activity of E1, E2, and E3
enzymes, and the process is reversible (deISGylation). Several screens have identified
cellular targets of ISGylation including molecules important for the activation of an
innate immune response, particularly RIG-I, JAK1, STAT1, PKR, and MxA [reviewed in
(Lenschow, 2010)]. The exact mechanism of how modification with ISG15 influences
these proteins’ activity is not well characterized; however, ISGylation is important for
protection and clearance of viral infections. It has been shown that ISG15 knock-out mice
are more susceptible to infection with influenza, herpes and Sindbis viruses, than are
wild-type mice (Lenschow et al., 2005, 2007). Coronavirus encoded PLPs, in addition to
DUB activity, have also been shown to be able to remove IGS15 conjugates from cellular
targets, an activity which might also contribute to virus pathogenesis.
DeISGylating activity has been demonstrated for several coronavirus PLPs.
DeISGylating activity of SARS-CoV PLpro and HCoV-NL63 PLP2 was demonstrated in
vitro (Nicholson et al., 2008). In addition, Clementz and co-workers showed that HCoVNL63 PLP2 has the ability to remove ISG15 conjugates from cellular proteins in a
catalytically dependent manner (Clementz et al., 2010). Moreover, the PLpro domain
from MERS-CoV has similar properties (Mielech et al., 2014; Yang et al., 2013)
suggesting that deISGylating activity of PLPs might be conserved between PLPs from
different coronavirus species.
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CELLULAR INNATE IMMUNITY SIGNALING
In the human body, there is a constant battle between viruses that infect cells and
the earliest immune response: the innate response. The innate immune response allows
for the establishment of an antiviral state which prevents viruses from replicating. In
addition, this early response signals through interferon to neighboring non-infected cells
limiting spread of the virus. Coronaviruses are successful pathogens and, to become such,
have had to evolve multiple mechanisms to inhibit innate immunity and replicate
efficiently. PLPs are hypothesized to inhibit the induction of innate immune in infected
cells.
In order to limit virus replication, cells evolved multiple mechanisms to activate
their defense systems. The innate immune system is the first line of defense against
pathogens. It plays very important roles in the recognition of viral infection and
stimulation of the adaptive immune response which will activate T cells and induce
production of antibodies (Le Bon & Tough, 2002; Theofilopoulos, Baccala, Beutler, &
Kono, 2005). When the virus enters the cell its pathogen associated molecular patterns
(PAMPs) can be recognized by pattern recognition receptors (PRRs) that will induce
signaling cascades to stimulate the production of proinflammatory cytokines and
chemokines, leading to establishment of an antiviral state in the cell. The schematic
depiction of innate immune signaling critical for limiting RNA virus replication is
presented in Figure 4.
For recognition of RNA viruses several PRRs are particularly important (Figure
4) (Le Bon & Tough, 2002). Toll-like receptors (TLRs) 3 and 7 are present in the
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Figure 4. Innate immunity signaling. Diagram on the left shows the schematic
depiction of recognition of RNA viruses and signaling cascades that lead to production of
proinflammatory cytokines and chemokines, one of which is interferon β. On the right the
diagram shows signaling by IFNβ binding to its receptor that leads to establishment of an
antiviral state.
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endosomes and can recognize RNA during virus entry (Alexopoulou, Holt, Medzhitov, &
Flavell, 2001). Viral RNA can also be recognized by TLR - independent sensors like
cellular helicases: retinoic acid inducible gene I (RIG-I) and melanoma differentiation
associated gene 5 (Mda5) (Kang et al., 2002; Yoneyama et al., 2004). Both RIG-I and
Mda-5 contain caspase recruiting (CARD)-like domain which interacts with downstream
mitochondria associated molecule MAVS (also known as IPS-1, Cardif, and VISA). This
interaction triggers signaling cascades that eventually lead to activation of transcription
factors IRF3, IRF7, and NF-ƙB (Kawai et al., 2005; Meylan et al., 2005; Seth, Sun, Ea, &
Chen, 2005; Xu et al., 2005). Activation of IRF3 requires activation of TBK1 and IKKε
kinases by MAVS. Kinases phosphorylate IRF3 and IRF7. Upon phosphorylation, IRF3
homodimerizes and translocates to the nucleus where it can act as a transcription factor.
To activate the NF-ƙB pathway, MAVS signals to activate a complex of three kinases,
IKKα/IKKβ/IKKγ, which phosphorylate IƙBα. Upon phosphorylation, IƙBα is poly-K-48
ubiquitinated which leads to its proteosomal degradation. This releases NF-ƙB which
translocates to the nucleus and, along with the IRF3 dimer, binds to promoters and
stimulate expression of proinflammatory cytokines [reviewed in (Yoneyama & Fujita,
2009)]. The major cytokines produced upon virus infection are type I interferons (IFN)
alpha and beta. Secreted IFN stimulates neighboring cells by binding to IFN receptor
(IFNAR) and activating the Jak/STAT pathway. Upon receptor binding Jak and Tyk2
kinases phosphorylate STAT1 and STAT2 respectively. This allows for the formation of
the heterodimer and its translocation to the nucleus, where upon binding to multiple
promoters, induce interferon inducible genes (ISGs) [reviewed in (Platanias, 2005)]. One
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of the interferon-induced pathways is oligoadenylate synthetase (OAS) and RNaseL
pathway. OAS is capable of catalyzing 2’,5’- phosphodiester bonds allowing for the
formation of ATP oligomers which bind to constitutively inactive monomer of RNaseL.
This induces RNaseL homodimerization and activation. Upon activation RNaseL is
capable of degradation of viral ssRNA (Sadler & Williams, 2008). Another important and
well-studied interferon-induced molecule is ISG15 which is conjugated to multiple
proteins which helps in the establishment of an antiviral state. The importance for ISG15
has been shown by the sensitivity of ISG15-/- mice to viruses such as Herpes virus or
Influenza (Lenschow et al., 2007). OAS, ISG15, and other ISGs contribute the antiviral
state which limits the virus replication and spread.

PAPAIN-LIKE PROTEASES AS ANTAGONISTS OF THE INNATE IMMUNE
RESPONSE
DUB and deISGylating activities of the coronavirus PLPs have been proposed as
a mechanism to block the induction of the cellular response to viral infection. DUB
activity might be important for blocking induction of cellular antiviral response because
ubiquitination controls innate immunity signaling (Figure 5). Devaraj and co-workers
determined that SARS-CoV PLpro can inhibit polyI:C and Sendai virus-induced IFNβ,
and that PLpro catalytic activity is important for antagonism. Co-expression of PLpro
with stimulators of interferon activation such as RIG-I, MAVS, TRIF, TBK1 or
IKKε reduced IFNβ induction. In contrast, PLpro was not able to inhibit IFNβ induced by
expression of a dominant active form of IRF3. The authors showed that PLpro can down-
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Figure 5. Ubiquitination of innate immunity signaling pathway. Schematic depiction
of innate immunity signaling cascade and ubiquitintation involved in regulation of this
process.

22

regulate phosphorylation of IRF3 and prevent IRF3 dimer formation. Furthermore, the
authors were able to co-immunoprecipitate IRF3 with transiently expressed PLpro, and
observed co-localization of IRF3 and nsp3/PLpro during SARS-CoV infection (Devaraj
et al., 2007). Subsequently, Frieman and co-workers also showed that PLpro inhibits the
IFN response. In addition, the authors showed that PLpro can inhibit NF-ƙB-luciferase
activity by stabilizing IƙBα, a molecule that has to be degraded in order to release the
transcription factor NF-ƙB, which activates proinflammatory responses (Frieman et al.,
2009). Later studies showed that PLpro can block TNFα-induced NF-ƙB activation, and
further that this block can be removed when the cells are treated with a PLpro inhibitor,
revealing a possible antiviral strategy (Clementz et al., 2010). Furthermore, a recent
analysis showed that the expression of SARS-CoV or MERS-CoV PLpro decreases
endogenous RNA levels of proinflammatory cytokines and chemokines in activated cells
(Mielech et al., 2014).

MULTIFUNCTIONAL ARTERIVIRUS PAPAIN-LIKE PROTEASES
The Arterivirus family of positive strand RNA viruses contains genomes ranging
from 10 to 14 kilobases. The Arterivirus family includes important pathogens such as
Equine Arteritis virus (EAV) that causes disease in horses, and Porcine Reproductive and
Respiratory Syndrome virus (PRRSV) that infects pigs and is lethal to piglets. These
diseases can lead to significant economic loss and there are currently no effective
vaccines or antiviral drugs available to treat infected animals.
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Arteriviruses encode at least one PLP that is responsible for proteolytic
processing of the virus polyprotein (Figure 2). The arterivirus genome has a similar
organization to the coronavirus genome and is composed of 2 large ORFs that encode
polyproteins pp1a and pp1ab, and 8-11 downstream ORFs that encode accessory and
structural proteins. The amino-terminal region of the ORF1 is processed by two or three
PLP domains. The PLP encoded within the amino-terminal region of nsp2, termed PLP2
or P2, has a similar function as SARS-CoV PLpro [(Snijder, Wassenaar, Spaan, &
Gorbalenya, 1995) and reviewed in (Snijder & Kikkert, 2013)]. The sequence recognized
by this protease domain is only partially conserved across the Arterivirus species. For
example, EAV PLP2 recognizes the sequence LIGG, whereas PRRSV P2 can recognize
cleavage sites containing either TTGG or PSGG. The partial conservation of the site
cleaved by the arterivirus PLP2s, and its similarity to motif recognized by cellular DUBs
and deISGylating enzymes, led to the hypothesis that arterivirus P2s might be
multifunctional enzymes.
Expression of the EAV PLP2 domain revealed that it indeed exhibits DUB
activity in cell culture (Frias-Staheli et al., 2007). DUB activity of the amino-terminal
region of nsp2 (Nsp2(N)) was confirmed in vitro. EAV Nsp2(N) can deubiquitinate K48-linked and K-63-linked polyubiquitin chains in a catalytic dependent manner, as
alanine mutants of the three predicted catalytic residues lost DUB activity (van Kasteren
et al., 2012). To address the possible role for Nsp2(N) DUB activity in the inhibition of
innate immunity, the authors determined the ubiquitination status of RIG-I which requires
K-63-linked polyubiquitination for activation. Studies have shown that DUB activity of
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Nsp2(N) from EAV can block RIG-I ubiquitination in a catalytic dependent manner (van
Kasteren et al., 2012). This led to the hypothesis that EAV DUB activity might be
important for blocking the innate immune response to viral infection. To test this
hypothesis, it was critically important to obtain structural information on how the enzyme
interacts with ubiquitin. With this information in hand, researchers can attempt to
generate PLP2 mutants that retain protease activity but are impaired for interaction with
ubiquitin.
The co-crystal structure of EAV PLP2 with ubiquitin was solved by van Kasteren
and co-workers (van Kasteren et al., 2013). EAV PLP2 adopts a two-domain fold and
shares a β-sheet core and two central helices with eukaryotic OTUs (Figure 3C).
Structural overlay of EAV PLP2 with yeast OTU1 resulted in a RMSD of 3.3 Å over 81
aligned Cα with only around 9% sequence identity. The Cys-His-Asn catalytic triad of
EAV PLP2 resides in a structurally conserved region of OTU DUBs (Figure 3D). What is
unique about the structure of EAV PLP2 is the presence of a zinc finger as a part of the
OTU domain. This zinc finger is critical for the structural integrity and catalytic activity
of EAV PLP2. The presence of a zinc finger has not been observed in other known OTUlike proteases. Thus, it has been proposed that EAV PLP2 may represent the first member
of a new class of zinc-dependent OTUs (van Kasteren et al., 2013).
The co-crystal structure of EAV PLP2 with ubiquitin revealed interaction sites
between the enzyme and ubiquitin that are distal to the active site (van Kasteren et al.,
2013). Using this structural information, the authors were able to successfully separate
PLP2 protease and DUB activities. Mutation of the ubiquitin-interacting residues of EAV
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PLP2 had no evident effect on protease activity but significantly reduced DUB activity in
overexpression studies. To study the effect of the DUB mutant on virus replication and
innate immunity, the authors used reverse genetics to recover two replication competent
mutant viruses (a single mutant I353R and a triple mutant T312A/I313V/I353R in the
EAV PLP2 domain) and showed that replication kinetics of these viruses were essentially
identical to the wild-type virus. However, the viruses with the mutant PLP2 domain had
lost the ability to deconjugate ubiquitin from cellular targets in virus-infected cells. In
addition, cells infected with the EAV DUB mutant viruses generated an elevated innate
immune response, particularly expression of IFNβ, IL8, and MX1, suggesting that DUB
activity is important for inhibition of the innate immune response (van Kasteren et al.,
2013). The EAV DUB mutant study was the first study to demonstrate that viral protease
and deubiquitinase functions can be separated. This is an important contribution because
it opens the door for the study of viral DUB activity in vaccines and as a target for
antiviral therapeutics.
Interestingly, EAV is not the only member of the Arterivirus family for which
multifunctional protease/DUB activity has been shown. PRRSV is a well-studied member
of the family which causes disease of high economic importance in pigs. The proteolytic
activity of PRRSV P2 has been well studied (Han, Rutherford, & Faaberg, 2010; Jun
Han, Rutherford, & Faaberg, 2009) and P2 has the ability to cleave ubiquitin conjugates
from cellular targets (Frias-Staheli et al., 2007). Sun and co-workers showed that P2 had
deubiquitinating activity in vitro and in cell culture. The authors showed that PRRSV P2
can block Sendai virus-induced IFNβ and inhibit NF-ƙB by preventing IƙBα degradation
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by its deubiquitination in cell culture. In addition, they generated several mutant versions
of P2 that had reduced ability to inhibit NF-ƙB-activation. To test if P2 can block NF-ƙB
activation in the context of the virus, the authors introduced these mutations into PRRSV.
Although some of the mutations that altered P2 activity in vitro could not be recovered as
viable virus, the authors did report two single amino acid P2 mutant viruses that showed
decreased ability to inhibit NF-ƙB-reporter activity and a decrease in the level of IƙBα in
infected cells (Sun, Chen, Lawson, & Fang, 2010). However, the authors did not address
whether protease or DUB activity was responsible for the effect they observed in infected
cells. The authors noticed that the mutant viruses had severe replication defects
suggesting that P2 protease activity, as well as DUB activity, may have been impaired
(Sun et al., 2010).
Similar to studies on coronavirus PLP activities, groups characterizing arterivirus
PLP domains investigated their deISGylating activity. Frias-Staheli and co-workers
showed that EAV P2/PLP2 is capable of deconjugating IGS15 from cellular proteins in
transfected cells (Frias-Staheli et al., 2007). Furthermore, a report by Sun and co-workers
showed that PRRSV P2 decreases endogenous ISG15 protein levels upon Sendai virus
stimulation, and that it has deISGylating activity in cell culture (Sun, Li, Ransburgh,
Snijder, & Fang, 2012). Furthermore, the authors generated PRRSV P2 mutants that had
reduced deISGylating activity. The first mutant had a 23 aa deletion in nsp2 (aa 402-424),
the second mutant had a 19 aa deletion in nsp2 (aa 402-420), and the third mutant had the
19 aa deletion and additional point mutation (S462A). When cells were transfected with
those mutants the endogenous levels of IGS15 was increased compared to cells
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transfected with the wild-type version of P2. Interestingly, the processing of nsp2/nsp3
was not affected by the deletion or deletion/point mutations in the P2 domain of the virus.
The authors were able to recover two viruses (19 aa deletion, and 19 aa deletion/S462A).
The growth kinetics analysis showed that those two viruses do not replicate as efficiently
as wild-type virus, which may be due to the inability to efficiently process the nsp2/nsp3
site in the replicase polyprotein (Sun et al., 2012). Further studies including solving the
X-ray crystal structure of the PRRSV P2 domain and determining to role of P2
DUB/deISGylating mutants on viral pathogenesis in animal models are needed.
Viruses have evolved many different mechanisms to down-regulate innate
immune response upon infection. The ability of a virus to block or delay the induction of
the antiviral state in an infected cell is likely an important contributor to pathogenesis.
Nidoviruses encode in their genomes several proteins that are capable of blocking or
delaying innate immune signaling. One of them is the papain-like protease, the
multifunctional enzyme that can act as a potent protease, DUB, deISGylating enzyme,
and antagonist of the innate immune response. Separating protease and DUB activities is
needed to fully understand the role of those proteins during virus replication. Thus far,
separating protease activity from DUB and IFN antagonism activity has been shown only
for the arterivirus EAV (van Kasteren et al., 2013). The specific mechanisms and the
contributions of arteri- and coronavirus PLPs to interferon antagonism during virus
infection and pathogenesis are an exciting new direction of research that may lead to the
development of effective vaccines and novel antiviral therapeutics.
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CORONAVIRUS INDUCTION OF INTERFERON AND INTERFERON
ANTAGONISTS
As cellular innate immunity mechanisms evolved, viruses co-evolved and
established multiple ways to inhibit the innate immune response. MHV and other
coronaviruses encode, in addition to PLPs, multiple accessory and multifunctional
proteins that can act as interferon antagonists. Below I will review the hypothesis and
data regarding inhibition of innate immunity by model coronavirus MHV.
In contrast to many RNA viruses, which upon infection and recognition by PRRs
induce robust type I interferon response, MHV-A59 and JHM strains have been shown
not to induce interferon response in multiple fibroblast cell lines such as L2 fibroblasts
and 17Cl1 cells (Roth-Cross, Martinez-Sobrido, Scott, Garcia-Sastre, & Weiss, 2007; Ye,
Hauns, Langland, Jacobs, & Hogue, 2007; Zhou & Perlman, 2007). In addition, MHV is
not capable of inducing IFNs in bone marrow derived dendritic cells which are known to
produce high amounts of IFNα and IFNβ (Zhou & Perlman, 2006). Multiple groups
observed no activation of IRF3 and NF-κB dependent promoters in MHV infected cells
(Roth-Cross et al., 2007; Zhou & Perlman, 2007). Two main mechanisms have been
proposed to explain the lack of interferon induction. The virus can either encode proteins
that act as IFN antagonists and/or the virus “hides” from the recognition by PRRs.
The proposed role of MHV PLP2 in inhibiting the induction of interferon is described
above.
Several groups showed that MHV is resistant to IFN treatment in cell culture and
proposed that the virus is capable of blocking signaling downstream of IFN receptors
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(Koetzner et al., 2010; Roth-Cross et al., 2007; Ye et al., 2007) (Figure 6). Zust and coworkers showed that expression of nsp1 can inhibit the induction of IFN genes. The virus
lacking functional nsp1 was not attenuated in vitro. However, mice infected with nsp1
mutant virus fully recovered from infection. The attenuation in mice could be reversed in
IFNAR-/- mice suggesting that nsp1 mediates IFN antagonism. The authors concluded
that nsp1 might be blocking signaling downstream of the IFN receptor since IFNα
pretreatment of macrophages led to dose-dependent inhibition of the mutant virus
replication (Zust et al., 2007).
Two reports from the Weiss laboratory showed that MHV co-infection of L2
fibroblasts can inhibit IFNβ protein levels upon Sendai virus (SV) and New Castle’s
Disease virus (NDV) infection. However, MHV can induce IFNβ mRNA levels late
during infection. Furthermore, MHV infection cannot prevent Sendai Virus or Newcastle
Disease Virus- induced IRF3 translocation to the nucleus (Rose, Elliott, MartinezSobrido, Garcia-Sastre, & Weiss, 2010; Roth-Cross et al., 2007). In the first report the
authors showed that MHV cannot block IFN induction completely in vivo, and they
detected significant amounts of IFNβ in the brains of infected mice. In addition, IFN
pretreatment and subsequent infection with MHV and NDV resulted in infection with
MHV only, suggesting that MHV does not block “general antiviral activities”. To
investigate the possible mechanism the authors determined that interferon did not
accumulate inside infected cells nor was degraded via proteosomal pathway. Thus, they
suggested that the inhibition occurs between mRNA synthesis and protein translation but
the exact mechanism remains to be determined (Roth-Cross et al., 2007). In a more recent
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Figure 6. Antagonists of innate immunity in MHV genome. Schematic depiction of
MHV genome, characterized IFN antagonists are depicted in green. Table below
summarizes the mechanisms of inhibition.
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publication, the authors determined that MHV preinfection cannot only inhibit induction
of interferon promoter but also delay expression interferon stimulated genes induced by
Sendai virus infection. Interestingly, MHV preinfection did not affect STAT1 or STAT2
activation, phosphorylation or nuclear translocation (Rose et al., 2010).
One proposed mechanism which explains the lack of IFN induction upon
infection is that MHV is not recognized by the typical PRRs known to recognize RNA
viruses. Early reports showed that MHV preinfection cannot prevent polyI:C mediated
activation of IFN, IRF3 and NF-kB dependent promoters. Moreover, the authors showed
that the overexpression of RIG-I, Mda5 or TLR3 is sufficient for IFN promoter induction
in the presence MHV infection suggesting that MHV is not recognized by PRRs and the
mechanism may involve virus “hiding” on DMVs during replication, which makes RNA
inaccessible for cytoplasmic sensors (Jackson et al., 2005; Schwartz, Chen, Lee, Janda, &
Ahlquist, 2004; Sims, Ostermann, & Denison, 2000; Zhou & Perlman, 2007).
Ye et al., determined that upon MHV infection protein kinase R (PKR) is not
phosphorylated and activated leading to a lack of phosphorylation of the transcription
factor eIF2α which is required to inhibit protein translation, a known antiviral mechanism
that limits virus replication. Further, the authors determined that 2',5'-oligoadenylate
synthetase (2’-5’ OAS), another dsRNA activated pathway is also not activated upon
MHV infection. The authors concluded that the virus does not induce RNase L activity
since no RNA degradation was observed in infected HeLa cells. These data support a
model where MHV replication intermediates are not recognized by PKR and 2’-5’OAS
sensors. Moreover, the authors showed that MHV A59 nucleocapsid N protein
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contributes to virus IFN resistance and inhibits 2’-5’ OAS pathway activity (Ye et al.,
2007). A report by Koetzner and co-workers proposed that the viral accessory protein
ORF5a is an interferon antagonist. Koetzner et al., used the observation that MHV-A59
in contrast to MHV-S is IFN resistant in L2 cells and 929 cells. The authors determined
that MHV-S, in contrast to all other strains of MHV, does not have ORF 5a in the
genome. The authors generated a MHV-A59 virus that had the 5a gene knocked out and
this virus was highly sensitive to IFN-α treatment. However; the chimeric virus was not
as sensitive as MHV-S; even when the ORF5a knock out was combined with substitution
of the nucleocapsid gene from MHV-S; suggesting that MHV A59 may encode additional
IFN antagonists. The authors showed that chimeric virus does not inhibit activation of
PKR and 2’-5’ OAS pathways and the exact mechanism by which ORF 5a mediates
antagonism remains to be determined (Koetzner et al., 2010).
Roth-Cross and co-workers showed that MHV ns2 protein has 2’-5’
phosphodiesterase activity and that this activity is required for IFN antagonism. The
authors generated a ns2 MHV mutant strain and determined that it can replicate in
fibroblasts but is attenuated in vivo (Roth-Cross et al., 2009). Further studies revealed that
the ns2 mutant is attenuated in macrophage cell lines (Roth-Cross et al., 2009). In a
recent paper, the authors reported that cellular 2’-5’ oligoadenylate is a target for ns2
which prevents activation of the RNaseL pathway and inhibits innate immune response
and the induction of an antiviral state in liver macrophages. This allows MHV to infect
hepatocytes and induce hepatitis (Zhao et al., 2012).
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In contrast to fibroblasts, MHV is capable of inducing significant interferon
responses in plasmacytoid DCs, brain macrophages/microglia, and oligodendrocytes (Li,
Liu, & Zhang, 2010; Roth-Cross, Bender, & Weiss, 2008; Zust et al., 2007). Li and coworkers showed that in oligodendrocytes, helicases RIG-I and Mda5 are important for
virus detection. However; another report suggests that MHV is not recognized by RIG-I
because RIG-I recognizes uncapped mRNA and MHV RNA is 5’ capped and
polyadenylated. This report proposes that virus “hides” from the recognition by this PRR
by mimicking cellular mRNA (Li et al., 2010). In agreement with this, is the observation
that recognition of virus infection in microglia is mediated by Mda5 helicase (and not by
RIG-I) which recognizes dsRNA, an intermediate present during virus replication.
MHV infection is organ restricted in mice. MHV A59 is hepatotropic and JHM is
a neurotropic strain. However, IFNAR-/- mice are highly susceptible to MHV infection,
and infection disseminates into multiple organs whereas upon infection of wild-type mice
infection is organ limited (Cervantes-Barragan et al., 2007). All these data lead to the
conclusion that IFN response limits virus replication in vivo. It is not clear yet if the virus
encodes antagonists and/or is not recognized upon infection which prevents IFN
induction in some cell types/organs.

ANTIVIRAL DRUGS TO CORONAVIRUS PAPAIN-LIKE PROTEASES
Despite the fact that SARS-CoV emerged over a decade ago and many efforts
have been made to develop specific coronavirus antiviral drugs to this day there are no
FDA approved anti-coronavirus therapeutics [reviewed in (Barnard & Kumaki, 2011)].
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Many proteins known to facilitate coronavirus replication in infected cells have been
shown to be valuable targets for antivirals [reviewed in Kilianski & Baker, 2014)].
Previous studies have shown that SARS-CoV papain-like protease (PLpro) which process
viral polyprotein during virus replication is an effective antiviral target, because the
protease activity is required for virus life cycle.
The first study reporting the usefulness of SARS-CoV PLpro as a drug target was
done by Ratia and co-workers. The authors screened a library of 50,080 compounds in
order to find drugs that inhibit SARS-CoV PLpro activity (Ratia et al., 2008). They
performed in vitro screen using a fluorescent-based high-throughput screening system.
The goal of this screen was to find non-covalent inhibitors that specifically target SARSCoV PLpro, because previous studies on covalent inhibitors of other viral cysteine
proteases have shown that covalent modification very often affects untargeted cellular
cysteine residues thus leading to significant cytotoxicity of those compounds (LeungToung, Li, Tam, & Karimian, 2002). The screen performed by Ratia and co-workers
identified a lead-compound with an IC50=20.1µM which was used for further
optimization. The generated optimized compound designated GRL0617 showed
increased potency in vitro (IC50=0.6µM) and was also effective in blocking SARS-CoV
replication in cell culture (EC50=14.5µM). Further, the authors showed that GRL0617 is
SARS-CoV PLpro specific inhibitor that does not affect human cysteine proteases
including cellular deubiquitinating enzymes (HAUSP, USP18, UCH-L1, UCH-L3). In
addition, the drug did not block HCoV-NL63 PLP2 activity supporting its specificity
towards SARS-CoV PLpro. Finally, the authors generated a co-crystal structure of
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SARS-CoV PLpro with the inhibitor revealing the mechanism by which the drug inhibits
protease activity. They found that the drug binds to the cleft that leads to the enzyme
active site via two hydrogen bonds and several hydrophobic interactions with enzyme
residues. The important finding came from the comparison of the structures of apoenzyme and enzyme-inhibitor complex. Inhibitor binding leads to the changes in the
flexible loop (Gly267-Gly272) of the enzyme. Binding of the drug closes the otherwise
flexible loop, which leads to the clamping of the inhibitor to the body of the protein. This
first study on SARS-CoV inhibitors was significant because it showed that PLpro is a
valuable target for the design of specific SARS-CoV inhibitors, presented the efficacy of
structure activity relationship in SARS-CoV PLpro drug design, and revealed drug
candidates that could be further optimized to increase potency (Ratia et al., 2008).
Further structure-based optimization of the compound described above
(GRL0617) led to two new SARS-CoV PLpro inhibitors of improved potency.
Compound 2 had a significantly reduced IC50 of 0.46µM, comparing to the leadcompound and also an improved ability to inhibit SARS-CoV replication (EC50=6.0µM).
The second compound generated had a slightly higher IC50 of 1.3 but had significantly
improved efficacy (EC50=5.2µM). Based on the crystal structure described by Ratia and
co-workers the model of compound 2 with SARS-CoV PLpro was generated facilitating
optimization of the compounds in the future (Ghosh et al., 2009).
The same screen of 50,080 compounds which discovered GRL0617 leadcompound, identified the second best compound (compound 3) with an IC50=59.2µM
towards SARS-CoV PLpro (Ghosh et al., 2010). This compound was used in further
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optimization and allowed for the synthesis of the compound termed 15g which is a very
potent inhibitor of SARS-CoV PLpro. The IC50 of this compound equals 0.32µM, and
EC50=9.1µM which is a significant improvement compared to the lead-compound 3.
Furthermore, the authors generated a crystal structure of the compound 15g with SARSCoV PLpro and found that even though the inhibitor binds to the same loop as the
inhibitor described by Ratia and co-workers, the specific interactions between inhibitor
and enzyme are significantly different, which gave new insights into drug-enzyme
interactions and can be used in the future to design inhibitors that can prevent SARS-CoV
replication more effectively (Ghosh et al., 2010).
Because none of the previously described studies reported inhibitors that had an
EC50 value that would suggest therapeutic application of the compound, further studies
on SARS-CoV PLpro inhibitors were needed. The recent report by Baez-Santos and coworkers used the knowledge from above described study and co-crystal structure of
SARS-CoV PLpro with inhibitor 15g to design new compounds that would block SARSCoV replication. My work on this project regarding evaluating of the efficacy of the
compounds to inhibit SARS-CoV replication is described in the results section. The new
structure-guided design led to the evaluation of several new candidates and showed that
compound 3k is the most effective in inhibiting the activity of purified enzyme
(IC50=0.2µM) and that it potently inhibits SARS-CoV replication. However, other drugs,
particularly 3e and 5c, are more metabolically stable than 3k and are still very potent
inhibitors of PLpro with EC50 values of 8.3µM and 9.5µM respectively, which makes
them more promising candidates for the future optimization. We also reported the crystal
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structure of compound 3k in complex with SARS-CoV PLpro, which revealed that
similar to compound 15g described by Ghosh and co-workers, 3k binds to a site adjacent
to the active site of the enzyme. The flexible loop (Gly267-Gly272) of the enzyme
changes its conformation upon binding of the compound which leads to the inhibition of
the enzyme activity (Báez-Santos et al., 2014).
Overall, even though currently there are no compounds that target SARS-CoV
PLpro that could be used in clinical trials due to relatively high EC50 values, the studies
that I described above gave a lot of information and directions for further optimization.
Furthermore, they showed the potential and effectiveness of structure-based design of
PLpro inhibitors and showed that non-covalent inhibitors of papain-like protease can be
effective and less toxic than drugs that covalently bind to enzymes.
In addition to the screen described above, Frieman and co-workers reported on a
new yeast-based screening technique that allowed them to identify inhibitors of SARSCoV PLpro. The authors showed that one of the identified compounds had the ability to
block specifically SARS-CoV replication (EC50<1µM), and was not effective against
influenza virus (Frieman et al., 2011). In this report the authors screened a relatively
small library of compounds (about 2,000) but showed the proof of principle that a yeastbased screen is a good assay to identify SARS-CoV PLpro inhibitors, and that it can be
used in the future in combination with structure-based optimization to develop more
potent drugs (Frieman et al., 2011).
Recently, Kilianski and co-workers tested compound 15g described by Ghosh and
co-workers for its ability to inhibit the activity of MERS-CoV PLpro in transfected cells;
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however, they found that this inhibitor is not active against MERS-CoV PLpro, which is
probably due to the differences in the structures of the enzyme and particularly the
flexible loop (Gly267-Gly272 in SARS-CoV structure) (Kilianski, Mielech, Deng, &
Baker, 2013). Thus, further studies and structure-based optimization of compounds are
needed to facilitate the development of inhibitors of MERS-CoV PLpro.
Taken together literature shows that there PLpro is a valuable target for anticoronavirus drugs; however, all drugs designed so far need further optimization and
validation before they can be used in the clinical settings. One of the challenges in the
development of anti-coronavirus therapeutics is the lack of natural infection which makes
it hard to evaluate the drugs’ efficacy. For this reason, and because a new coronavirus can
emerge into the human population at any time, now the efforts are focused more on
designing of the broad spectrum antivirals. The efficacy of this kind of drugs can be
tested in the context of natural infection (against HCoV-NL63 which causes common
colds). In addition, the availability of broad spectrum anti-coronavirus drugs and/or
vaccines can be beneficial if a new coronavirus with pandemic potential emerges.

CHAPTER II
MATERIALS AND METHODS

CELLS AND TRANSFECTIONS
HEK293T and VeroE6 cells were cultured in Dulbecco's Modified Eagle Medium
(DMEM) with 10% fetal calf serum (FCS) and 2% glutamine. Transfections were
performed with 70% confluent HEK293T cells in cell bind plates (Corning) using
TransIT-LT1 Reagent (Mirus) according to manufacturer’s protocol. DBT cells were
cultured in Minimal Essential Medium with 5% FCS, 2% L-glutamine, and 10% Tryptose
Phosphate Broth (TPB). BHK-R cells were kindly provided by Dr. M. Denison
(Vanderbilt University Medical Center) laboratory and maintained in DMEM media
supplemented with 10% FCS, 2% L-glutamine, and 0.8mg/ml G418.

EXPRESSION PLP CONSTRUCTS AND MUTAGENESIS
The MERS-CoV PLpro (pcDNA-MERS-PLpro) expression plasmid and
generation of catalytic mutant were described previously (Kilianski, Mielech, Deng, &
Baker, 2013). Initial pcDNA-SARS-PLpro wild-type and catalytic mutant expression
plasmids were described elsewhere (Clementz et al., 2010).
The constructs expressing HCoV-HKU1 (amino acids), HCoV-OC34, HCoV229E, SARS-CoV PLpro and FIPV PLP2s with in frame V5 epitope tag in pCDNA39
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V5/His-B were codon optimized and synthetized (Genscript). To generate catalytic
mutants Gibson Assembly (New England Biolabs) technique according to manufacturer’s
protocol was used with primers indicated in Table 2. The sequences of all constructs are
shown in Appendix 1.

MHV PLP2 EXPRESSION CONSTRUCTS AND MUTAGENESIS
To generate WT PLP2 expression constructs we obtained synthetic codonoptimized MHV PLP2 sequences (amino acids 1611-1970 PLP2-A, and amino acids
1525-1911 PLP2-B of MHV-A59) (GeneScript). The PLP2-A sequence was amplified
with primers which introduced restriction sites facilitating cloning into pCAGGS vector
as well as in frame V5 tag. Two step PCR was used to generate pCAGGS-PLP2-A
construct. First, reaction was performed with forward primer F1 and reverse primer R1.
Reverse primer R2 was used in secondary reaction (Table 3). The product was generated
using Pfu polymerase. Upon verification on 1% agarose gel, the PCR products were
purified using Wizard SV Gel and PCR Clean Up System (Promega). The products were
digested with SacI, and XmaI (Fermentas) and introduced into pCAGGS vector. To
generate deletion mutants two additional restriction sites (KpnI and MluI) were
introduced using PCR that facilitated generating multiple truncations. Mutagenic primers
used are shown in Table 3. Codon-optimized synthetic PLP2-B sequence was cloned into
pCAGGS vector bearing KpnI and MluI sites generated in steps described above. For
mutagenesis of PLP2-B construct the overlapping PCR strategy was used for each
mutant. The primary reactions were performed with combination of forward mutagenic

Table 2. Primers used to generate catalytic mutants of PLP2 constructs

41

Table 3. Primers used to generate MHV PLP2-A mutants
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primer and reverse outside primer, and reverse mutagenic primer and forward outside
primer (Table 4).Upon verification on 1% agarose gel, purified PCR products were used
in the secondary reaction with forward and reverse outside primers. The products were
verified and purified as described above, and digested with restriction enzymes KpnI and
MluI (Fermentas). Following purification PCR products were ligated with digested and
purified pCAGGS vector using T4 ligase (New England Biolabs) for 2 hours at RT.
Then the ligation mix was transformed into One Shot TOP 10 Competent Cells (Life
Technologies). To generate the deletion mutants single PCR reaction was performed
using primers described in Table 4. Gibson Assembly technique according to
manufacturer’s protocol was used to generate PLP2-ubiquitin interaction mutants. The
introduced mutations were verified by sequencing. Sequences of all used constructs are
gathered in Appendix 1. Primers used to generate DUB mutants are shown in Table 5.

EXPRESSION PLASMIDS
For the luciferase assay experiments we used IFNβ-Luc provided by John Hiscott
(Jewish General Hospital, Montreal, Canada), Renilla-luciferase expression plasmids
pRL-TK (Promega), NF-κB reporter expression plasmid pGL4 32 [luc2 NF-kB-RE
Hyrgo] (Promega), N-RIG-I expression plasmid was provided by Ralph Baric (University
of North Carolina). The pEF-BOS MDA5 (Addgene #27225) and pEF-BOS MAVS
(Addgene #27224) expression plasmids were gifts of Kate Fitzgerald (University of
Massachusetts Medical School). pcDNA3.1-Flag-Ub was kindly provided by Dr.
Adriano Marchese (Loyola University Medical Center), pcDNA3-myc6-mISG15 was a

Table 4. Primers used to generate MHV PLP2-B mutants
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Table 5. Primers used to generate MHV PLP2-B mutants
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gift of Dr. Min-Jung Kim (Pohang University of Science and Technology, Pohang,
Republic of Korea). pcDNA3-Ube1L, pcDNA3-UbcH8, and pcDNA-Herc5 were
provided by Dr. Robert M. Krug (University of Texas).

DEISGYLATING ACTIVITY ASSAY
HEK293T cells in 12-well plates were transfected with 10, 25, 50, 100 ng of
indicated PLP expression construct wild-type or catalytic mutant, and 250 ng pISG15myc, 125 ng pUbcH8, 125 ng pUbe1L, and 125 ng pHerc5. At 20 hours posttransfection, cells were lysed with lysis buffer (20mM Tris (pH 7.5), 150mM NaCl, 1mM
EGTA, 1mM EDTA, 1% Triton X-100, 2.5mM Na pyrophosphate, 1mM betaglycerophosphate, 1mM Na ortho-vanadate, 1µg/ml leupeptin). Proteins were separated
by SDS-PAGE, and transferred to PVDF membrane using a semi-dry transfer apparatus
(BioRad). Following transfer, the membrane was blocked using 5% dried skim milk in
TBST buffer (0.9%NACl, 10mM Tris-HCl, pH=7.5, 0.1% Tween 20) over night at 4OC.
The membrane was incubated with mouse anti-myc antibody (MBL) at the dilution of
1:2500. The membrane was washed 3 times for 15 minutes in TBST buffer. Following
the membrane was incubated with secondary goat-anti-mouse-HRP antibody at the
dilution 1:5000 (Amersham). Then the membrane was washed 3 times for 15 minutes in
TBST buffer. The detection was performed using Western Lighting Chemiluminescence
Reagent Plus (PerkinElmer) and visualized using FluoroChemE Imager (Protein Simple).
To verify expression of the PLpro the membrane was probed with mouse anti-V5
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antibody (Invitrogen) at the dilution 1:5000. Mouse anti-calnexin antibody (Cell Signal)
at the dilution 1:2000 was used to determine loading standard.

DEUBIQUITINATING (DUB) ACTIVITY ASSAY
To assess DUB activity, HEK293T cells in 12-well plates were transfected with
400 ng pcDNA3.1-Flag-Ub and 0.25, 0.5, or 1µg of indicated PLP expression construct
wild-type or catalytic mutant. At 18 hours post-transfection, cells were lysed with 100µl
of lysis buffer, SDS-PAGE and transferred to PVDF membrane as described above.
Membrane probing was performed using mouse anti-Flag M2 antibody (Sigma) at the
dilution of 1:2000.

LUCIFERASE REPORTER ASSAY
HEK293T cells in 24-well plates were transfected using with 50ng Renillaluciferase, 100ng IFN-β-luc or 100ng ISRE-luc, and indicated PLP expression plasmids.
As a stimulation 150ng pEF-BOS MDA5, or 50ng pEF-BOS MAVS, or 50ng N-RIG-I
per well was transfected. Empty pCDNA3.1-V5/His-B vector plasmid was used to
standardize the total amount of DNA used for transfection. At 16 hours-post transfection
cells were lysed using 1X Passive Lysis buffer (Promega). Alternatively, the cells were
transfected with 50ng pGL4 32 [luc2 NF-κB-RE Hyrgo], 100ng IFN-β-luc and wild-type
or catalytic mutant PLP expression plasmids for 12 hours and then treated with 10ng/µl
TNFα (Roche) for 4 hours, and lysed. For all experiments Firefly and Renilla luciferase
were measured using Dual Luciferase Reporter Assay System (Promega) and
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luminometer (Veritas). Results were normalized to Renilla luciferase expression control.
Experiments were performed in triplicate. Remaining lysates were incubated with Lysis
buffer A and analyzed by SDS-PAGE as described above. The presence of PLPs was
detected using mouse anti-V5 antibody (Invitrogen) at the dilution 1:5000.

pGlo ENDPOINT ASSAY
HEK293T in cells in 24-well CellBind plates (Corning) were transfected with
150ng pGlo (Promega) pGlo-RLKK construct, 25ng pRL-TK (Promega), and increasing
amounts of protease expression plasmid. After 20 hours, cells were lysed with 1X
passive lysis buffer (Promega) and 25ul of lysate was taken and assayed for luciferase
activity using dual luciferase activating reagents (Promega).

pGlo LIVE-CELL ASSAY
HEK293T were transfected with 37.5ng pGlo (Promega) pGlo-RLKGG construct
and 50ng of PLP expression plasmids. 18 hours post-transfection GloSensor (Promega)
reagent diluted 1:50 in DMEM+10% FCS was added. Plates were imaged using a
luminometer (Veritas) every hour for 5 hours.

qRT-PCR ANALYSIS
HEK 293T cells in 12-well plates were transfected with 300ng pEF-BOS MDA5
or 100ng N-RIG-I and 200ng of plasmids expressing wild-type, catalytic mutant or
indicated PLP mutants. Empty vector plasmid pCDNA3.1-V5/His-B vector was used to
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standardize the total amount of DNA in each sample. The cells were lysed 18 hours-post
transfection with Buffer RLT (Qiagen) and RNA was extracted using RNeasy Mini
(Qiagen). Reverse transcription was performed using 1 µg of total RNA and the RT2
First Strand Kit (Qiagen) according to manufacturer’s protocol. 1 µl of cDNA was used
to set up qRT-PCR reaction according to the manufacturer’s protocol using Single Primer
Assay for IFNβ, CXCL10, and CCL5 (SABiosciences) or Human Innate and Adaptive
immune response gene array (SABiosciences). CT values were normalized to
housekeeping gene (RPL13).

GENERATING THE NSP3 MUTANT VIRUS
To generate a mutant MHV-A59 a previously described method was used (Yount,
Denison, Weiss, & Baric, 2002). Briefly B plasmid was mutagenized using primers
described Table 6. All plasmids encoding complete virus genome were digested with
restriction enzymes (New England Biolabs) and gel purified. Further, the fragments were
ligated using T4 ligase at 4OC overnight. The ligation reaction was isopropanol
precipitated and in vitro RNA transcription was performed using mMESSAGE
mMASCHINE Kit (Applied Biosystems) according to the following protocol: 40.5OC for
25 min, 37.5OC for 50 min, 40.5OC for 25 min. RNA was electroporated into BHK-R
cells, and seeded into DBT cells. The detailed protocol is described in Appendix 2.

Table 6. Primers used to generate mutant viruses
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TEMPERATURE SHIFT EXPERIMENT
DBT cells in 6-well plates were infected with 0.1 MOI of icMHV-A59 or AM2.
The supernatant was collected every 2 hours and the virus titer was determined using
plaque assay. Plaque assay was performed as follows: DBT cells seeded in 6 well-plates
were infected with 300 µl of serial dilution of virus stock. The plates were incubated for
1hour at 37OC, with rocking every 15 minutes. Upon infection the inoculum was
removed and 2ml of media/agar (1:1 of 2xMEM 2%FCS and 0.8% Noble agar) layer was
applied. The plates were incubated at 37OC for 48 hours and fixed with 10%
formaldehyde for at least 1 hour. Upon that time the cells were stained with crystal violet.

EXPRESSION AND PURIFICATION OF V1613S MUTANT PROTEIN
Sequence encoding MHV PLP2 domain (residues 1525-1910 of polyprotein 1ab
from MHV strain A59) was cloned into LIC vector pEV-L8, which is a modified pET-30.
The expression of wild type PLP2 and V1613S mutant was performed with Escherichia
coli strain BL21 (DE3) cells. Cultures were grown in LB medium at 37°C until the
optical density at 600nm (A600) reached 0.6, and then induced with 0.1mM isopropyl-βD-thiogalactopyranoside (IPTG). WT PLP2 was induced at 25°C for 6h, while V1613S
mutant was induced at 18°C overnight. Cells were harvested by centrifugation at 5,000
rpm for 20min (4°C) and frozen at -80°C. The cell pellet from 1L culture was then
resuspended in 40ml buffer A (25mM Tris pH 7.0, 500mM NaCl, 20mM imidazole,
5mM βME) supplemented with flakes of lysozyme and DNase, lysed through sonication
and centrifuged at 13,000 rpm for 30min (4°C). The supernatant was filtered through a
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0.45μm membrane (Millipore) and loaded onto a 5ml Ni HisTrapHP column (GE
healthcare) pre-equilibrated with buffer A. Then column was washed with buffer A
supplemented with 5% buffer B (25mM Tris pH 7.0, 500mM NaCl, 500mM imidazole,
5mM βME) until the UV was back to the baseline. The protein was eluted through a
gradient of 5%-100% buffer B in 30 column volumes (CV). Fractions collected were
pooled upon activity and purity assessment, followed by TEV protease (His-tagged)
cleavage overnight at 4C along with dialysis into buffer C (25mM Tris pH 7.0, 100mM
NaCl, 10mM βME). Then His-tag cleaved PLP2 was separated from uncleaved PLP2 and
TEV through another step of Ni HisTrap column. The flowthrough collected was
concentrated using Millipore Micron concentrators to a volume of less than 2ml, and
loaded onto a Superdex-75 Hiload 26/60 column (GE Healthcare) pre-equilibrated with
buffer D (50mM HEPES pH 7.0, 100mM NaCl, 10mM DTT), and eluted at a flow rate of
2ml/min. Fractions were pooled upon activity and purity assessment, and flash-frozen in
2% glycerol and stored at -80°C. This experiment was performed by Y. Chen, Purdue
University.

ENZYMATIC ACTIVITY OF V1613S PURIFIED PROTEIN
Wild-type PLP2 and the V1613S mutant were incubated at 25°C for different time
periods (5-50min). At each time point, the activity of both enzymes was measured at
25°C with 50µM RLRGG-AMC as the substrate and 5µM enzyme. The experiments
were performed in triplicate. Similar experiments were carried out when the enzymes
were incubated at 30°C. To analyze the data, the ratio of the reaction rate at time t to the
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rate at time 0 was plotted in logarithmic scale against incubation time. Kinetic data of the
V1613S PLP2 incubated at 30°C are fitted to a first-order exponential decay model
(Ratet/Rate0 = e-kt), from which the inactivation rate constant kinact and half-life t1/2 can be
determined. Other data are fitted to a line since no significant temperature inactivation is
observed. This experiment was performed by Y. Chen, Purdue University.

THERMAL MELT ANALYSIS USING CIRCULAR DICHROISM (CD)
Thermal melting analysis of wild-type PLP2 and V1613S mutant was carried out
with a Chirascan circular dichrosim (CD) spectrometer (Applied Photophysics) equipped
with a temperature control system (Quantum Northwest Inc.) by monitoring CD at
220nm while increasing the temperature at step interval 0.4°C and rate 0.5°C/min.
Protein sample was hold in a 10mm cell (Starna Cells) with magnetic stirring. Thermal
scan was performed with wild-type PLP2 or V1613S in three independent experiments.
The melting temperature (Tm) was calculated as the first derivative peak determined
using SigmaPlot. This experiment was performed by Y. Chen, Purdue University.

MOUSE STUDIES
C57BL/6 mice were purchased from The Jackson Laboratory. The mice were
maintained and performed at Loyola University Chicago in accordance with all federal
and university guidelines. 4-week old C57BL/6 male mice were anesthetized with
ketamine/xylazine prior to intracranial injection with 600 pfu of icMHV-A59 or AM2.
The body weight loss was monitored daily over time. The mice were humanely sacrificed
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when they have lost 25% of the initial body weight. The mice infected with AM2, and
age-matched controls were challenged with 6,000 pfu of icMHV-A59 9 weeks post
primary infection. The body weight loss was monitored daily over time. The mice were
humanely sacrificed when they have lost 25% of the initial body weight.

SARS-CoV ANTIVIRAL ACTIVITY ASSAY
VeroE6 cells in 96 well plates were infected with SARS-CoV Urbani strain
(provided by the Centers for Disease Control and Prevention) MOI of 10 or mock
infected with serum-free media. The plates were incubated for 1 hour at 37OC, 5% CO2.
After that time virus inoculum was removed and replaced with DMEM 2% FCS and
serial dilutions of antiviral compounds (from 40µM to 1.8µM). The cell viability was
determined after 48hours using The CellTiter-Glo Luminescent Cell Viability Assay
(Promega) according to manufacturer’s protocol. The experiments were performed in
triplicates. Work was performed in BSL-3 facility according to the BSL-3 protocol and
all liquid infectious waste was treated with bleach. All solid waste was autoclaved.

CHAPTER III
RESULTS

INVESTIGATING THE ABILITY OF SMALL MOLECULE PAPAIN-LIKE
PROTEASE SELECTIVE INHIBITORS TO BLOCK SARS-CoV REPLICATION
IN INFECTED CELLS

SARS-CoV is a highly pathogenic virus with 10% mortality. Thus far there are no
FDA approved antiviral drugs against SARS-CoV. Previous studies showed that the
papain-like protease (PLpro) from SARS-CoV is required for virus replication because it
cleaves viral polyprotein to generate replication complexes. Moreover, SARS-CoV
PLpro has a possible role in virus pathogenesis because of its reported deubiquitinating,
deISGylating and interferon antagonism activities. All these properties make SARS-CoV
PLpro a good target for small molecule inhibitors. Previous high-throughput screens
identified several compounds that had the ability to inhibit SARS-CoV replication with
micromolar EC50 values (Ghosh et al., 2010; Ratia et al., 2008). However, the potencies
of these PLpro inhibitors were not low enough to have a therapeutic potential. Thus
further optimization and structure-activity relationship (SAR) analysis based on crystal
structure, was performed to generate a new series of potent SARS-CoV PLpro inhibitors.
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My goal was to evaluate the newly designed compounds’ ability to inhibit SARSCoV replication in cell culture and determine their EC50 values. Out of over 30 new small
molecule inhibitors that were tested in vitro, I evaluated 10 drugs that had the lowest IC50
values ranging from 0.2 to 12.7µM against purified enzyme. All experiments with SARSCoV were performed in the Biosafety Level 3 (BSL-3) laboratory according to approved
protocols. To determine the EC50 of tested compounds, I infected VeroE6 cells in 96 well
plates with SARS-CoV for one hour. After that time the media was replaced with media
containing serial dilutions of compounds. The plates were incubated for 48 hours and the
cells were lysed. The cells viability was determined using the CellTiter-Glo Luminescent
Cell Viability Assay (Promega). The data are summarized in the Table 7 and
representative cell viability graphs for two compounds are shown in Figure 7. I found that
several compounds with the highest IC50 values (>1.6 µM) did not show inhibitory
activity towards SARS-CoV replication in infected cells. In contrast, the compounds that
had IC50 lower that 1.0 µM were able to inhibit SARS-CoV replication. The determined
EC50 values for those compounds ranged from 14.45 µM for the least active inhibitor to
5.5 µM for the most active compound CCG 203 888. My results indicate that the SAR
analysis was very effective and that new compounds have improved potency. Moreover, I
found that IC50 value is a good indicator of the probable efficacy of the drug in infected
cells. Finally, I determined that compound CCG 203 888 is a very good candidate for
further optimization. Additionally, our collaborators found that this drug has relatively
low cytotoxicity suggesting that this small molecule inhibitor is worth further evaluation
and optimization (Báez-Santos et al., 2014).
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Figure 7. SARS-CoV PLpro inhibitor CCG 203 888 inhibits the replication of
SARS-CoV. VeroE6 cells were infected with SARS-CoV. After 1 hour incubation,
inoculum was replaced with media containing compound CCG203888 (A) or
CCG203494 (B) in serial dilution concentration. Cell viability was measured 48
hours post infection using CellTiter-Glo Luminescent Cell Viability Assay
(Promega). The error bars represent SD of triplicates within a single experiment. The
figure shows representative data from at least two independent experiments.
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Table 7. Potency of selected SARS-CoV inhibitors. The table shows IC50 values for
selected compounds. VeroE6 cells were infected with SARS-CoV for 1 hour and then
incubated in the presence of the serial dilutions of the drug. Cell viability was measured
48 hours post infection using CellTiter-Glo Luminescent Cell Viability Assay (Promega).
EC50 values were determined in triplicates in at least two independent experiments using
GraphPad Prism software. These data are published in (Báez-Santos et al., 2014).
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INVESTIGATING MULTIFUNCTIONALITY OF PAPAIN-LIKE PROTEASE
(PLpro) FROM A NOVEL CORONAVIRUS MIDDLE EAST RESPIRATORY
SYNDROME CORONAVIRUS (MERS-CoV)

MERS-CoV PLpro has deISGylating and deubiquitinating activities
MERS-CoV is a recently emerged coronavirus with about 45% mortality in
human population. Unfortunately there are no FDA approved antiviral drugs or vaccines
against this coronavirus. In order to facilitate the development of antiviral strategies I
evaluated whether a predicted papain-like protease (PLpro) domain from MERS-CoV is a
valuable target for protease inhibitors and vaccines.
MERS-CoV PLpro is encoded within nonstructural protein 3 (nsp3) of the
replicase polyprotein. To gain insight into the potential activity of MERS-CoV PLpro,
our collaborators at Purdue University used the high-resolution X-ray structure of SARSCoV PLpro in apo-enzyme form (PDB: 2Fe8, chain C) to generate a homology model of
MERS-CoV PLpro. The homology model displays several conserved structural features
between MERS-CoV and SARS-CoV PLpro; including the ubiquitin-like domain (UBL),
a catalytic triad consisting of C1594–H1761–D1776, and the ubiquitin-binding domain at
the zinc finger. To model ubiquitin (Ub) into the zinc finger of MERS-CoV PLpro, the
electron density of SARS-CoV PLpro in complex with Ub aldehyde (Ubal) for
refinement and energy minimization of the model in complex with Ub was used. The
model displays a nearly perfect fit of the Ub moiety in the zinc finger with orienting Ub
C-terminal extension towards the enzymes subsites and catalytic triad (Figure 8).
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Figure 8. Modeling MERS-CoV PLpro onto the SARS-CoV PLpro-ubiquitinaldehyde structure. Homology model of MERS-CoV PLpro (blue cartoon and gray
surface) aligns with the overall structural architecture found in SARS-CoV PLproUbiquitin-aldehyde complex PDB:4MM3 (beige cartoon), including the ubiquitin
binding domain at the zinc finger and the extended Ub-like (Ubl) domain. Ubiquitin
(red) modeled into the zinc finger domain of MERS-CoV PLpro, with its C-terminus
reaching the active site. An enlargement of predicted MERS-CoV PLpro active site
superimposed onto the SARS-CoV PLpro active site suggests that the MERS-CoV
PLpro catalytic triad is composed of C1594–H1761–D1776 and the putative
oxyanion hole residue is L1590 (Mielech et al., 2014).
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From this model, I hypothesized that the PLpro domain from MERS-CoV, like SARSCoV is a multifunctional enzyme with protease, deubiquitinating and deISGylating
activity.
To determine if PLpro from recently emerged MERS-CoV is a multifunctional
enzyme I designed a codon-optimized synthetic construct to express wild-type PLpro.
The synthetic MERS-PLpro extends from amino acids 1485 to 1802 of ORF1a, with the
addition of 2 amino acids at the N-terminus to allow efficient translation (methionine and
alanine) and a V5 epitope tag on the C-terminus (Figure 9A). Using Gibson Assembly
technique (New England Biolabs) I generated a catalyctic mutant where the predicted
calatytic cysteine C1594 (PLproCA) residue is mutated to alanine. Cysteine 1594 is
predicted to be the active site cysteine nucleophile that attacks the substrate peptide bond
and mutation to alanine should significantly reduce or abolish enzymatic activity (Figure
8). First, I tested the protease activity of MERS-CoV PLpro using transcleavge assay.
HEK293T cells were transfected with plasmids expressing increasing doses of MERSCoV wild-type PLpro, or PLproCA, along with a plasmid DNA expressing the SARSCoV nsp2-3-GFP substrate. The nsp 2-3-GFP substrate is commonly used to assess the
cleavage ability of transiently expressed CoV PLPs. I detected evidence of processing of
the nsp2-3-GFP substrate in the presence of the catalytically active form of MERSPLpro, but not in the presence of the catalytic mutant MERS-PLpro (Figure 9B). These
data confirm that the putative PLP domain located within nsp3 of the MERS-CoV
genome indeed functions as a PLP capable of cleaving LXGG-containing polyprotein
substrates. These data have been described in (Kilianski, Mielech, Deng, & Baker, 2013).
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Figure 9. Proteolytic activity of MERS-CoV PLpro. A) Schematic diagram of MERSCoV ORFs and the papain-like protease (PLpro) domain within nonstructural protein 3
(nsp3). Expression plasmid pcDNA-MERS-PLpro (amino acids 1485-1802) and the
predicted catalytic cysteine residue 1594 are indicated. B) To determine protease activity
HE293T cells were transfected with nsp2/nsp3-GFP plasmid and plasmids expressing
wild-type (WT) or catalytic mutant (CA) MERS-CoV PLpro. Cell lysates were analyzed
by western blot 24 hours post-transfection. Figure shows representative data from at least
two independent experiments (Kilianski, Mielech, Deng, & Baker, 2013; Mielech et al.,
2014).
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To assess the DUB activity of MERS-CoV PLpro, I transfected HEK293T cells
with plasmid expressing Flag-Ub and increasing amounts of wild-type PLpro or
PLproCA. I harvested cell lysates at 18 hours post-transfection to evaluate the presence
of ubiquitinated proteins using western blot. I determined that wild-type PLpro can
deubiquitinate multiple cellular substrates, and that PLpro catalytic activity is required for
DUB activity (Figure 10B). This DUB activity is also observed with expression of
SARS-CoV PLpro, consistent with previous reports (Barretto et al., 2005; Frieman et al.,
2009; Lindner et al., 2005, 2007; Ratia et al., 2006). In these experiments, I noticed the
difference in the expression levels of SARS-CoV and MERS-CoV PLpros in transfected
cells, which may be due to differences in codon optimization in the MERS-CoV PLpro
construct. Further in vitro studies using purified enzymes are needed to determine the
relative kinetics of SARS-CoV and MERS-CoV PLpro DUB and deISGylating activities.
To determine the deISGylating activity of MERS-CoV PLpro, HEK293T cells
were transfected with c-myc-ISG15 plasmid, ISG15 conjugation machinery, and
increasing amounts of plasmids expressing MERS-CoV PLpro wild-type and catalytic
mutant C1594A (PLproCA). In addition, the cells were transfected with plasmids
expressing SARS-CoV PLpro wild-type or catalytic mutant (C1651A). 20 hours posttransfection cell lysates were evaluated for the presence of ISGylated proteins. Both
MERS-CoV and SARS-CoV PLpro can deconjugate ISG15 from multiple cellular
substrates in a dose-dependent manner. In contrast, PLpro catalytic mutants did not
deconjugate ISG15, indicating that catalytic activity of PLpro is required for its
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Figure 10. Enzymatic activities of SARS-CoV PLpro and MERS-CoV PLpro. A)
DeISGylating activity of SARS-CoV PLpro and MERS-CoV PLpro. HEK293T cells
were transfected with myc-ISG15, E1, E2, E3 ISGylating machinery plasmids, and wildtype (WT) or catalytic mutant (CA) PLpro expression plasmids. At 18 hours post
transfection, cells were lysed and analyzed by Western blotting. B) Deubiquitinating
activity of SARS-CoV PLpro and MERS-CoV PLpro. HEK293T cells were transfected
with Flag-Ub expression plasmid, and wild type (WT) or catalytic mutant (CA) PLpro.
Cells were lysed 18 hours post transfection and analyzed by Western blotting. Figure
shows representative data from at least two independent experiments (Mielech et al.,
2014).
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deISGylating activity (Figure 10A). Thus, MERS-CoV PLpro like SARS-CoV PLpro
(Lindner et al., 2007) has deISGylating activity.
Taken together, my data indicate that MERS-CoV PLpro is a potent deISGylating
enzyme that also exhibits DUB activity and that both activities require cysteine 1594 for
catalysis, likely in the context of the predicted catalytic triad (Figure 8).
MERS-CoV PLpro is an interferon antagonist
Coronavirus PLPs have been shown to block interferon β (IFNβ) induction in
transfected cells (Clementz et al., 2010; Devaraj et al., 2007; Frieman et al., 2009). In
addition, the deubiquitinase function of an arterivirus PLP has been shown to have a role
in interferon antagonism during virus infection (van Kasteren et al., 2013). Therefore, I
assessed the ability of MERS-CoV PLpro to antagonize interferon production. First, I
addressed if MERS-CoV PLpro can inhibit MDA5 induced IFNβ reporter, since MDA5
has been implicated in recognition of coronaviruses during virus infection (Zust et al.,
2011). I transfected HEK293T cells with plasmids expressing IFN-β-luciferase, Renilla
luciferase, pEF-BOS-MDA5 (Rothenfusser et al., 2005) and increasing amounts of wildtype PLpro or PLproCA. At 16 hours post-transfection I assessed luciferase reporter
activity. I determined that MERS-CoV PLpro can potently inhibit MDA5 mediated
induction of IFNβ in a dose-dependent manner and that catalytic activity of MERS-CoV
PLpro is required for IFNβ antagonism (Figure 11A). Using overexpression of an active
form of RIG-I, I determined that MERS-CoV PLpro can also inhibit N-RIG-I induced
IFNβ reporter. Similarly to the experiment with MDA5 stimulation, the catalytic activity
of MERS-CoV PLpro is necessary for IFNβ antagonism upon N-RIG-I stimulation
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Figure 11. Interferon antagonism activity of MERS-CoV PLpro. HEK293T cells
were transfected with plasmids expressing wild-type (WT) or catalytic mutant PLpro
(CA), plasmids expressing IFNβ-luc (A, B, and C), or NF-κB-luc (D), Renilla-luc, and
the stimulator indicated at the top of the figure. For A-C, at 16 hours post-transfection,
cells were lysed and luciferase activity was measured. For D, at 10 hours posttransfection cells were treated with TFNα for 4 hours, lysed and luciferase activity was
measured. Experiments were performed in triplicate. Error bars represent standard
deviation of the mean (Mielech et al., 2014).
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(Figure 11B). Upon recognition of viral RNA by pattern recognition receptors (PRRs)
such as MDA5 or RIG-I the signal is transmitted downstream via mitochondrial antiviral
signaling protein (MAVS). Thus, I tested if PLpro is able to inhibit MAVS induced IFNβ
reporter. To stimulate the IFNβ reporter, I overexpressed pEF-BOS-MAVS in HEK293T
cells, co-expressed reporters, and either the wild-type PLpro or PLproCA. I found that
PLpro, but not PLproCA inhibits MAVS induced IFNβ reporter (Figure 11C).
In addition, experiment performed by Andy Kilianski, tested the ability of MERSCoV PLpro to inhibit NF-κB reporter activity as observed with SARS-CoV PLpro.
HEK293T cells were transfected with plasmids expressing NF-κB luciferase, Renilla
luciferase, and MERS-CoV wild-type PLpro or PLproCA, treated cells with TNFα to
activate the NF-κB pathway, and harvested cell lysates at 4 hours post-treatment to assess
luciferase activity. Wild-type PLpro reduced induction of NF-κB reporter in a dosedependent manner and the catalytic cysteine residue is required for this activity (Figure
11D). Taken together these results indicate that MERS-CoV PLpro is an interferon
antagonist and that catalytic activity is required for the antagonism. In addition, PLpro
can reduce TNFα-mediated induction of NF-κB reporter activity and catalytic activity is
also required.

MERS-CoV PLpro and SARS-CoV PLpro inhibit expression of proinflammatory
cytokines.
To further investigate the role of coronavirus PLpros in inhibiting innate immune
responses I tested the effect of MERS-CoV PLpro on the expression of endogenous
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cytokines. First, using the Human Innate & Adaptive Immune Responses PCR Array
(SABiosciences) I determined that in HEK293T cells CCL5 (RANTES), IFNβ, and
CXCL10 (IP-10) mRNA levels are upregulated more than 20-fold upon MDA5
stimulation and therefore selected these genes for further analysis. To determine the
effect MERS-CoV PLpro and SARS-CoV PLpro on cytokine expression, I performed
qRT-PCR to measure mRNA levels encoding CCL5, IFNβ, and CXCL10 levels in the
presence of CoV PLpros. HEK293T cells were transfected with pEF-BOS-MDA5, and
wild-type or catalytic mutants of MERS-CoV or SARS-CoV PLpros. At 18 hours posttransfection the total RNA was extracted and qRT-PCR was performed. I found that both
MERS-CoV and SARS-CoV PLpro can potently inhibit (over 3-fold reduction)
expression of CCL5 upon MDA5 stimulation and that catalytic activity is required for
this inhibition (Figure 12A). In agreement with the results from luciferase reporter
assays, I observed that expression of IFNβ in MDA5 stimulated cells is inhibited in the
presence of wild-type MERS-CoV PLpro and SARS-CoV PLpro (Figure 12B). CXCL10
mRNA levels were also significantly reduced (p<0.0005) when wild-type, but not
catalytic mutant versions of MERS-CoV PLpro and SARS-CoV PLpro were expressed
(Figure 12C). These findings show for the first time that both MERS-CoV PLpro and
SARS-CoV PLpro can reduce induction of endogenous proinflammatory cytokines in
cells, and that the mechanism requires catalytic activity.
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Figure 12. Proinflammatory cytokine expression in the presence of SARS-CoV
PLpro or MERS-CoV PLpro. HEK293T cells were transfected with plasmids
expressing MDA5 and wild-type (WT) or catalytic mutants (CA) of MERS-CoV PLpro
or SARS-CoV PLpro. At 18 hours post-transfection, cells were lysed and mRNA levels
of CCL5, IFNβ and CXCL10 were determined using qRT-PCR. Data represents fold
increase of mRNA levels compared to unstimulated cells (2^-ΔΔCt). The figure shows the
results from representative experiments performed in triplicates and are shown as means,
error bars represent SEM. Experiments were performed in duplicate. * p<0.0005,
**p<0.001, ***p<0.01(Mielech et al., 2014).
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INVESTIGATING MULTIFUNCTIONALITY OF PREDICTED PAPAIN-LIKE
PROTEASE (PLP) DOMAINS FROM SELECTED ALPHA AND
BETACORONAVIRUSES

Generating expression constructs of HCoV-HKU1, HCoV-OC43, HCoV-229E, and
FIPV PLPs
To investigate whether PLP multifunctionality is a conserved feature among
coronaviruses I wanted to test the activities of PLPs from selected alpha and
betcoronaviruses. Particularly, I tested PLPs from HCoV-HKU1, HCoV-OC43, HCoV229E, and feline coronavirus Feline Infectious Peritonitis Virus (FIPV). All mentioned
coronaviruses contain two predicted PLP domains within their genome. PLP2 domains
were used to design expression constructs because PLP2, not PLP1, domains from
HCoV-NL63 and MHV, as well as SARS-CoV and MERS-CoV PLpors, are
multifunctional enzymes. In addition, PLP2 domains have higher similarity to PLpros
than PLP1 domains. The PLPs sequences were predicted based on sequences of SARSCoV and MERS-CoV PLpros. The goal was to keep the predicted catalytic residues and
extend the constructs so they include possible N-terminal ubiquitin-like (UBL) domains.
The full lengths of the constructs were determined by counting the amino acids following
predicted catalytic aspartic acid residue at the C-terminal end the constructs. Next, the
synthetic expression constructs of putative PLPs with in frame V5 epitope tags were
synthesized by Genscript. Further, I used site-directed mutagenesis and Gibson Assembly
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Technique to generate catalytic mutants of predicted catalytic cysteine residues of all
constructs. The successful mutagenesis was confirmed by sequencing.

HCoV-HKU1, HCoV-OC43, HCoV-229E, and FIPV PLPs are multifunctional
enzymes
To determine the catalytic activity of HCoV-HKU1, HCoV-OC43, HCoV-229E,
and FIPV PLPs Andy Kilianski from our laboratory performed transcleavage assay and
found that all PLP2s can cleave SARS-CoV PLpro substrate nsp2/nsp3-GFP in
transfected cells in catalytic dependent manner presumably by the recognition of
conserved LXGG motif (Kilianski, dissertation). In addition, to test the catalytic activity
of these PLP2s I used end-point pGLO assay described by our group previously.
HEK293T cells were transfected with plasmid expressing pGLO substrate (pGLORLKGG) recognized by the PLP2, Renilla-luciferase, wild-type PLP2s, PLP2s catalytic
mutants, and SARS-CoV PLpro or SARS-CoV PLpro catalytic mutant as a control. 18
hours post-transfection cells were lysed and luciferase activity was measured. I
determined that all PLPs are capable of cleaving of the pGLO substrate with LKGG motif
(Figure 13). Interestingly, none of the PLP2s was as efficient at the cleavage as SARSCoV PLpro. In addition, expression of HCoV-229E PLP2 and HCoV-OC43 PLP2 led to
only small but statistically significant increase in luciferase activity over mock. These
data suggest that HCoV-HKU1, HCoV-OC43, HCoV-229E, and FIPV PLPs cleave
LXGG motif. Further studies with species specific-substrates are needed to evaluate if
there are in fact quantitative differences in catalytic activities of those PLP2s.
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Figure 13. Proteolytic activity of HCoV-HKU1, HCoV-OC43, HCoV-229E, and
FIPV PLPs . HEK293T cells were transfected with pGLO-RLKGG plasmid and either
wild-type (WT) or catalytic mutant (CA) of indicated PLPs. At 18 hours post-transfection
cells were lysed and luciferase activity was determined using Dual Luciferase Assay.
Experiments were performed in triplicate. Error bars represent standard deviation. The
figure shows representative data from two independent experiments.
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Next, I determined if HCoV-HKU1, HCoV-OC43, HCoV-229E, and FIPV PLPs
have DUB activity by transfecting HEK293T cells with plasmids expressing PLP2s, their
corresponding catalytic mutants and Flag-Ub. As a control for DUB assay, I used SARSCoV PLpro and HCoV-NL62 PLP2 which are well characterized DUBs. Upon western
blot analysis I found that, even though there is less than 10% identity between tested
PLPs, the DUB activity is a conserved PLpro and PLP2 function (Figure 14). All tested
PLP2s showed DUB activity in a dose dependent manner and catalytic activity is
required for their DUB activity. Overall my results suggest that PLPs’ multifunctionality
is conserved among alpha and betacoronaviruses.

EVALUATING THE ROLE OF PAPAIN-LIKE PROTEASE IN PATHOGENESIS

PART I: MHV-A59 NSP3 UBIQUITIN-LIKE DOMAIN IS REQUIRED FOR
PROTEIN STABILITY AND VIRUS PATHOGENESIS

Generating expression construct of MHV PLP2
SARS-CoV and MERS-CoV are human respiratory pathogens that require BSL-3
conditions for research. Other human coronavirus such as HCoV-NL63, HCoV-HKU1,
HCoV-OC43 and HCoV-229E replicate poorly in cell culture. To facilitate my research, I
used murine model coronavirus, mouse hepatitis virus (MHV) in order to evaluate the

74

Figure 14. Deubiquitinating activity of HCoV-HKU1, HCoV-OC43, HCoV-229E,
and FIPV PLPs . HEK293T cells were transfected with Flag-Ub expression plasmid,
and wild-type (WT) or catalytic mutant (CA) PLP2 or PLpro. Cells were lysed 18 hours
post-transfection and analyzed by western blotting. (A) HCoV-OC43 PLP2, (B) HCoV229E PLP2, (C) HCoV-HKU1 PLP2, (D) FIPV PLP2, (E) SARS-CoV PLpro, (F) HCoVNL63 PLP2. Figure shows representative data from two independent experiments.
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pathogenesis of the mutants affecting papain-like protease. First, I had to determine if
similar to other coronaviruses, MHV papain-like protease (PLP) is a multifunctional
enzyme.
MHV encodes two PLP domains in its genome. PLP1 is required for the cleavage
of the polyprotein between nsp1/nsp2 and nsp2/nsp3. PLP2 has more sequence similarity
to SARS-CoV and MERS-CoV PLpro as it cleaves polyprotein at the nsp3/nsp4 junction
by the recognition of the LXGG motif (Kanjanahaluethai & Baker, 2000) . For those
reasons I focused my research on PLP2 domain. I designed a PLP2 construct with in
frame V5 epitope tag extending from amino acids 1611 to 1970 of the MHV-A59
genome. The construct was codon optimized; splice sites were removed, and synthesized
by Genscript. I cloned the construct into a pCAGGS-MCS vector to facilitate the
expression of protein in mammalian cells (PLP2-A). Next, I used site-directed
mutagenesis to mutate predicted catalytic cysteine residue (C1716) to alanine to generate
the catalytic mutant (PLP2-A CA).
MHV PLP2 is a protease and deubiquitinase
To determine if MHV PLP2 is a multifunctional enzyme I tested its protease,
deubiquitinase and interferon antagonism activities. To determine proteolytic activity of
MHV PLP2, I transfected HEK293T cells with PLP2-A and PLP2-A CA in the presence
plasmid expressing SARS-CoV nsp2/nsp2-GFP substrate which contains the LXGG
sequence recognized by the protease during virus infection. The GFP tag allows for the
detection of the substrate and the cleavage product using western blot. I determined that
wild-type PLP2 has the ability to cleave the nsp2/nsp3 substrate (Figure 15A). In
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Figure 15. Enzymatic activities of MHV PLP2. (A) To determine protease activity
HE293T cells were transfected with nsp2/nsp3-GFP plasmid and plasmids expressing
wild-type (WT PLP2-A) or catalytic mutant (C1716A) PLP2. Cell lysates were analyzed
by western blot 24 hours post-transfection. (B) HEK293T cells were transfected with
Flag-Ub expression plasmid, and wild-type (WT PLP2-A) or catalytic mutant (C1716A)
PLP2 Cells were lysed 18 hours post-transfection and analyzed by western blot. Figure
shows representative data from at least two independent experiments.
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addition, catalytic activity of this protein is required for the cleavage as the catalytic
mutant failed to cleave to substrate.
Since MHV PLP2 recognizes LXGG, next I tested if it can remove ubiquitin
molecules in transfected cells similar to cellular DUBs that recognize the RLRGG motif.
I transfected HEK293T cells with plasmids expressing PLP2-A or PLP2-A CA, and the
plasmid expressing Flag-Ub. 20 hours post-infection I lysed the cells and determined the
levels of ubiquitinated proteins by western blot. I found that MHV PLP2 is a potent
deubiquitinase since the levels of ubiquitinated proteins were significantly reduced upon
expression of wild-type PLP2-A (Figure 15B). In contrast, the expression of catalytic
mutant resulted in no change in ubquitinated proteins compared to cells transfected with
the plasmid expressing Flag-Ub alone, supporting the multifunctionality of MHV PLP2.

MHV PLP2 is an interferon antagonist
To further evaluate MHV PLP2 multifunctionality, I determined if MHV PLP2
can act as an interferon antagonist using luciferase assay. First, I tested if MHV PLP2 can
inhibit a broad IFN induction signal generated by infecting the cells with a known IFN
inducer Sendai virus (SV). HEK293T cells were transfected with increasing doses of
PLP2-A or PLP2-A CA, plasmids expressing IFN-β-luciferase and Renilla luciferase. At
4 hours post-transfection cells were infected with SV, and 6 hours post-infection the cells
were lysed and luciferase activity was determined. As predicted, infection with SV led to
the induction of IFN-β promoter. The MHV PLP2 was able to inhibit this induction in
dose dependent manner and its catalytic activity is required for IFNβ antagonism (Figure
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16A). Next, I determined if MHV PLP2 can block IFN induction upon stimulation by
overexpression of specific pattern recognition receptors (PRR) such as active form of
RIG-I (N-RIG-I) and MDA5. I found that MHV PLP2 can inhibit IFN induction in both
cases. MHV PLP2 inhibits RIG-I induced IFN in a dose dependent manner and catalytic
activity is required MHV PLP2 IFN antagonism (Figure 16B). PLP2 can also potently
inhibit MDA5 induced IFN; however, in this case the catalytic activity of the protein is
not required (Figure 16C). Expression of the PLP2-A CA reduced induction of IFN upon
MDA5 stimulation but not to the same level as wild-type protein which suggests the
existence of catalytic independent mechanism of inhibition of IFN activation upon
MDA5 stimulation.
To evaluate at which step in innate immune signaling cascade PLP2 might work
as antagonist, I performed luciferase assay using MAVS overexpression as a stimulator.
MAVS is an adaptor protein that functions downstream of RIG-I and MDA5, and
transmits the signal to activate expression of proinflammatory cytokines and chemokines.
I found that MHV PLP2 inhibits IFN induction upon MAVS stimulation in a dose
dependent manner and that catalytic activity is not required for antagonism (Figure 16D).
These data suggest that MHV PLP2 inhibits IFN activation downstream of MAVS in the
signaling cascade.
In addition, to evaluate the IFNβ promoter activation, I tested if MHV PLP2 can
inhibit interferon stimulated response element (ISRE) and specific NF-κB activation. To
determine if MHV PLP2 blocks ISRE activation, I transfected HEK293T cells with
plasmids expressing ISRE luciferase, Renilla luciferase, N-RIG-I, and PLP2-A
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Figure 16. Interferon antagonism activity of MHV PLP2. HEK293T cells were
transfected with plasmids expressing wild-type (WT) or catalytic mutant PLP2 (CA),
plasmids expressing IFNβ-luc, Renilla-luc, and the stimulator is indicated at the top of
the figure. At 16 hours post-transfection, cells were lysed and luciferase activity was
measured. Experiments were performed in triplicate. Error bars represent standard
deviation. The figure shows data from at least two independent experiments.
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Figure 17. Interferon antagonism activity of MHV PLP2. HEK293T cells were
transfected with plasmids expressing wild-type (WT) or catalytic mutant PLP2 (CA),
plasmids expressing ISRE-luc (A), NF-κB-luc (B), and Renilla-luc. (A) Cells were
stimulated by overexpression of N-RIG-I. At 16 hours post-transfection, cells were lysed
and luciferase activity was measured. (B) 10 hours post-transfection cells were treated
with TFNα for 4 hours, lysed and luciferase activity was measured Experiments were
performed in triplicate. Error bars represent standard deviation. The figure shows
representative data from at least two independent experiments.
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wild-type or CA. When luciferase activity was assessed 16 hours post-transfection, I
found that MHV PLP2 can inhibit induction of ISRE, and that catalytic activity of MHV
PLP2 is required for this inhibition (Figure 17A). To test if MHV PLP2 can inhibit NFκB activation, HEK293T cells were transfected with plasmids expressing NF-κB
luciferase, Renilla luciferase, and PLP2-A wild-type or CA, treated cells with TNFα to
activate the NF-κB pathway, and at 4 hours post-treatment cell lysates were harvested to
assess luciferase activity. Wild-type PLP2 reduced induction of NF-κB reporter in a
dose-dependent manner and catalytic cysteine residue is required for this activity (Figure
17B).
To determine if MHV PLP2 can inhibit induction of endogenous proinflammatory
cytokines and chemokines I used qRT-PCR. First, I investigated the effect of MHV PLP2
on the expression of IFNβ. I transfected HEK293T cells with PLP2-A or PLP2-A CA and
N-RIG-I expression plasmid. Using qRT-PCR I determined the levels of IFNβ mRNA in
transfected cells. I found that MHV PLP2 can reduce endogenous IFNβ levels in
catalytic dependent manner (Figure 18A). Further, I used Human Innate & Adaptive
Immune Responses PCR Array (SABiosciences) to determine which, other than IFNβ,
genes expression is inhibited in the presence of MHV PLP2 upon RIG-I and MDA5
overexpression. I found that upon N-RIG-I stimulation 9 genes were upregulated over 4
fold, compared to mock transfected cells, including: CCL5, CXCL10, DDX58, IFNβ,
IL8, IRF7, MX1, STAT1, and TLR3 (Figure 18B). MHV PLP2 was able to reduce the
levels of expression of all those genes. In contrast, overexpression of MDA5 led to
upregulation of only 4 genes in array: CCL5, CXCL10, DDX58, and IFNβ (Figure 18C).
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Figure 18. Interferon antagonism activity of MHV PLP2. HEK293T cells were
transfected with plasmids expressing wild-type PLP2 (WT) and N-RIG-I, or Mda5 as
stimulator. At 16 hours post-transfection cells were lysed and total RNA was isolated.
(A) qRT-PCR for IFNβ was performed. Data are normalized to RPL13A expression
levels. Experiments were performed in triplicate. Error bars represent standard deviation.
(B and C) qRT-PCR for human Innate and Adaptive Immune response (SABiosciences)
was performed. Data are presented as fold change over non-stimulated cells. The figure
shows data from two independent experiments.
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Similar to the results with N-RIG-I overexpression, PLP2 expression reduced mRNA
levels of all those cytokines and chemokines (Figures 18B and 18C). Taken together my
data suggest that MHV PLP2 is an interferon antagonist. Those results and the
observation that MHV PLP2 is a multifunctional enzyme with protease and
deubiquitinase activities allowed me to use MHV PLP2 as a model for other coronavirus
PLPs in further studies.

PLP2 deletion analysis and mutagenesis
To determine the minimal domain of MHV PLP2 required for multifunctionality
of the enzyme I performed deletion analysis of MHV PLP2-A construct (Figure 19).
Using overlapping PCR and subsequent cloning I generated N-terminal and C-terminal
19 amino acid truncations of the PLP2 (termed Δ1-Δ9) keeping catalytic residues intact.
All introduced mutations were confirmed by sequencing. The mutants were tested for
their ability to cleave a polyprotein substrate using the transleavage assay, and for their
ability to antagonize innate immune response using the luciferase assay.
To test catalytic activity of the mutants I transfected HEK293T cells with
plasmids expressing wild-type PLP2 (PLP2-A), PLP2-A CA, or various PLP2 mutants
along with a plasmid expressing the SARS-CoV nsp2-3-GFP substrate. The presence of
the cleavage product was not detected for the mutants Δ4, Δ5, and Δ6, suggesting that
those residues are absolutely required for PLP2 protease activity. Mutants Δ1-Δ3 had
reduced protease activity compared to wild-type PLP2. In contrast mutants Δ7-Δ9
showed similar catalytic activity to wild-type proteins suggesting that those residues are
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Figure 19. Schematic diagram of MHV PLP2. Diagram of MHV ORFs and the papainlike protease (PLP2) domain within nonstructural protein 3 (nsp3). Expression plasmid
pCAGGS-MHV PLP2-A (amino acids 1611-1970) and PLP2-B (amino acids 15251911), and the predicted catalytic cysteine residue 1716 are indicated.
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dispensable for PLP2 protease activity (Figure 20A). Following, I determined the ability
of deletion mutants to antagonize IFNβ induction. I transfected HEK293T cells with
increasing doses of PLP2-A or PLP2-A CA, or various PLP2 deletion mutants, and
plasmids expressing IFNβ-luciferase, Renilla luciferase, and N-RIG-I as a stimulator. I
determined luciferase activity 16 hours post-transfection. Since mutants 47-Δ6 did not
show proteolytic activity I did not test those mutants in the luciferase assay. I found that
the ability of deletion mutants to antagonize interferon induction correlated well with
their proteolytic activity. The Δ7-Δ9 mutants which had intact catalytic activity
efficiently inhibited IFN induction upon N-RIG-I stimulation, whereas Δ1-Δ3 mutants
have lost the ability to antagonize induction of IFN (Figure 20B).
Because mutant Δ1 have reduced protease activity I wanted to evaluate whether
all amino acids from this region were required for the protease activity. To do that I
generated N-terminal 4 amino acid truncations of the PLP2-A construct (termed Δ1-A –
Δ1-D). I also mutated all charged residues within Δ1 region to alanine to determine if
those residues are required for PLP2 activities (D1612A, D1618A, R1623A, and
E1629A). To evaluate these deletion mutants I performed the transcleavage assay and
luciferase assay as described above. I found that all deletion mutants Δ1-A to Δ1-D had
decreased proteolytic activity and lost the ability to block induction of interferon
suggesting that 4 amino acids at the N-terminal of PLP2 construct are required for both
efficient processing of the substrate as well as PLP2’s ability to act as an IFN antagonist
(Figures 21A-C). Interestingly, charged residues within 20 N-terminal amino acids are
also not required for PLP2 catalytic activity and IFN antagonism. The alanine mutants
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Figure 20. Activities of MHV PLP2 deletion mutants. (A) To determine protease
activity HE293T cells were transfected with nsp2/nsp3-GFP plasmid and plasmids
expressing wild-type (WT PLP2-A) or catalytic mutant (C1716A), or indicated PLP2
mutants. Cell lysates were analyzed by western blot 24 hours post-transfection (B)
HEK293T cells were transfected with plasmids expressing wild-type (WT) or catalytic
mutant PLP2 (CA), or indicated PLP2 mutants, plasmids expressing IFNβ-luc, Renillaluc, and N-RIG-I. At 16 hours post-transfection, cells were lysed and luciferase activity
was measured. Experiments were performed in triplicate. Error bars represent standard
deviation. The figure shows data from two independent experiments.
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Figure 21. Activities of MHV PLP2 mutants. (A) To determine protease activity
HE293T cells were transfected with nsp2/nsp3-GFP plasmid and plasmids expressing
wild-type (WT PLP2-A) or catalytic mutant (C1716A), or indicated PLP2 mutants. Cell
lysates were analyzed by western blot 24 hours post-transfection (B) HEK293T cells
were transfected with plasmids expressing wild-type (WT) or catalytic mutant PLP2
(CA), or indicated PLP2 mutants, plasmids expressing IFNβ-luc, Renilla-luc, and N-RIGI. At 16 hours post-transfection, cells were lysed and luciferase activity was measured.
Experiments were performed in triplicate. Error bars represent standard deviation. The
figure shows data from two independent experiments.
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D1612A, D1618A, R1623A, and E1629A had catalytic activity and were able to block
induction of IFN to the same levels as wild-type PLP2. Taken together these data suggest
that 4 N-terminal amino acids of the PLP2 are critical for PLP2 proteolytic activity and
IFN antagonism (Figures 21A-C).
MHV PLP2 crystal structure revealed that 60 N-terminal amino acids make
ubiquitin-like domain (UBL). This fold is conserved between SARS-CoV PLpro and
MHV PLP2 (Figure 22). To evaluate if the N-terminal region of PLP2 UBL is truly
required for the PLP2 activities, and to determine if the effects that I observe are not due
to overall misfolding, since those are 4 N-terminal residues of the protein, I generated a
new PLP2 construct termed PLP2-B (Figure 19). I decided to extend the construct at the
N-terminus by including residues from MHV-A59 genome, and also to shorten the Cterminus since I saw no change in PLP2 activities for Δ7 construct. The new construct
extended from amino acid 1525 to 1911 of MHV-A59 genome with in frame V5 epitope
tag, and it was codon optimized, splice sites removed, and synthesized by Genscript. I
cloned the ORF into the mammalian expression plasmid pCAGGS-MCS. Next, I
generated the catalytic mutant in which the catalytic cysteine C1716 was mutated to
alanine (PLP2-B CA).
Next, to determine protease activity of the new PLP2 construct I transfected
HEK293T cells with plasmid expressing nsp2/nsp3-GFP, and plasmids expressing either
wild-type PLP2-B, catalytic mutant PLP2-B CA (C1716A), or PLP2-A. 24 hours posttransfection cells were lysed and analyzed by western blot. I found that wild-type PLP2-B
is efficiently cleaving the substrate with comparable activity to PLP2-A, whereas the
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Figure 22. Alignment of SARS-CoV PLpro and MHV PLP2 UBL domains. A)
Linear alignment of SARS-CoV, MERS-CoV, and MHV PLP2 UBL domains. V1613 is
indicated by arrow B) Alignment of crystal structures of SARS-CoV PLpro UBL (beige)
and MHV PLP2 UBL (purple). The alignments were generated by Y. Chen, Purdue
University.

90

catalytic mutant PLP2-B CA lost the ability to cleave nsp2/nsp3-GPF substrate (Figure
23A). The new construct upon expression showed ability to antagonize IFN induction to
the same extent as PLP2-A (Figures 23 C-D). Further, I tested the ability if new PLP2-B
construct had DUB activity. To validate that I transfected HEK293T cells with plasmids
expressing Flag-Ub, and wild-type PLP2 (PLP2-B), PLP2-B CA. Using western blot
analysis I determine the levels of ubiquitinated proteins in transfected cells. I found that
wild-type PLP2-B is efficient DUB and that catalytic activity of the protein is required
for DUB activity (Figure 23B).
With the knowledge that the new PLP2-B construct expresses multifunctional
PLP2 I performed deletion analysis and mutagenesis of 4 amino acid (1611-1614,
VDVL) span within PLP2 UBL domain. To do that I generated 4 amino acid deletion
(VDVL 1611-1614, and termed the construct PLP2-B2), quadruple mutant of VDVL
region to SSSS (PLP-B3), and a set of double mutants where 2 amino acids of VDVL
region were mutated to serine (termed PLP2-B4 to PLP2-B7) (see Table 8 for the
reference). I also made single mutants: V1611S, D1612K, and V1613S. All mutations
were confirmed by sequencing.
To determine the effect of the mutations on the PLP2 multifuctionality, I tested
the mutants using transcleavge assay to determine proteolytic activity, luciferase assay to
determine the mutants ability to act as IFN antagonists, and DUB assay to determine their
DUB activity. The experiments were performed as described above. I found that all
mutants had reduced but detectable proteolytic activity compared to wild-type PLP2
(Figures 24A-B). In addition, all of the mutants had decreased DUB activity and lost the
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Figure 23. Activities of MHV PLP2-B construct. (A and B) To determine protease and
DUB activity HEK293T cells were transfected with nsp2/nsp3-GFP plasmid (A) or FlagUb expression plasmid (B) and plasmids expressing wild-type (WT PLP2-A or PLP2-B),
or catalytic mutant (CA), or indicated PLP2-B mutants. Cell lysates were analyzed by
western blot. (C, D) HEK293T cells were transfected with plasmids expressing wild-type
(WT) or catalytic mutant PLpro (CA), or PLP2-B mutants, plasmids expressing IFNβluc, Renilla-luc, and N-RIG-I (C), or MDA5 (D). At 16 hours post-transfection, cells
were lysed and luciferase activity was measured. Experiments were performed in
triplicate. Error bars represent standard deviation. The figure shows data from two
independent experiments.

92

Figure 24. Activities of MHV PLP2-B UBL mutants. (A) To determine protease
activity HE293T cells were transfected with nsp2/nsp3-GFP plasmid and plasmids
expressing wild-type (WT PLP2-A or PLP2-B), or catalytic mutant (CA), or indicated
PLP2-B mutants. Cell lysates were analyzed by western blot 24 hours post-transfection.
(B) HEK293T cells were transfected with Flag-Ub expression plasmid, and wild-type
(WT PLP2-B) or catalytic mutant (C1716A) PLP2, or indicated PLP2-B mutants. Cells
were lysed 18 hours post-transfection and analyzed by western blot. The figure shows
representative data from at least two independent experiments.
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Figure 25. Interferon antagonism activity of MHV PLP2-B UBL mutants. HEK293T
cells were transfected with plasmids expressing wild type (WT) or catalytic mutant PLP2
(CA), or indictaed PLP2-B mutants, plasmids expressing IFNβ-luc, Renilla-luc, and NRIG-I. At 16 hours post-transfection, cells were lysed and luciferase activity was
measured. Experiments were performed in triplicate. Error bars represent standard
deviation. The figure shows representative data from at least two independent
experiments.
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Table 8. Enzymatic activities of MHV PLP2 mutants.
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ability to inhibit induction of IFN (Figures 24C-D, and 25A-B). Overall, these results
suggest that VDVL region of PLP2 UBL domain is required for PLP2 activity.
Interestingly, this region is homologous among coronaviruses including SARS-CoV, and
specifically V1613 residue is highly conserved (Figure 22).

V1613S mutant virus is temperature sensitive
To determine the role of PLP2 UBL domain for virus replication and virus
pathogenesis I introduced 1611-1614 deletion or V1613S mutation into the infectious
clone MHV-A59 (icMHV-A59) using reverse genetics described by Yount and coworkers (Yount et al., 2002). First, using site-directed mutagenesis I engineered deletion
or point mutation within B fragment of icMHV-A59 genome. I sequenced the whole B
plasmid to make sure the construct contained only the desired deletion or point mutation.
Next, I digested plasmids that correspond to whole MHV-A59 genome with restriction
enzymes, and ligated to generate icMHV-A59 mutant genomes. Then, I performed in
vitro RNA transcription, electroporated RNA into BHK-R cells and applied the on the
monolayer of DBT cells. I monitored the cells for syncytia formation. I was able to
recover both viruses; however, syncytia in V1613S mutant (AM2) appeared within 24
hours post-electroporation (Figure 27A), whereas, for the 1611-1614 deletion mutant
(AM1), the syncytia appeared upon 5 days post-electroporation (Figure 26A). In addition,
AM1 virus generated very small plaques, it grew only to the titer of 1X103 (upon several
passages), and replicated poorly at 37OC (Figure 26B-C). Thus, in my further studies I
focused on V1613S mutant virus. I observed that when wild-type or AM2 virus is used in
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Figure 26. Generation of AM1 (VDVL/SSSS) virus. A) Syncytia present on BKH-R
and DBT cells 5 days upon RNA electroporation. B) Plaques assay results. DBT cells
were infected with AM1 or icMHV-A59. Cells were fixed and stained 48 hours postinfection. C) Growth kinetics of AM1 in comparison with wild-type virus. DBT cells
were infected with MOI 0.1 and virus titer was determined at the indicated time points by
plaque assay. The figure shows representative data from at least two independent
experiments.

97

Figure 27. Plaque Assay of DBT cells infected with icMHV-A59 or AM2 virus. A)
Syncytia present on BKH-R and DBT cells 5 days upon RNA electroporation. (B-D)
DBT cells were fixed and stained 48 hours post-infection. Figure shows plaque assay of
the supernatant performed at 37OC (B), 39.5OC (C), and 40.5OC (D). *p<0.05,
**p<0.001. Figure shows representative data from at least two independent experiments.
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plaque assay at 37OC, AM2 generates slightly smaller plaques that icMHV-A59 (Figure
27B). In contrast, when the plaques assay was performed at 39.5OC, AM2 virus generated
much smaller plaques (Figure 27C). Interestingly, when the plaque assay was performed
at 40.5OC the AM2 virus was not able to produce any plaques suggesting the replication
defect at higher temperature (Figure 27D).
To determine the replication kinetics of the AM2, I infected DBT cells with wildtype isogenic icMHV-A59 or AM2 virus with the MOI 0.1. The cells were incubated at
37OC and the supernatant was harvested at the indicated time points. The virus titer in the
supernatant was determined using plaque assay on DBT cells. I determined that AM2
replicated with similar kinetics, and to similar titers as icMHV-A59 (Figure 28A).
Further, I determined if AM2 is impaired when grew at higher temperature. To do this, I
infected DBT cells with MOI 0.1 with icMHV-A59 or AM2 at 37OC. At 6 hours postinfection, cells were moved to 39.5OC. The virus titer was determined at indicated time
points by plaque assay on DBT cells at 37OC. I found that replication kinetics is delayed
for AM2 as compared to icMHV-A59 (Figure 28B). At 14 hours post infection AM2 has
a significantly lower titer (about half a log) than wild-type virus, suggesting that AM2
has a replication defect at higher temperature.
Next, I evaluated if incubation time at 37OC was important for the ability of the
virus to replicate at higher temperature. To do that, I performed a temperature shift
experiment by infecting DBT cells with AM2 or icMHV-A59 and incubating the cells at
37OC for 2, 4, or 6 hours. After the indicated time the cells were moved to 40.5OC. The
virus titer was determined using plaque assay at 14 hours post-infection. I found that the
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Figure 28. Replication kinetics of AM2 virus. DBT cells were infected with AM2
mutant or icMHV-A59 at the MOI 0.1. At indicated time points virus titers were
determined by plaque assay. B) DBT cells were infected at the MOI 0.1 at 37OC with
AM2 or icMHV-A59. 6 hours post-infection cells were moved to 39.5OC Virus titer was
measured at the indicated time points. C) DBT cells were infected at the MOI 0.1 at 37OC
with AM2 or icMHV-A59. At the indicated time points cells were moved to 40.5O Virus
titer was measured at 14 hours post-infection. The error bars represent standard deviation
of the mean of two independent plaque assays. *p<0.05.
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shorter incubation time at 37OC, the bigger the difference between the titer of AM2
compared to icMHV-A59. When the cells were incubated at 37OC for 6 hours the
difference between the titers was about half a log, whereas when the cells were incubated
at 37OC for only two hours the AM2 has a two log difference in final titer compared to
icMHV-A59 (Figure 28C). Taken together these data suggest that AM2 virus encoding
V1613S mutation has a temperature sensitive phenotype.

V1613S mutation impairs protein activity and stability
The observation that the time of incubation at 37OC had a dramatic impact on the
replication of the virus and in order to understand the temperature sensitive phenotype of
the AM2 mutant, our collaborators at Purdue University purified wild-type and V1613S
mutant PLP2 (Figure 29A). Next, they incubated purified proteins at 25OC or 30OC. Each
enzyme activity was determined at 25OC at indicated time points using RLRGG-AMC as
a substrate. When both wild-type and V1613S mutant PLP2s were incubated at 25OC
both enzymes had similar activity over the time course at the level of 100% (Figure 28B).
In contrast, when both proteins were incubated at higher temperature (30OC) the activity
of V1613S mutant protein decrease over time whereas wild-type protein maintained
100% activity over time (Figure 29B).
To determine stability of the mutant protein our collaborators performed circular
dichroism (CD) analysis of wild-type and V1613S mutant proteins. They monitored CD
at 220nm while increasing the temperature at step intervals. The determined melting
temperature was 6.8OC lower for the mutant protein than for the wild-type protein (Figure
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Figure 29. Stability of V1613S purified protein. A) Expression and purification of
V1613S protein separated by SDS-PAGE. B) Temperature-dependent inactivation of the
V1613S mutant. The activity of WT PLP2 and the V1613S were measured after
incubation at 25°C and 30°C for different time periods, and then normalized to the
activity at 0min (Ratet/Rate0: rate at time t over initial rate). C) Thermal stability of WT
and V1613S mutant PLP2. CD at 220nm was monitored over a range of temperature.
Three independent experiments were performed for both WT PLP2 (grey) and V1613S
mutant (black). Data generated by Y. Chen, Purdue University.
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29C), suggesting that the mutant protein is less stable and unfolds at the lower
temperature than the wild-type PLP2. Taken together these data suggest that V1613S
mutation lowers the overall protein stability which leads to a decrease enzymatic activity
at higher temperature (30OC).

AM2 has reduced pathogenesis in infected mice
To determine the effect of the UBL mutation on virus pathogenesis, I infected 4
week old male C57B/L6 mice with 600 pfu of wild-type and AM2 virus by intracranial
injections. I monitored weight loss and the mice were humanly sacrificed when they lost
25% of initial body weight. I found that mice infected with wild-type virus succumb
to infection by day 7. In contrast, the mice infected with AM2 survived the infection
(Figure 30A). These data suggest that AM2 has reduced pathogenesis compared to wildtype virus.

AM2 immunized mice are protected from challenge with wild-type virus
To determine if primary infection with AM2 virus can protect mice from
challenge with wild-type virus I infected AM2 and age-matched naïve control C57B/L6
mice with 6000 PFU of icMHV-A59 9 weeks post-primary infection. I monitored body
weight lost over the course of infection and I found that naïve mice lost a significant
percent of initial body weight starting at day 3 post-infection (Figure 30B). In contrast,
AM2 immunized mice did not lose any weight and did not have any symptoms of disease
upon challenge (Figure 30B). These data indicate that immunization with AM2 mutant
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Figure 30. AM2 is attenuated in mice and generates protective immune response. A)
C57BL/6 mice were infected with 600 pfu icMHV-A59 or AM2 intracranially and
monitored for survival (N=7 for each group). Survival was monitored over the time. B)
C57BL/6 mice immunized with AM2 mutant and naïve age-matched controls were
challenged with 6000 pfu icMHV intracranially 9 weeks post-primary infection. The
mice were monitored for body weight loss. Error bars represent SEM.
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can protect the mice from wild-type infection suggesting that AM2 is a possible vaccine
candidate.

PART II: SEPARATING MHV PAPAIN-LIKE PROTEASE PROTEASE AND
DEUBIQUITINASE ACTIVITIES

MHV PLP2 crystal structure reveals ubiquitin-specific protein fold of the enzyme
To understand the role of PLP2 DUB activity in virus pathogenesis and to
facilitate the development of the vaccines toward coronaviruses it is necessary to separate
protease and DUB activity of PLP. This information is a key to generate DUB deficient
viruses that are still able to replicate and process viral polyprotein during virus
replication. To enable this process a crystal structure of the enzyme is required to
visualize interaction sites between the enzyme and a ubiquitin or polyubiquitin chain.
Our collaborators at Purdue University tried to crystalize MHV PLP2 using the PLP2-A
protein. It was not until I generated and tested the PLP2-B construct that they were able
to obtain crystals of MHV PLP2 which allowed for the generation of the crystal structure
of the enzyme. The crystal structure revealed that similar to SARS-CoV PLpro, and
despite the low amino acid sequence identity (28%), MHV PLP2 belongs to the ubiquitin
specific protein (USP) family of deubiquitinating enzymes. The predicted catalytic triad
consisting of C1716, H1873, and D1887 was confirmed. Additionally, the crystal
structure showed that upstream of PLP2 there are the ubiquitin-like domain (UBL), and
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Figure 31. X-ray Crystal structure of MHV PLP2. A ribbon representation of the
overall structure of MHV PLP2. The catalytic triad and VDVL residues in the UBL
domain are represented in balls. UBL - ubiquitin-like domain, SUD-C-like – SARS
unique domain C. Structure was generated by Y. Chen, Purdue University (Chen et al., in
preparation).
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SARS unique domain (SUD). The presence of SUD in PLP2-B construct was likely the
key factor that enabled protein crystallization (Figure 31) (Chen et al., in preparation).

Separating MHV PLP2 protease and deubiquitinase (DUB) activities
Obtaining the crystal structure of MHV PLP2 was an important step in order to
separate protease and DUB activities of MHV PLP2. To facilitate the mutagenesis of
MHV PLP2 to separate protease and DUB activity the model of MHV PLP2 with
ubiquitin was generated (Figure 32). The model was prepared using a known co-crystal
structure of SARS-CoV PLpro with ubiquitin aldehyde (Ratia et al., in press, Chou et al.,
2014). The model of MHV PLP2 and ubiquitin identified residues on PLP2 that likely
interact with ubiquitin. Using site-directed mutagenesis and the Gibson Assembly
technique I generated 5 alanine mutants of PLP2: R253, R257, E279A, F290, and Y302.
All mutations were confirmed by sequencing. First, I tested if the generated mutants had
protease activity. To do this I transfected HEK293T cells with plasmids expressing wildtype PLP2 (PLP2-B), PLP2-B CA, or various PLP2 mutants along with a plasmid DNA
expressing the SARS-CoV nsp2-3-GFP substrate as described earlier. I detected evidence
of cleavage of the nsp2-3-GFP substrate in the presence of the catalytically active form of
MHV PLP2, but not in the presence of the catalytic mutant. The expression of PLP2
mutants led to cleavage of the substrate at various degrees. R257A mutant cleaves the
substrate to the similar levels as wild-type PLP2; R253A, E279A, and F290A mutants
have reduced protease activity; whereas Y302A mutant is not able to cleave the substrate
similar to catalytic mutant of the PLP2 (Figure 33A). All mutant proteins, except R257A,
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Figure 32. Model of ubiquitin-PLP2 interaction. Modeled MHV-PLP2 (beige)
interaction with ubiquitin (green), residues of PLP2 that interact with ubiquitin are shown
in sticks. Model generated by Y. Chen, Purdue University.
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Figure 33. Activities of MHV PLP2 mutants. (A) To determine protease activity
HE293T cells were transfected with nsp2/nsp3-GFP plasmid and plasmids expressing
wild-type (WT PLP2-B), catalytic mutant (CA), or indicated PLP2-B mutants. Cell
lysates were analyzed by western blot 24 hours post-transfection. (B) HEK293T cells
were transfected with Flag-Ub expression plasmid, and wild-type (WT PLP2-B) or
catalytic mutant (CA), or indicated PLP2-B mutants. Cells were lysed 18 hours posttransfection and analyzed by western blot. (C) HEK293T cells were transfected with
plasmids expressing wild-type (WT) or catalytic mutant (CA), or indicated PLP2-B
mutants, plasmids expressing IFNβ-luc, Renilla-luc, and N-RIG-I. At 16 hours posttransfection, cells were lysed and luciferase activity was measured. Experiments were
performed in triplicate. Error bars represent standard deviation. The figure shows
representative data from at least two independent experiments.
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were expressed to the same levels as wild-type PLP2 as seen on the western blot. Even
though I was not able to detect the expression of R257A on a western blot I think the
protein was expressed because I could observe its catalytic activity. Detailed sequencing
analysis revealed a point mutation in the sequence of V5 epitope tag which explains the
inability to detect this protein on a western blot using mouse anti V5 antibody.
Importantly, the sequence of the PLP2 ORF was intact and included the desired R257A
mutation.
To further characterize the mutants I determined their DUB activity by
transfecting HEK293T cells with plasmid expressing Flag-Ub, PLP2-B, PLP2-B CA, or
various PLP2 mutants. I detected potent DUB activity of wild-type PLP2 but not catalytic
mutant (as described in the previous sections). The E279A mutant had similar DUB
activity to wild-type PLP2. R253A, R257A, and Y302A mutants had intermediate
phenotype between DUB activity of wild-type PLP2 and complete lack of DUB activity
of catalytic mutant. Interestingly, the F290A mutant lost the ability to deubiquitinate
cellular proteins to the level of catalytic mutant (Figure 33B). To test if DUB assay data
correlate with the ability of mutant PLP2s to work as interferon antagonists, I performed
luciferase assay. I transfected HEK293T cells with increasing doses of PLP2-B or PLP2B CA, plasmids expressing IFN-β-luciferase, Renilla luciferase, and N-RIG-I as a
stimulator. I found that the R253A and R257A mutants can potently inhibit induction of
interferon. The E279A mutant slightly reduced interferon induction upon N-RIG-I
stimulation. Interestingly, the Y302A and F290A mutants lost the ability to inhibit
induction of interferon (Figure 33C). The Y302A did not exhibit protease activity and for
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this reason was not a good candidate for introduction of this mutation into the virus.
However, the F290A mutant has protease activity (although slightly reduced compared to
wild-type PLP2), lacks DUB activity and interferon antagonism activity making it a good
candidate to test the role of DUB activity on virus pathogenesis.
To evaluate the effect of the F290A mutation in the context of the virus I used
reverse genetics technique to generate mutant virus. I introduced the F290A mutation
using site-directed mutagenesis and Gibson Assembly assay into B fragment of icMHVA59 genome. Upon restriction digest of all fragments I ligated them to generate a whole
genome. This ligation product was purified and used for an in vitro RNA transcription
reaction. Next, I electroporated RNA into BHK-R cells and applied them on a monolayer
of DBT cells and incubated the cells at 37OC. Unfortunately, I was not able to recover the
mutant virus. To make sure there were no mistakes in the procedure I generated wild-type
icMHV-A59 using the same fragments (except that I used wild-type B fragment) and
procedure. The protocol was effective and I could recover the wild-type virus. To test if
the reason why I did not generate the F290A mutant was the fact that the virus is
temperature sensitive, I repeated the procedure but this time upon electroporation I
incubated the cells at 30OC. Unfortunately, this time I did not also recover the virus.
These data suggest that the F290A mutation prevents virus replication. This might be due
to the defect in proteolytic activity of the F290A that I observed in transfected cells. In
addition, our collaborators at Purdue University purified the F290A protein and found
that DUB activity of the F290A mutant with ubiquitin as substrate is much lower than for
wild-type protein, and the F290A mutant does not have activity with peptide substrate
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suggesting that the F290A mutant virus might not be able to process the polyprotein thus
explaining why I could not recover this mutant virus.
The results that I gathered facilitated refinement of the MHV PLP2 - ubiquitin
model and allowed me to predict new sites of hydrophobic interaction between MHV
PLP2 and ubiquitin (Figure 34). Using site-directed mutagenesis and the Gibson
Assembly technique I generated the following mutants: I249R, F270A, R281E, Y302F,
I304A, and V313A. In addition, based on previous analysis I generated R253A/R257A
double mutant, because catalytic activity of single mutants was comparable to wild-type
PLP2, and their DUB activity was slightly reduced. I expected that by combining the
single mutants I would generate a DUB deficient mutant that maintains good protease
activity. The presence of all mutations was confirmed by sequencing.
To test catalytic activity of the newly generated mutants HEK293T cells were
transfected with plasmids expressing wild-type PLP2 (PLP2-B), PLP2-B CA, or various
PLP2 mutants along with a plasmid DNA expressing the SARS-CoV nsp2-3-GFP
substrate. The presence of the cleavage product was detected by western blot. The I249R
cleaved the substrate more efficiently that wild-type PLP2. F270A, I304A, and the
R253A/R257A double mutant had catalytic activity similar to wild-type PLP2. Two
mutants V313A and Y302F had reduced catalytic activity. Finally, in the presence of
R281E mutant the band of the cleavage product was almost non-detectable (Figure 35A).
Although described above transcleavage assay in transfected cells gave me
qualitative understanding of PLP2 mutants’ catalytic ability I wanted to obtain
quantitative results, especially because previously found F290A mutant had catalytic
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Figure 34. Model of ubiquitin-PLP2 interaction. Top modeled MHV-PLP2 interaction
with ubiquitin (surface representation, and residues of PLP2 that interact with ubiquitin
are shown in sticks). Bottom representation of SARS-CoV PLpro with ubiquitin (surface
representation, and residues of PLpro that interact with ubiquitin are shown in sticks).
The model was generated by Dr. S. Savinov, Purdue University.
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Figure 35. Proteolytic activity of MHV PLP2 mutants. (A) HE293T cells were
transfected with nsp2/nsp3-GFP plasmid and plasmids expressing wild-type (WT PLP2B), or catalytic mutant (CA), or indicated PLP2 mutants. Cell lysates were analyzed by
western blot 24 hours post-transfection. (B) HEK293T cells were transfected with pGLORLKGG plasmid and either wild-type (WT) or catalytic mutant (CA) of indicated PLP2
mutants. At 18 hours post-transfection media was change and cell permeable substrate
was added. Luciferase activity was measured at indicated time points. Experiments were
performed in triplicate. The figure shows representative data from two independent
experiments.

114

activity in transcleavage assay but failed to generate mutant virus. For this reason I
decided to test the mutants using recently described by our laboratory live-cell pGLO
assay (Kilianski, Mielech, Deng, & Baker, 2013). HEK293T cells were transfected with
plasmid expressing substrate (pGLO-RLKGG) recognized by the PLP2, wild-type PLP2
(PLP2-B), PLP2-B CA, or various PLP2 mutants. 20 hours post-transfection cell
permeable luciferase substrate was added to the cells, and luciferase activity was
measured every hour for 5 hours. I found that the kinetics of substrate cleaved by wildtype PLP2 was similar to the cleavage kinetics of F270A and R253A/R257A double
mutants. The R281E mutant, even though I observed slight catalytic activity using
transceleavge assay, did not cleave pGLO substrate, similar to catalytic mutant PLP2.
Y302F, I304A, and V313A mutants had intermediate ability to cleave the substrate
(Figure 35B). Interestingly, F290A mutant which was used here as a control, did not
cleave pGLO substrate supporting previous data and explaining the inability to recover
the mutant virus with this mutation.
To evaluate DUB activity of the new mutants I transfected HEK293T cells with
plasmids expressing Flag-Ub, and wild-type PLP2 (PLP2-B), PLP2-B CA, or various
PLP2 mutants. Using western blot analysis I determined the levels of ubiquitinated
proteins in transfected cells. I found that the I249R mutant, which had increased protease
activity, had also increased DUB activity. In contrast, the R281E mutant that did not have
catalytic ability did not also have DUB activity and its phenotype resembled catalytic
mutant of PLP2. Additionally, the F290A, Y302F, I304A, V313A, and R253A/R275A
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double mutant had slightly reduced DUB activity compared to wild-type PLP2 (Figure
36A).
To determine the effect of the PLP2 mutations on PLP2 deISGylating activity,
HEK293T cells were transfected with c-myc-ISG15 plasmid, ISG15 conjugation
machinery, and plasmids expressing PLP2-B, PLP2-B CA, and various PLP2 mutants. 20
hours post-transfection cell lysates were evaluated for the presence of ISGylated proteins.
Wild-type PLP2 can deconjugate ISG15 from multiple cellular substrates. In contrast,
PLP2 catalytic mutant did not deconjugate ISG15. Interestingly the PLP2 mutations
seemed to have a stronger effect on PLP2 deISGylating thank DUB activity. The I249R
mutant had more robust deISGylating activity than wild-type PLP2. In contrast, all other
mutants tested (F270A, R281E, Y302F, I304A, V313A, and R253A/R257A) showed
decreased deISGylating activity comparable to PLP2 catalytic mutant (Figure 36B).
Finally, I tested the interferon antagonism activity of the PLP2 mutants. I
transfected HEK293T cells with increasing doses of PLP2-B or PLP2-B CA, or, PLP2
mutants, plasmids expressing IFNβ-luciferase, Renilla luciferase, and N-RIG-I as a
stimulator. 16 hours post-transfection the cells were lysed and luciferase activity was
measured. I determined that three mutants had reduced ability to antagonize induction of
IFN upon RIG-I stimulation: I249R, F270A, Y302F. In addition, the remaining mutants:
R253A/R257A, R281E, I304A, and V313A have lost the ability to antagonize IFN
induction (Figure 37).
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Figure 36. Activities of MHV PLP2 mutants. HEK293T cells were transfected with
Flag-Ub expression plasmid (A) or Myc-ISG15 and ISGytylating machinery plasmids
(B), and wild-type (WT PLP2-B) or catalytic mutant (C1716A) PLP2, or indicated PLP2
mutants. Cells were lysed 18 hours post-transfection and analyzed by western blot. The
figure shows representative data from at least two independent experiments.
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Figure 37. Interferon antagonism activity of MHV PLP2 mutants. HEK293T cells
were transfected with plasmids expressing wild-type (WT) or catalytic mutant (CA), or
indicated PLP2 mutants, plasmids expressing IFNβ-luc, Renilla-luc, and N-RIG-I. At 16
hours post-transfection, cells were lysed and luciferase activity was measured.
Experiments were performed in triplicate. Error bars represent standard deviation. The
figure shows representative data from at least two independent experiments.
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Taken together these data suggest that thus far no mutant has allowed me to
separate the protease and DUB activity of MHV PLP2 completely. Three mutants:
F270A, I304A, and R253A/R257A have reduced DUB activity and maintain protease
activity suggesting that those might have stronger effect on DUB activity when combined
together in triple or quadruple mutants.
In addition to testing mutants that potentially disrupted the hydrophobic
interaction between ubiquitin and PLP2, I generated a PLP2 mutant that targeted the
predicted interaction of PLP2 with isoleucine (I44) patch on the ubiquitin molecule. The
I44 patch is known to be one of the main interaction sites between ubiquitin and its
interaction partners. In addition, van Kastern and co-workers showed that interaction with
this path is critical for the interaction between ubiquitin and PLP2 from Equine Arteritis
Virus (EAV). The overall fold of EAV PLP2 is much different (EAV PLP2 belongs to
ovarian tumor domain (OTU) family of deubiquitinating enzymes) from MHV PLP2 thus
these data obtained from EAV studies cannot be extrapolated to coronavirus PLP2.
However, I used the knowledge that the I44 patch is important for interactions with
ubiquitin partners and model of MHV PLP2 to predict the residues that likely interact
with the I44 patch residues: I44, V70, and L8. I predicted that I44 interacts with F290,
V70 interacts with I249, and L8 interacts with T328 (Figure 38).
To test this hypothesis I generated MHV PLP2 triple mutant:
I249V/F290W/T328A (termed IFT) using site-directed mutagenesis and Gibson
Assembly technique. The triple mutation was confirmed by sequencing. Using the
transcelavage assay I determined that I249V/F290W/T328A have protease activity
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Figure 38. Predicted interaction between MHV PLP2 and ubiquitin Ile44 patch. The
modeling of interaction between Ile 44 patch on ubiquitin (in green) with MHV PLP2 (in
beige). Model was generated by Y. Chen, Purdue University.
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Figure 39. Proteolytic activity of MHV PLP2 triple mutant (I249V/F270W/T328A).
(A) To determine protease activity HE293T cells were transfected with nsp2/nsp3-GFP
plasmid and plasmids expressing wild-type (WT), or catalytic mutant (CA), or PLP2
triple mutant (IFT). Cell lysates were analyzed by western blot 24 hours posttransfection. (B) HEK293T cells were transfected with pGLO-RLKGG plasmid and
either wild-type (WT) or catalytic mutant (CA) or PLP2 triple mutant (IFT). At 18 hours
post-transfection media was change and cell permeable substrate was added. Luciferase
activity was measured at indicated time Experiments were performed in triplicate.
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comparable to wild-type PLP2 (Figure 39A). To determine how efficient is the
I249V/F290W/T328A mutant in the cleavage of the pGLO-RLKGG substrate I
transfected HEK293T cells with plasmid expressing the substrate, PLP2-B, PLP2-B CA,
and I249V/F290W/T328A mutant. As additional controls, I transfected the cells with
F290A and V1613S mutant expression plasmids. I found that the I249V/F290W/T328A
mutant is as efficient at cleaving the substrate as wild-type PLP2. In contrast, F290A and
PLP2 catalytic mutant were not able to cleave the substrate (Figure 39B). These data
suggest that the I249V/F290W/T328A mutant is an efficient protease. To validate if this
mutant has a deficiency in DUB activity, I transfected HEK293T cells with plasmids
expressing Flag-Ub, and wild-type PLP2 (PLP2-B), PLP2-B CA, or various PLP2
mutants. Using western blot analysis I determined the levels of ubiquitinated proteins in
transfected cells. I found that I249V/F290W/T328A mutant was as efficient DUB as
wild-type PLP2 (Figure 40). These data suggest that this triple combination of mutations
is not sufficient to separate PLP2 protease and DUB activities. However, further testing
of various mutants that likely disrupt interaction between PLP2 and the I44 patch on
ubiquitin is necessary to determine if the I44 patch is a site required for PLP2 – ubiquitin
interaction. Table 9 summarizes data generated for all the mutants.
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Figure 40. Deubiquitinating activity of MHV PLP2 triple mutant. HEK293T cells
were transfected with Flag-Ub expression plasmid and wild-type (WT) or catalytic
mutant (CA), or indicated PLP2 mutants. Cells were lysed 18 hours post-transfection and
analyzed by western blot.
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Table 9. Enzymatic activity profile of MHV PLP2 mutants. The table summarizes the
results obtained for generated mutants.

CHAPTER IV
DISCUSSION

VALIDATING

SMALL

MOLECULE

INHIBITORS

OF

SARS-CoV

REPLICATION
The recent emergence of MERS-CoV highlighted the importance of the
development of antiviral drugs that can block coronavirus replication. Thus far, many
efforts have been made to generate inhibitors of SARS-CoV replication. Papain-like
proteases are attractive targets for the design of anti-coronavirus drugs because PLPs
activity is required for virus replication. Previously described high-throughput screens
identified candidate compounds that block SARS-CoV replication (Ghosh et al., 2009,
2010; Ratia et al., 2008). However, because of quite high EC50 values for those drugs,
further optimization of those compounds was needed to facilitate the introduction of the
drugs into clinical settings. During my research I evaluated the ability of second
generation compounds to inhibit SARS-CoV replication. My results indicate that
optimized compounds have lower EC50 values than previously tested SARS-CoV PLpro
inhibitors (Table 7).

The best compound in terms of ability to inhibit SARS-CoV

replication is compound CCG 203888 with EC50 of 5.27µM. This compound, as
determined by Y. Baez-Santos (Purdue University) is the most effective in inhibiting the
activity of purified enzyme (IC50=0.2µM). However, the analysis of stability of this drug
124
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during metabolism showed that CCG 203888 stability is reduced compared to other
compounds such as CCG 206552 and CCG 206553 (Báez-Santos et al., 2014).
Interestingly, those two compounds also have a potent ability to inhibit SARS-CoV
replication with EC50 values of 8.78µM and 9.07µM respectively. Thus, CCG 206552
and CCG 206553 are now the most promising candidates and should be further
optimized. In addition, co-crystal structures of SARS-CoV PLpro with compounds CCG
203888 and CCG 203885 have been resolved which allows for the further optimization of
the inhibitors to design even more potent drugs (Báez-Santos et al., 2014).
Since MERS-CoV emerged into the human population many previously described
compounds that have the ability to inhibit SARS-CoV PLpro, have been tested for their
ability to inhibit MERS-CoV PLpro. Unfortunately, they were not effective against
MERS-CoV PLpro. Kilianski and co-workers showed that potent SARS-CoV PLpro
inhibitor, benzodioxolane derivative (compound 15g described in Gosh et al., 2010) is
not capable of inhibiting MERS-PLpro activity in transfected cells. The authors
hypothesized that the lack of inhibition was due to differences in structure of MERS-CoV
and SARS-CoV PLpros at the drug binding site (Kilianski, Mielech, Deng, & Baker,
2013). This hypothesis needs to be further evaluated when the crystal structure of
MERS-CoV PLpro is available. In addition, the ability of other SARS-CoV PLpro
inhibitors to block MERS-CoV activity remains to be determined. Thus far, no broadspectrum inhibitor for coronavirus PLPs has been described. However, it is critical to
work and optimize not only specific SARS-CoV PLpro and MERS-PLpro inhibitors but
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also broad-spectrum inhibitors that could be available in case of the emergence of a new
coronavirus with pandemic potential.

INVESTIGATING MULTIFUNCTIONAL VIRAL PROTEASES
Viruses must “do more with less” because of the compact nature of their
genomes. One example of this is the multifunctional papain-like protease (PLP) domain
encoded in all members of the order Nidovirales. Nidoviruses, including those in the
coronavirus and arterivirus families, encode one or more PLP domain. These PLPs are
critical for proteolytic processing of the viral replicase polyprotein. In addition to
protease activity, many of these PLPs have also been shown to act as viral DUBs, able to
deconjugate ubiquitin and ISG15 from cellular substrates. Coronavirus DUB activity was
first proposed by molecular modeling of the SARS-CoV PLpro domain which predicted
that the protease would be multifunctional (Sulea et al., 2005). Indeed, analysis of the
DUB activity of purified coronavirus PLPs and the X-ray crystal structure of SARS-CoV
PLpro fully support the initial prediction of viral DUB activity (Barretto et al., 2005;
Chen et al., 2007; Lindner et al., 2005; Ratia et al., 2006, 2008). Analysis of PLPs from
coronaviruses and arteriviruses have revealed conserved DUB activity; although the
enzymes in the coronavirus family fall into the Ubiquitin Specific Protease (USP) family
whereas the arterivirus PLPs are in the Ovarian Tumor (OTU) domain family of enzymes
(Figure 3). The identification of a newly emerged coronavirus, Middle East Respiratory
Syndrome CoV (MERS-CoV), provided an opportunity to evaluate PLpro enzymatic
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activity and develop new hypotheses about how this protease/DUB may contribute to
viral pathogenesis.
SARS-CoV PLpro is a deISGylating and deubiquitinating enzyme (Lindner et al.,
2005, 2007; Ratia et al., 2006). HCoV-NL63 encodes two papain-like proteases PLP1
and PLP2 in the genome. Only PLP2, which has 22% homology to SARS-CoV PLpro, is
a multifunctional enzyme with deISGylating and DUB activities (Clementz et al., 2010).
The modeling of the MERS-CoV PLpro domain onto the structure of SARS-CoV led to
the prediction of viral DUB/deISGylating activity (Figure 8). Although the enzyme is
only ~30% identical to SARS-CoV PLpro at the amino acid level my data suggest that
multifunctionality of MERS-CoV PLpro and other coronavirus PLPs is conserved. First, I
showed that predicted PLP domains from various alpha and betacoronaviruses can be
expressed in mammalian cells and that they are catalytically active. I showed that not
only MERS-CoV PLpro, but also HCoV-229E, HCoV-OC43, HCoV-HKU1, MHV and
FIPV can recognize LXGG motif and cleave a polyprotein substrate (Figures 9A, 13, and
15A). The differences in the efficiency of substrate cleavage betweem those PLPs are
noticeable. However, the substrate that I used in the assays is a native substrate
recognized by SARS-CoV during virus replication. For many PLPs the cleavage sites
have not been determined previously, only predicted. It needs to be further verified if
there are true differences in the cleavage efficiency and whatever they contribute to the
pathogenesis associated with a particular virus.
Further studies showed that DUB activity of PLPs is also a conserved feature.
All tested alpha and betacoronavirus PLPs showed an ability to cleave polyubiquitin
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chains in transfected cells in a catalytic dependent manner (Figures 10B, 14, and 15B).
The degree of PLPs’ DUB activity varies; however, because western blotting is not a
quantitative assay I cannot directly compare PLPs’ DUB activities with each other.
Further in vitro studies with purified enzymes are needed to quantitatively compare PLPs
DUB activities. Nevertheless, all tested PLPs including MERS-CoV, HCoV-229E,
HCoV-OC43, HCoV-HUK1, MHV and FIPV showed efficient DUB activity. DUB
activity of MERS-CoV PLpro and MHV PLP2 has been also shown by other groups
supporting my conclusions (Wang, Chen, Zheng, Cheng, & Tang, 2011; Yang et al.,
2013; Zheng et al., 2008). DeISGylating activity of MERS-CoV PLpro and MHV PLP2
is also conserved (Figures 10A and 35B). The deISGylating activity of HCoV-229E,
HCoV-OC43, HCoV-HUK1, and FIPV remains to be determined.
It is interesting that the multifunctionality of coronavirus PLPs is conserved while
there is less than 10% identity between their sequences. However, the overall polarity of
the PLP domain is conserved suggesting that the structure might facilitate protein
functions (Figure 41). Moreover, the variability of the PLP domain sequences suggests
high flexibility of the structure that maintains its functions. The crystal structures of
HCoV-229E, HCoV-OC43, HCoV-HUK1, and FIPV PLPs remain to be solved.
However, the recently obtained by our collaborators crystal structure of MHV PLP2
revealed structural similarity between SARS-CoV PLpro and MHV PLP2 (Chen et al., in
preparation). Both structures have similar ubiquitin specific protein (USP) fold, even
though the sequence identity between these two proteases is about 28%, supporting the
idea that the overall structure facilitates enzyme multifunctionality (Figure 31).
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Figure 41. Alignment of coronavirus papain-like proteases and hydrophobicity
characteristics of amino acid side chains. According to the hydrophobicity table of
Kyte & Doolittle, 1982. The most hydrophobic residues according to this table are
colored red and the most hydrophilic ones are colored blue. Figure generated by A.
Kilianski, Loyola University Chicago.
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INVESTIGATING PAPAIN-LIKE PROTEASE ABILITY TO INHIBIT INNATE
IMMUNE RESPONSE AND THE ROLE OF DUB/DEISGYLATING ACTIVITY
IN INNATE IMMUNE EVASION
Because ubiquitination controls innate immunity signaling and that ISGylation is
important for antiviral responses upon infection, the DUB activity and deISGylating
activity of PLPs have been implicated to have a role in antagonism of the innate immune
response.

As discussed above, the deISGylating and DUB activities of PLPs are

conserved. In addition, SARS-CoV PLpro, HCoV-NL63 and porcine epidemic diarrhea
virus PLP2s have been shown to act as IFN antagonists (Clementz et al., 2010; Devaraj et
al., 2007; Frieman et al., 2009; Xing et al., 2013).
Coronaviruses have been shown to modulate immune responses upon infection,
however, the mechanisms involved in the regulation are not yet clear (Totura & Baric,
2012). Cytokine and chemokine responses to SARS-CoV in non-lymphatic cells and
infected patients results in low levels of several cytokines, including CCL5 and IFNβ
(Spiegel & Weber, 2006; Wong et al., 2004). In addition, CXCL10, CCL5, and IFNβ
among others, are not induced in cloned bronchial epithelial cell line and human alveolar
type II cells infected with SARS-CoV early post infection (Qian et al., 2013; Yoshikawa
et al., 2010). The innate immune response to MERS-CoV is also intriguing. Microarray
analysis of MERS-CoV infection of Calu-3 cells results in a distinct immune response
compared to SARS-CoV infection. Expression of multiple genes involved in activation of
adaptive immune responses, such as MHC class I and II, are downregulated in MERSCoV infected cells (Josset et al., 2013). The ability of SARS-CoV and MERS-CoV to
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modulate early immune responses is likely due to multiple proteins encoded within virus
genomes that may act as interferon antagonists.
Previous reports showed that several coronavirus proteins can block the activation
of innate immune responses, particularly the interferon β (IFNβ) response (Totura &
Baric, 2012). Structural proteins, such as SARS-CoV nucleocapsid (N) and membrane
protein (M), in addition to being critical elements of the viral particles, have been shown
to block the IFN response. Several accessory proteins (SARS-CoV ORF3b, ORF6, and
Mouse Hepatitis Virus ns2) are known to act as antagonists of innate immunity
(Kopecky-Bromberg, Martínez-Sobrido, Frieman, Baric, & Palese, 2007; Zhao et al.,
2012). Moreover, MERS-CoV accessory protein 4 has been reported to block IFN
induction (Niemeyer et al., 2013). In addition, nonstructural proteins including nsp1,
nsp7, nsp15 have been implicated as IFN antagonists (Frieman et al., 2009; Kamitani,
Huang, Narayanan, Lokugamage, & Makino, 2009). As described above PLPs encoded
within nsp3 have been shown to block IFN induction as well.
In my dissertation I determined that MERS-CoV PLpro and MHV PLP2 are
interferon antagonists and that they block induction of interferon elicited by various
stimuli including RIG-I, MDA5, MAVS, and Sendai virus suggesting that the protease
activity is important for inhibition of innate immunity downstream of the pattern
recognition receptors (Figures 11and 16). Further, I found that both MERS-CoV and
SARS-CoV PLpros can modulate exogenous levels of proinflammatory cytokines and
chemokines (Figure 12) (Mielech et al., 2014). Moreover, reports from other groups
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support these findings (Yang et al., 2013; Zheng et al., 2008). It remains to be determined
at exactly which step during activation of innate immune response PLPs function.
PLPs from arteriviruses are also known to block IFN responses. The N terminal
region of nsp2 encodes the PLP in porcine reproductive and respiratory syndrome virus
(PRRSV). This PLP has been characterized as an ovarian tumor domain (OTU) with
deubiquitinating and deISGylating ability (Frias-Staheli et al., 2007). In addition, Sun et
al., showed that PRRSV PLP domain can block Sendai virus induced IFNβ, and can also
inhibit NF-ƙB by preventing IƙBα degradation by its deubiquitination (Sun et al., 2010).
A more recent report showed that PLP also has deISGylating activity which suggests
multiple roles of PRRSV PLP in antagonism of innate immunity (Sun et al., 2012). The
nsp2 of another member of the Arteriviridae, equine arteritis virus (EAV), has
deubiquitinating and deISGylating activities as well (Frias-Staheli et al., 2007). The
deubiquitinating ability of EAV PLP can block RIG-I induced IFN by inhibiting
ubiquitination of RIG-I which is required for its activation (van Kasteren et al., 2012).
Co-crystal structure of EAV PLP with ubiquitin revealed potential interaction sites
between those molecules, and mutagenesis studies showed that PLP DUB activity is
required for inhibition of innate immunity in infected cells (van Kasteren et al., 2013).
Specific deubiquitinating and deISGylating activities have been shown for Crimean–
Congo hemorrhagic fever virus (CCHFV) which is a highly pathogenic negative strand
virus belonging to the family Bunyaviridae. The L protease of CCHFV contains an OTU
domain with the ability to cleave ISG15 modification. L protease can remove ISG15-
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mediated immune protection of IFNAR-/- mice and make them highly susceptible to
Sindbis virus infection (Frias-Staheli et al., 2007).
Overall, my results and reports from multiple laboratories studying a variety of
coronavirus, arterivirus and bunyavirus proteases indicate that the deubiquitinating and
deISGylating activity of viral proteases play an important role in inhibition of innate
immune responses and possibly virus pathogenesis. In my dissertation, I characterized the
PLPs from MERS-CoV and MHV revealing the deISGylating and deubiquitinating
activities, and that they can act as interferon antagonists. Moreover, I determined that
protease multifunctionality is a conserved feature of PLPs from various alpha and
betacoronaviruses including HCoV-OC43, HCoV-229E, HCoV-HKU1, and FIPV.
Further, I determined for the first time that SARS-CoV PLpro and MERS-CoV PLpro
can block induction of several endogenous proinflammatory cytokines, which are critical
for establishing an antiviral state in infected cells. My data show that the antagonism of
innate immune responses mediated by MERS-CoV and SARS-CoV PLpros is not limited
to IFNβ, but may affect the expression of many cellular cytokines. Further, my results
suggest that PLpro might contribute to the modulation of innate immune responses upon
SARS-CoV and MERS-CoV infection, however, the exact mechanism and the role of
coronavirus PLpro DUB and deISGylating activity in this process remains to be
determined. My efforts towards understanding the role of PLP2 DUB activity in the
inhibition of innate signaling are presented in the following sections.
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INVESTIGATING THE ROLE OF UBIQUITIN-LIKE DOMAIN IN VIRUS
PATHOGENESIS
Viruses evolved multiple strategies to facilitate productive infection. Highly
pathogenic viruses such as coronaviruses, encode multiple proteins in their genomes that
contribute to their pathogenesis. In my dissertation I investigated the role of the ubiquitin
like (UBL) domain upstream of PLP2 from MHV in virus pathogenesis. Bioinformatic
analysis predicts the presence of a UBL domain upstream of the PLP in all sequenced
coronaviruses suggesting that it might play an important role in virus life cycle and
making it a valuable target for antiviral drugs and vaccines development.
As my results and others show, PLPs are multifunctional enzymes and their
protease, deubiquitinase, deISGylating and interferon antagonism activities have been
reported. However, the role of the UBL domain located upstream of PLPs is poorly
understood. Only the role of the UBL domain upstream of SARS-CoV PLpro has been
investigated. It has been shown that the UBL domain is required for PLpro ability to
inhibit the induction of interferon β but not for PLpro protease and DUB activity
(Frieman et al., 2009). However, another group showed contradicting result that SARSCoV PLpro domain is dispensable for IFN antagonism (Clementz et al., 2010). My data
reveald a physiological role for the UBL domain in the virus life cycle and indicate that
the UBL of MHV PLP2 is important for efficient protease activity and virus
pathogenesis.
To determine the role of the UBL domain I performed deletion analysis and sitedirected mutagenesis of the UBL domain in the context of two PLP2 expression
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constructs. I performed site-directed mutagenesis of the N-terminal residues of UBL
domain (amino acids 1611 to 1614 of MHV-A59 genome) and I found that the mutation
of those residues to serine residues led to a decrease in protease activity in transfected
cells (Figures 20A, 21A, and 24A). Even a single amino acid substitution in this region is
able to decrease proteolytic activity of the PLP2 (Figure 24B). To determine the role of
the UBL domain in virus pathogenesis I generated two mutant viruses using reverse
genetics. The first mutant had four amino acids mutated to serine (1611-1614), termed
AM1. Another virus had a single amino acid substitution (V1613S), termed AM2. I
decided to generate this single amino acid mutant because V1613 is a conserved residue
between UBL domains of MHV and highly pathogenic human coronaviruses such as
SARS-CoV and MERS-CoV (Figure 22A).
I found that AM1 produced pinpoint plaques on DBT cells. Further, I found that
AM1 replicated with slower kinetics than wild-type virus and never reached high titer
that is classical for wild-type virus. AM1 replicated only to low titer of 1x103 pfu/ml. In
contrast, AM2 replicated with efficiency similar to wild-type virus. For this reason and
because V1613 residue is conserved among coronaviruses I decided to focus the
remaining work on this mutant. The plaque assays performed for this virus showed that it
forms slightly smaller plaques at 37OC. Further analysis showed that AM2 is a
temperature sensitive virus and produces significantly smaller plaques at 39.5OC, and no
plaques at 40.5OC (Figure 27B). AM2 growth kinetics was slightly, but significantly
impaired at 39.5OC. In addition, temperature shift experiments showed that AM2 titers
are significantly reduced upon temperature shift, supporting the temperature sensitive
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phenotype (Figure 28C). Interestingly, the virus growth ability was dependent upon the
time infected cells were incubated at 37OC before they were moved to 40.5OC i.e. the
longer the cells were incubated at 37OC, the lower the difference between AM2 and wildtype virus final titers. These observations could suggest that the incubation at 37OC
allows for the accumulation of functional PLP2 in infected cells that could perform the
function in trans to cleave the polyprotein when the cells were moved to 40.5OC, which
could mask the true defect associated with reduced PLP2 activity.
To address the mechanism of AM2 temperature sensitivity biochemical analysis
of purified enzyme containing V1613S mutation was performed at Purdue University. It
was determined that compared to wild-type counterpart V1613S mutant protein had
reduced protease activity upon incubation at 30OC, but not at 25OC supporting
temperature sensitivity of the mutant virus (Figure 29B). Of note, the enzyme was
unstable at 37OC excluding the ability to determine enzyme activity at this temperature
(Y. Chen, unpublished observation). To gain insights into the underlying cause of
reduced activity of the enzyme at higher temperature the circular dichroism analysis of
the purified enzyme was performed. The analysis showed that the mutant has a
significantly lower than the wild-type protein melting temperature indicating stability
defect associated with the V1613S mutation (Figure 29C). These results can explain the
effect that I saw in the temperature shift experiments. The incubation at 37OC might
allow for the generation of pool of stable PLP2 that can act in trans upon temperature
shift. The longer the time at 37OC the more of properly folded enzyme is available later
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leading to smaller defect in virus growth. In contrast, when the infection occurs at 37OC
for a shorter time the pool of properly folded and active PLP2 is smaller and cannot
facilitate robust virus replication. The activity of PLP2 and processing of the polyprotein
in the context of virus replication remains to be determined.
The availability of MHV PLP2 crystal structure determined at Purdue University
facilitates the discussion regarding the role of V1613 and UBL domain in the PLP2
stability (Figure 31) (Chen et al., in preparation). The UBL domain is located upstream
of the PLP2 domain, similar to the UBL domain of SARS-CoV (Ratia et al., 2006).
Residues V1611 to L1614 are building a β-sheet within the MHV PLP2 UBL domain.
Interestingly, the residues V1611 and V1613 are buried inside the UBL domain structure
(Figure 22B). This could explain why AM1 is severely impaired and why AM2 is
temperature sensitive. The quadruple mutant (AM1) disrupted the entire β-sheet structure
and overall structure of the UBL domain. Further, a single amino acid mutation V1613S
was sufficient to have a negative impact on UBL domain structure that resulted in an
overall stability defect of the entire enzyme. It remains to be determined if the stability of
UBL domain of other coronaviruses, including SARS-CoV and MERS-CoV where the
valine residue is conserved, is required for PLpro overall stability.
My results show for the first time that PLP2 stability is important for MHV
pathogenesis and show the physiologic role of the UBL domain in virus virulence.
I determined that in contrast to infection with wild-type virus, AM2 is attenuated in a
lethal model of intracranial inoculation in mice (Figure 30A). My data also suggest that
infection with AM2 induces a protective immune response in infected mice. Mice
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infected with AM2 are not susceptible to the disease upon challenge with wild-type virus
(Figure 30B).
Overall my results highlight the importance of the UBL domain in maintaining
PLP2 stability and virus pathogenesis. Thus far, literature has not described the role of
the UBL domain in MHV or any other coronavirus infection. What is more, there has
been only one report indicating the role of only one other nsp3 encoded protein in viral
pathogenesis. An ADP-ribose-1’’-phosphatase (ADRP) domain was shown to be
important for MHV virulence (Eriksson, Cervantes-Barragán, Ludewig, & Thiel, 2008).
An ADRP domain inactive mutant virus does not cause acute hepatitis but replicates
efficiently in infected animals. Infection with the ADRP mutant virus leads to reduced
serum ALT levels compared to infection with wild-type virus. The proposed mechanism
involves induction of proinflammatory cytokines such as IL-6 and TNFα. It remains to be
determined if infection with AM2 leads to changes in inflammatory responses in infected
mice.
The ability of AM2 to efficiently replicate in infected mice and its attenuated
phenotype make this virus a potential vaccine candidate. Thus far, there are no FDA
approved vaccines against any coronavirus. The ADRP mutant virus mentioned above
has not been tested for its protective ability. Several live-attenuated virus vaccine
candidates for SARS-CoV have been reported but their efficacy remains to be
determined. SARS-CoV lacking exonuclease (ExoN) activity is an attenuated vaccine
candidate. ExoN activity is important for proofreading of the RNA-dependent RNA
polymerase and virus that lacks this activity acquires mutations during passages (Graham
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et al., 2012). Another example of a live-attenuated vaccine candidate is a recently
described mutant lacking 2’-O-methyltransferase activity that has been shown to have an
attenuated phenotype in infected mice. Infection with this mutant virus generated a
protective immune response in immunized animals (Menachery et al., 2014). The
resistance to reversion to the virulent phenotype of those vaccine candidates remains to
be determined and is a key factor in evaluating live-attenuated vaccines.
The knowledge gained from my results can be extrapolated to other
coronaviruses, especially human pathogens such as SARS-CoV and MERS-CoV. The
valine residue that is mutated in an attenuated AM2 virus is conserved among the UBL
domains of SARS-CoV and MERS-CoV PLpro making it a possible target for future
vaccine development. It is likely that a single amino acid mutation will not be sufficient
to maintain attenuated phenotype due to the high mutation rate in RNA viruses. Longterm studies are needed to determine the likelihood of acquiring mutations that will result
in reversion to the virulent phenotype. In the case of AM2, two nucleotides were changed
when the V1613S mutation was introduced into AM2 (GTC codon was changed into
TCC), which changed the polarity of the residue. Two nucleotide changes make it more
difficult for the virus to revert; however, only one nucleotide would have to be changed
in order to change serine to phenylalanine. Phenylalanine, similar to valine, is a non-polar
amino acid thus it is possible that this substitution could facilitate correct conformation of
the UBL domain, and reversion to the virulent phenotype. On the other hand, introduction
of phenylalanine with significantly larger side chain compared to valine could also
disrupt the overall UBL domain folding, thus this hypothesis remains to be tested.
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Overall, it might be necessary to combine the AM2 mutant with other mutations, for
example, ExoN mutant, to generate a fully efficacious and resistant to reversion vaccine
candidate.
Overall, my results for the first time show the biological importance of the
coronavirus UBL domain. I showed that the UBL domain confers PLP2 stability and is
important for virus pathogenesis in vivo and that targeting UBL domain is a new potential
way to generate attenuated viruses and vaccine candidates.

SEPARATING MHV PAPAIN-LIKE PROTEASE PROTEASE AND
DEUBIQUITINASE ACTIVITIES
The multifunctionality of PLPs has been described in the literature and the
previous sections of the discussion. The intriguing question is why are PLPs
multifunctional? What is the role of DUB and/or deISGylating activities in virus
replication and pathogenesis? Several efforts have been made to answer those questions
by studies designed to separate the protease and DUB activities of PLPs. Studies on
arterivirus PLP2 showed that it was possible to generate a mutant virus that was able to
replicate, but did not have DUB activity (van Kasteren et al., 2013). This virus is able to
induce proinflammatory response in infected cells; however, the role of DUB activity in
virus pathogenesis has not been determined. Furthermore, the knowledge from this study
cannot be extrapolated to coronaviruses because of the significant differences between
structures of arterivirus PLPs which belong to OTU family of DUBs, and coronavirus
PLPs which belong to USP family of DUBs (Mielech, Chen, Mesecar, & Baker, 2014).
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In order to separate the protease and DUB activities of coronavirus PLPs cocrystal structures of SARS-CoV PLpro with a ubiquitin moiety have been obtained by
two groups (Chou et al., 2014; Ratia et al., 2014). Both groups made efforts to separate
the protease and DUB functions of PLpro using the information obtained from co-crystal
structures and mutagenesis. However, neither one tested the role of DUB activity in virus
pathogenesis. That is because it is very hard to study mutants of SARS-CoV because it is
a BSL-3 pathogen. For this reason it is beneficial to work towards separating protease
and DUB activities of a model coronavirus MHV, which has a convenient BSL-2 reverse
genetics system and also allows for studying the effect of the mutagenesis on virus
pathogenesis in the context of infection in the natural host.
For a long time, it was almost impossible to try to separate MHV PLP2 DUB and
protease activities because the crystal structure of the enzyme was not available, and with
only 28% identity between SARS-CoV PLpro and MHV PLP2 the alignments failed to
generate an accurate model of MHV PLP2. Importantly, the crystal structure of MHV
PLP2 was generated giving the hope of separating PLP2 protease and DUB activities
(Figure 31) (Chen et al., in preparation). The obtained crystal structure facilitated the
modeling of MHV PLP2 with SARS-CoV PLpro-ubiquitin co-crystal structure and
allowed for predicting the residues on MHV PLP2 that likely interact with ubiquitin that
are distal to the catalytic triad. If those interaction sites were mutated the interaction
between PLP2 and ubiquitin would be disrupted and I could separate protease and DUB
activity of PLP2.
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The goal was to generate a mutant that maintains protease activity to facilitate
virus replication but has decreased DUB activity to test the role of DUB activity in virus
pathogenesis. First modeling revealed five residues that could be important for the
interaction between MHV PLP2 and ubiquitin namely R253, R257, E279, F290, and
Y302. I generated mutants of all of those residues to alanine with the goal of disrupting
the interaction mediated by either charge of the amino acid (arginine or glutamic acid),
polarity (tyrosine), or large side chain (phenylalanine). I found that the R253A, R257A
E279A, and Y302A mutations only moderately disrupted PLP2 DUB activity. The
reduction with DUB activity correlated with a reduction in interferon antagonism (Figure
33). Further, all mutants except R257A had decreased protease activity, or no protease
activity as in the case of Y302A. Interestingly, F290A had significantly reduced DUB
activity comparable to catalytic mutant of the protein and maintained protease activity to
some extent. Those observations suggested that the F290A might be a valuable candidate
to be tested in the context of the virus. Thus, I tried to generate the mutant virus using
reverse genetics; however, I was not able to recover viable virus at 37OC or, predicting
possible temperature sensitive phenotype, at 30OC. This suggested that F290 is required
for virus replication and presumably proteolytic processing of the polyprotein, or PLP2
structure. Further in vitro analysis using purified protein performed at Purdue University
supported this conclusion because F290A mutant does not exhibit proteolytic activity (Y.
Chen, unpublished observation). These data suggest that mutating the F290 residue to
alanine resulted in too dramatic change for the virus; however, it is possible that mutating
F290 to another amino acid that would maintain the long side chain, such as isoleucine,
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could be sufficient to facilitate virus replication but reduce the DUB activity enabling
testing of my hypothesis. Further mutagenesis of this residue is required to resolve this
issue.
Even though the first set of mutants did not reveal the residues that would enable
separating PLP2 protease and DUB activities, it allowed for the refinement of the MHV
PLP2- ubiquitin model (Figure 34). This new, refined model showed new residues on
PLP2 that likely interact with ubiquitin molecule. In the second screen of mutants I tested
seven new candidates. I generated a double R253A/R257A mutant because previous data
showed that both single mutants have reduced DUB activity and that R257A maintains
protease activity suggesting that combining those two mutations could lead to a stronger
phenotype i.e. loss of DUB activity. Further, I generated the following mutants I249R
(changing the non-polar amino acid to a positively charged), R281E (changing the
positive charge to negative), and Y320F (changing the polar amino acid to non-polar). I
also made three alanine mutants F270A, I304A, and V313A to reduce the size of the
amino acid side chain. The analysis showed that the R281E mutation impairs proteolytic
activity to the level of the catalytic mutant (Figure 35). However, I found that three
mutants R253A/R257A, F270A and I304A exhibit protease activity comparable to wildtype PLP2. Furthermore, they all have reduced DUB activity although to various degrees
(Figure 36A). It would be interesting to combine those mutations to generate double and
triple mutants to determine if the degree of loss of DUB activity can be improved.
Interestingly, I249R mutation increases all activities of PLP2 (Figures 35 and 36).
The increased activity of this mutant could be because positively charged arginine present
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at position 249 could enhance catalytic activity of the protein and/or binding with the
substrates. It remains to be determined if increased activity of the I249R mutant would
have an impact on virus replication and/or pathogenesis in vivo. It is possible that too
efficient processing could be detrimental to the virus. On the other hand, such a virus
could be even more pathogenic than wild-type due to the enhanced ability to inhibit an
innate immune response.
When I tested the mutants for their deISGylating activity I found that many of
them, including I304A, F270A, and R253A/R257A have completely lost their
deISGylating ability, and Y302F and V313A showed partial reduction (Figure 36B). It
has been shown that the degree of deISGylating and DUB activities of PLPs vary
depending on the virus, for example SARS-CoV PLpro is a better deISGylating than
deubiquitinating enzyme (Ratia et al., 2006). MHV PLP2 seems to exhibit the opposite
preference and in vitro studies showed that this enzyme is a better DUB than
deISGylating enzyme (Chen et al., in preparation). For this reason I might have seen
stronger phenotypes when the mutants were tested in the context of the deISGylating
assay. However, I cannot say that I separated MHV PLP2 protease and deISGylating
activities for Y302F and V313A because the reduction in deISGylating activity might be
due to a small decrease in protease activity and the fact that the deISGylating assay is
more sensitive than the DUB assay. Nevertheless, F270A, I304A, and R253A/R257A
have completely lost deISGylating activity while maintaining protease activity, thus it
would be important to determine the effect of these mutations on virus pathogenesis.
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Finally, using the knowledge from the arterivirus study I generated a triple MHV
PLP2 mutant with the goal of separating MHV PLP2 protease and DUB activities.
Previous studies on the interaction of ubiquitin with various substrates showed that the
isoleucine 44 (Ile 44) patch on the ubiquitin molecule was an important site required for
the interaction between ubiquitin and DUBs (Hospenthal, Freund, & Komander, 2013).
Furthermore, EAV PLP2 co-crystal structure with ubiquitin showed that the Ile 44 patch
is the site of interaction between those two molecules (van Kasteren et al., 2013). The Ile
44 patch consists of three residues isoleucine 44, valine 70, and leucine 8. The modeling
predicted that the residues on MHV PLP2 that are likely interacting with the Ile 44 patch
are F290, I249, and T328 (Figure 38). Considering the information gained from the EAV
study I generated a triple mutant where the amino acid changes were not very dramatic. I
mutated phenylalanine to tryptophan keeping the size and polarity of the amino acid, but
removing the phenyl ring. I mutated isoleucine 249 to valine, also a non-polar amino
acid. Finally, I changed threonine 328 to alanine changing the polarity of amino acid.
This triple mutant showed protease activity comparable to the wild-type protein;
however, the DUB activity of this mutant was maintained as well. It may be informative
to generate single mutants of those resides to determine if they independently have any
effect on protease and/or DUB activity. Since I know from previous experiments that
I249R mutation increases PLP activity it might be similar for the I249V mutant which
might be masking a potential effect of the F290W and T328A mutations. Further studies
are needed to determine if residues of the Ile 44 patch are required for the interaction
between MHV PLP2 and ubiquitin.
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During my dissertation research I found several candidate mutants that can be
further optimized and tested to separate PLP2 protease and DUB activities. It will be
interesting to determine the role of DUB activity on virus pathogenesis and/or replication.
The hypothesis is that the DUB activity may be important for inhibition of the innate
immune response, which is partially supported by the EAV PLP2 study (van Kasteren et
al., 2013). However, it is also possible that PLP2 DUB activity might be important for
controlling other processes during virus replication, for example double membrane
vesicles formation (DMV) that mediate virus replication, or the packaging of virus
particles.
Papain-like protease deubiquitinating activity might also be involved in the
formation of replication complexes or double member vesicles (DMV) during the virus
life cycle. Formation of DMVs is critical for coronavirus replication and formation of
DMVs has been observed by multiple groups (Knoops et al., 2008, Snijder et al., 2006).
More recently it has been shown that transfection of plasmids encoding full length
nonstructural protein 3 (nsp3), nsp4, and nsp6 from SARS-CoV is sufficient to induce the
formation of DMV-like structures that resemble DMV present during SARS-CoV
infection (Angelini et al., 2013). Further, the authors showed that nsp3 alone is sufficient
to induce membrane proliferation, which might be due to either production or expansion
of already existing membranes (Angelini et al., 2013). Because SARS-PLpro is encoded
within nsp3 it is reasonable to hypothesize that multifunctional PLpro might be involved
in the accumulation of membranous structures or DMV formation.
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The origin of the membranes that form DMVs during SARS-CoV infection is not
known. However; the recent investigation of membrane structures during infection with
avian coronavirus, Infectious Bronchitis Virus (IBV), showed that even though DMVs
are present, previously undescribed structures are present as well. Upon IBV infection the
authors observed novel membranous structure that they termed zippered endoplasmic
reticulum and spherules that appeared to be invaginations of zipped ER (Maier et al.,
2013). This was the first report suggesting the origin of membrane rearrangements during
CoV infection and also showed that the spherules are connected with the cytoplasm by
the channel with 4.4nm diameter that could facilitate transport of newly synthetized RNA
from the spherule to the cytoplasm for virion assembly (Maier et al., 2013). A PLpro
domain is predicted to be present in the IBV genome thus it is possible that it might play
a role in the formation of zipped ER spherules. Deubiquitinating activity of PLPs might
be directly involved in the formation of membrane rearrangements or it might also
facilitate the interaction with host proteins that are responsible for the generation of
membranous structures and formation of virus replication complexes. Furthermore, not
only PLP DUB activity might be critical for this process but also the above described
UBL domain of PLP. UBLs have been shown to have different roles and functions in the
context of different DUBs. Ubl domains can impact enzyme activity and specificity, and
also be involved in the recruitment of other non-target proteins. For example, the Ubl
domain of USP14 is required for targeting of this cellular DUB to the proteasome, where
USP14 removes ubiquitin molecules from proteins that are modified with K-48-linked
ubiquitin which directs them for proteosomal degradation (Hu et al., 2005). Thus, it is
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possible that PLP UBL domain targets it to the replication complexes or recruits other
host proteins to form DMVs or spherules. Further studies using electron microscopy and
mutants that lack DUB activity could help answer this question.

SUMMARY
In my dissertation I investigated the enzymatic activity of coronavirus papain-like
proteases. I determined that PLPs are multifunctional enzymes with protease,
deubiquitinase, deISGylating and interferon antagonism activities. I found that PLPs
multifunctionality is conserved among various alpha and betacoronaviruses, suggesting
that PLPs are valuable targets for the development of antiviral drugs and vaccines. My
studies with efficacious inhibitors of SARS-CoV replication that target PLpro support
this observation.
Further, I determined, for the first time, that the UBL domain that is located
upstream of the MHV PLP2 domain is important for protein stability and virus
pathogenesis. The UBL mutants alone, or in conjunction with other known attenuating
mutations, might be new vaccine candidates in the future.
Finally, my research enabled generation of MHV PLP2 crystal structure that is a
valuable tool in studying MHV PLP2. The knowledge from the crystal structure and
modeling facilitated the mutagenesis with the goal of separating PLP2 protease and
deubiquitinase activities. I generated three mutants that have reduced DUB activity and
maintain protease activity that can be further validated. Separating DUB and protease
activities in the context of the virus will facilitate studies on the role of DUB activity in
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virus replication and pathogenesis, and can lead to the development of new vaccine
candidates for coronaviruses.

APPENDIX I:
SEQUENCES OF CONSTRUCTS USED FOR EXPERIMENTS
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1. MERS-CoV PLpro
MERS-CoV PLpro sequence optimized for expression in human cells. The native
MERS-PLpro sequence (from amino acids 1485 to 1802) was subjected to codon
optimization, removal of putative splice acceptor and splice donor sites, and addition of
restriction sites (in bold) for cloning, and in frame V5 epitope tag (in orange). The
synthetic sequence was cloned into pCDNA3.1-V5/His-B at the EcoRI and PmeI sites.
GAATTCACCATGGCTACTATCGAGGTGCTGGTGACTGTGGATGGAGTGAACT
TTCGGACTGTGGTGCTGAACAACAAAAATACTTATCGGTCTCAGCTGGGGTG
CGTGTTCTTTAACGGCGCCGACATCTCCGATACTATTCCCGACGAGAAGCAG
AACGGACACTCTCTGTACCTGGCTGACAATCTGACAGCAGATGAGACTAAGG
CCCTGAAAGAACTGTACGGCCCCGTGGATCCTACCTTTCTGCACAGATTCTAT
TCTCTGAAGGCCGCTGTGCATGGATGGAAAATGGTGGTCTGCGACAAGGTCC
GGTCTCTGAAACTGAGTGATAACAATTGTTACCTGAATGCTGTGATCATGACA
CTGGACCTGCTGAAGGATATCAAATTTGTGATTCCTGCTCTGCAGCACGCATT
CATGAAGCATAAAGGCGGAGACAGCACCGACTTCATCGCCCTGATTATGGCT
TATGGCAACTGTACATTCGGAGCACCAGACGATGCCAGTCGCCTGCTGCATA
CTGTGCTGGCAAAGGCCGAGCTGTGCTGTTCAGCCCGAATGGTGTGGAGGGA
ATGGTGCAATGTCTGTGGCATTAAGGACGTGGTCCTGCAGGGACTGAAAGCA
TGCTGTTACGTGGGGGTCCAGACTGTGGAAGATCTGAGGGCCAGAATGACCT
ATGTCTGCCAGTGTGGAGGAGAGCGACACCGACAGCTGGTGGAACATACCAC
ACCCTGGCTGCTGCTGTCAGGCACACCCAACGAGAAGCTGGTGACTACCAGC
ACTGCTCCCGACTTCGTGGCCTTCAACGTGTTCCAGGGAATCGAAACCGCCGT
GGGGCACTATGTCCATGCTCGACTGAAGGGAGGGCTGATTCTGAAATTTGAT
AGCGGGACCGTGAGCAAAACATCCGACTGGAAGTGCAAAGTGACAGATGTC
CTGTTCCCTGGCCAGAAGTATTCAAGCGACTGTGGCAAGCCTATTCCTAACCC
TCTGCTGGGACTGGATTCAACATGAGTTTAAAC
2. MHV PLP2-A
MHV-PLP2-A sequence optimized for expression in human cells. The native MHV
PLP2 sequence (from amino acids 1611 to 1970) was subjected to codon optimization,
removal of putative splice acceptor and splice donor sites, and addition of restriction sites
(in bold) for cloning, and in frame V5 epitope tag (in orange). The synthetic sequence
was cloned into pCAGSS-MCS at the SacI, and XmaI sites.
GAGCTCACCATGGCCGTCGATGTCCTGTGCACTGTCGATGGCGTCAACTTTAG
AAGCTGCTGCGTCGCTGAAGGGGAGGTGTTTGGGAAGACTCTGGGGTCAGTG
TTCTGCGACGGCATCAATGTGACTAAGGTCAGGTGTTCCGCCATCTACAAGG
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GGAAAGTGTTCTTTCAGTATTCAGATCTGAGCGAGGCTGACCTGGTGGCAGT
CAAAGATGCCTTCGGCTTTGACGAACCCCAGCTGCTGAAGTACTATACAATG
CTGGGAATGTGCAAATGGTCCGTGGTGGTGTGCGGCAATTACTTCGCCTTTAA
GCAGAGCAACAATAACTGCTATATCAACGTGGCTTGTCTGATGCTGCAGCAC
CTGTCTCTGAAATTCCCAAAGTGGCAGTGGCAGGAGGCATGGAATGAATTCC
GAAGTGGGAAGCCCCTGCGGTTTGTGAGTCTGGTCCTGGCTAAAGGATCATT
CAAGTTTAACGAGCCTTCCGACTCTATTGATTTCATGAGGGTCGTGCTGCGAG
AAGCAGATCTGAGCGGAGCTACATGCAATCTGGAGTTCGTGTGCAAATGTGG
CGTCAAGCAGGAACAGCGGAAGGGGGTGGACGCCGTCATGCACTTCGGAAC
TCTGGACAAAGGCGATCTGGTGAGAGGGTACAACATCGCTTGCACCTGTGGC
AGCAAGCTGGTGCATTGCACACAGTTCAATGTGCCTTTTCTGATCTGTTCCAA
CACCCCTGAGGGGAGGAAACTGCCAGACGATGTCGTGGCCGCTAACATTTTC
ACCGGCGGGTCTGTGGGACACTACACACATGTGAAGTGCAAACCAAAGTACC
AGCTGTATGATGCATGTAATGTGAACAAGGTCAGCGAGGCCAAAGGCAACTT
CACCGACTGTCTGTATCTGAAAAACCTGAAGCAGACTTTTAGCTCCGTGCTGA
CCACATTCTACCTGGACGATGTGAAGTGCGTCGAGTATAAACCTGATCTGTCA
CAGTACTATTGTGAAAGCGGGAAATACTATACCAAGCCAATCATCAAGGCCC
AGTTCCGCACTTTTGAGAAGGTGGACGGGGTCTACACCAATTTCAAACTGGG
TAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTGACCCGGG
3. MHV PLP2-B
MHV-PLP2-B sequence optimized for expression in human cells. The native MHV
PLP2 sequence (from amino acids 1525 to 1911) was subjected to codon optimization,
removal of putative splice acceptor and splice donor sites, and addition of restriction sites
(in bold) for cloning. The synthetic sequence was cloned into pCAGSS-MCS PLP2-AΔ7-V5 at the KpnI and MluI sites.
GGTACCGAGGTGGAAGCTCTGCGACACGATATCCAGCTGGACGATGACGCCA
GGGTCTTCGTGCAGGCTAATATGGATTGCCTGCCCACCGACTGGAGACTGGT
GAACAAATTTGATTCCGTCGACGGCGTGCGGACAATCAAGTACTTCGAGTGT
CCTGGCGGAATTTTCGTGAGCAGCCAGGGAAAGAAATTCGGCTATGTGCAGA
ATGGAAGCTTTAAAGAAGCCTCTGTGAGTCAGATTCGCGCACTGCTGGCCAA
TAAGGTCGATGTGCTGTGCACCGTCGACGGGGTGAACTTCCGAAGCTGCTGC
GTGGCTGAGGGCGAAGTGTTCGGAAAAACACTGGGGAGCGTGTTTTGCGACG
GCATCAACGTCACTAAGGTGAGGTGTTCCGCCATCTACAAGGGAAAAGTGTT
CTTTCAGTATTCCGATCTGTCTGAGGCTGACCTGGTCGCAGTGAAGGATGCCT
TCGGCTTTGACGAACCACAGCTGCTGAAATACTATACAATGCTGGGGATGTG
CAAGTGGCCCGTGGTGGTGTGCGGCAATTACTTCGCTTTTAAGCAGTCAAAC
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AACAACTGCTACATCAACGTGGCATGTCTGATGCTGCAGCATCTGAGCCTGA
AATTCCCTAAGTGGCAGTGGCAGGAGGCCTGGAATGAATTCCGGTCCGGAAA
GCCACTGCGCTTTGTCAGTCTGGTGCTGGCTAAAGGGTCATTCAAGTTTAACG
AGCCCTCAGATAGCATTGACTTCATGAGGGTCGTGCTGAGAGAAGCTGATCT
GTCTGGCGCAACTTGCAATCTGGAGTTTGTCTGCAAATGTGGCGTGAAGCAG
GAACAGCGGAAAGGAGTCGACGCAGTGATGCACTTCGGCACCCTGGATAAG
GGAGACCTGGTGCGCGGGTACAACATCGCCTGCACTTGTGGATCTAAGCTGG
TGCATTGCACCCAGTTCAATGTGCCATTTCTGATCTGTAGTAACACACCCGAG
GGGAGAAAGCTGCCTGATGACGTGGTGGCCGCTAACATTTTCACCGGGGGCT
CTGTCGGCCACTACACACATGTGAAGTGCAAACCCAAGTACCAGCTGTATGA
TGCATGTAATGTCAACAAAGTGAGTGAGGCCAAGGGCAACTTCACCGACTGT
CTGTATCTGAAAAACCTGAAGACGCGT
4. HCoV-229E PLP2
HCoV-229E PLP2 sequence optimized for expression in human cells. The native HCoV229E PLP2 sequence (from amino acids 1693 to 2019) was subjected to codon
optimization, removal of putative splice acceptor and splice donor sites, and addition of
restriction sites (in bold) for cloning, and in frame V5 epitope tag (in orange). The
synthetic sequence was cloned into pCDNA3.1-V5/His-B at the EcoRI and PmeI sites.
GAATTCACCATGGCAGCCGAGGCAAAAGTCATTACAATCAAGGTCACAGAA
GATGGCGTCAATGTCCACGATGTCACAGTCACTACCGATAAAAGCTTCGAGC
AGCAAGTGGGGGTCATCGCCGACAAGGATAAAGACCTGTCTGGCGCTGTGCC
TAGTGACCTGAACACCTCAGAGCTGCTGACAAAGGCCATTGATGTGGACTGG
GTCGAGTTCTACGGGTTTAAAGACGCAGTGACTTTCGCCACCGTCGATCACA
GCGCATTTGCCTATGAATCCGCTGTGGTCAACGGCATCAGAGTGCTGAAGAC
AAGCGATAACAATTGCTGGGTGAATGCTGTCTGTATCGCACTGCAGTACTCTA
AGCCACATTTCATTAGTCAGGGACTGGACGCCGCTTGGAACAAATTTGTGCT
GGGGGATGTCGAGATTTTCGTGGCATTTGTCTACTATGTGGCCCGGCTGATGA
AGGGGGATAAAGGCGACGCCGAAGATACCCTGACAAAGCTGAGCAAATACC
TGGCTAATGAGGCACAGGTGCAGCTGGAACACTATAGCTCCTGCGTGGAGTG
TGACGCTAAGTTTAAAAACTCTGTGGCAAGTATCAATTCAGCCATCGTGTGCG
CTTCCGTCAAGAGGGATGGAGTGCAGGTCGGGTACTGCGTGCATGGCATCAA
ATACTATAGTAGGGTCAGATCAGTGCGGGGACGCGCAATCATCGTGAGCGTC
GAGCAGCTGGAACCATGCGCTCAGAGCCGACTGCTGTCCGGAGTGGCCTATA
CCGCTTTCAGCGGCCCCGTGGACAAGGGACACTACACAGTGTATGATACTGC
CAAGAAAAGCATGTATGATGGCGACAGGTTTGTGAAGCATGACCTGAGCCTG
CTGTCCGTGACTTCTGTGGTCATGGTCGGCGGATATGTCGCCCCCGTGAACAC
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CGTCAAGCCCAAACCTGTGATCAATCAGCTGGACGAAAAGGCTCAGGGCAA
ACCTATTCCTAATCCTCTGCTGGGACTGGACTCAACATAAGTTTAAAC
5. HCoV-OC43 PLP2
HCoV-OC43 PLP2 sequence optimized for expression in human cells. The native
HCoV-OC43 PLP2 sequence (from amino acids 1628 to 1952) was subjected to codon
optimization, removal of putative splice acceptor and splice donor sites, and addition of
restriction sites (in bold) for cloning, and in frame V5 epitope tag (in orange). The
synthetic sequence was cloned into pCDNA3.1-V5/His-B at the EcoRI and PmeI sites.
GAATTCACCATGGCTCTGTTTCTGGATAAGGTGGACATTCTGCTGACCGTGGA
TGGCGTCAACTTTACCAATAGATTTGTGCCCGTCGGCGAGTCTTTCGGAAAGT
CCCTGGGGAACGTGTTCTGCGATGGAGTCAACGTGACCAAGCACAAATGTGA
CATCAATTACAAGGGGAAAGTGTTCTTTCAGTTCGATAACCTGAGCTCCGAG
GACCTGAAGGCTGTGCGGTCTAGTTTCAATTTTGATCAGAAAGAACTGCTGG
CATACTATAATATGCTGGTGAACTGCTTTAAGTGGCAGGTGGTCGTGAATGG
GAAGTATTTCACCTTTAAACAGGCCAACAATAACTGCTTCGTCAACGTGTCCT
GTCTGATGCTGCAGTCTCTGCACCTGACCTTCAAGATTGTGCAGTGGCAGGAG
GCTTGGCTGGAGTTCAGGAGCGGCAGACCAGCCCGGTTTGTCGCTCTGGTGC
TGGCAAAGGGCGGATTCAAATTTGGAGACCCCGCAGATAGCCGCGACTTCCT
GCGAGTCGTGTTTTCCCAGGTGGATCTGACAGGCGCCATCTGTGACTTCGAGA
TTGCTTGCAAGTGTGGGGTGAAACAGGAACAGAGGACAGGCCTGGATGCCGT
CATGCACTTTGGAACTCTGTCTAGAGAGGATCTGGAAATCGGGTACACTGTG
GACTGCAGTTGTGGCAAGAAACTGATCCATTGCGTGAGGTTCGACGTGCCCT
TTCTGATTTGTTCAAACACCCCCGCAAGCGTGAAGCTGCCTAAAGGGGTCGG
CAGCGCCAATATCTTCATTGGCGATAACGTGGGACACTACGTCCATGTGAAG
TGCGAGCAGAGTTACCAGCTGTATGACGCTTCAAATGTCAAGAAAGTGACTG
ATGTCACCGGAAAGCTGTCAGACTGTCTGTATCTGAAGAACCTGAAACAGAC
TTTCAAAAGTGTGCTGACCACATACTATCTGGACGATGTCAAGGGCAAGCCT
ATTCCTAATCCTCTGCTGGGCCTGGACTCAACCTGAGTTTAAAC
6. HCoV-HKU1 PLP2
HCoV-HKU1 PLP2 sequence optimized for expression in human cells. The native
HCoV-HKU1 PLP2 sequence (from amino acids 1701 to 2025) was subjected to codon
optimization, removal of putative splice acceptor and splice donor sites, and addition of
restriction sites (in bold) for cloning, and in frame V5 epitope tag (in orange). The
synthetic sequence was cloned into pCDNA3.1-V5/His-B at the EcoRI and PmeI sites.
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GAATTCACCATGGTCCTGCTGGCTAAGAAGATTGATGTGCTGCTGACAGTGG
ATGGAGTGAACTTTAAGAGTATTTCCCTGACAGTGGGCGAGGTCTTCGGGAA
GATCCTGGGCAACGTCTTTTGCGACGGCATTGATGTGACTAAGCTGAAATGTT
CTGACTTCTACGCCGATAAAATCCTGTACCAGTATGAGAATCTGTCACTGGCA
GACATTAGCGCCGTGCAGAGCTCCTTCGGGTTTGATCAGCAGCAGCTGCTGG
CTTACTATAACTTCCTGACCGTGTGCAAGTGGAGCGTGGTCGTGAATGGCCCC
TTCTTTTCTTTTGAACAGAGTCACAACAATTGCTACGTCAACGTGGCATGTCT
GATGCTGCAGCATATCAACCTGAAGTTCAACAAGTGGCAGTGGCAGGAGGCA
TGGTATGAGTTCAGGGCAGGCAGACCACACCGACTGGTCGCTCTGGTGCTGG
CAAAGGGACATTTCAAATTTGATGAGCCCAGCGACGCTACAGATTTCATCCG
CGTCGTGCTGAAGCAGGCCGACCTGTCCGGAGCTATTTGTGAGCTGGAACTG
ATCTGCGACTGTGGCATCAAGCAGGAATCCCGAGTCGGAGTGGATGCTGTGA
TGCACTTCGGGACCCTGGCAAAGACAGACCTGTTTAACGGATATAAAATCGG
GTGCAATTGTGCCGGGAGAATTGTGCATTGCACAAAGCTGAACGTGCCTTTC
CTGATCTGTTCCAATACTCCCCTGTCTAAAGATCTGCCTGACGATGTCGTGGC
CGCTAATATGTTTATGGGCGTCGGAGTGGGGCACTACACCCATCTGAAGTGC
GGATCTCCATACCAGCACTATGATGCCTGTAGTGTCAAGAAATACACTGGCG
TGTCAGGATGCCTGACCGACTGTCTGTATCTGAAGAACCTGACCCAGACATTC
ACTAGTATGCTGACAAACTATTTTCTGGATGATGTGGAAATGGGCAAGCCTA
TCCCTAACCCTCTGCTGGGCCTGGACTCAACCTGAGTTTAAAC
7. FIPV PLP2
FIPV PLP2 sequence optimized for expression in human cells. The native FIPV PLP2
sequence (from amino acids 1488 to 1811) was subjected to codon optimization, removal
of putative splice acceptor and splice donor sites, and addition of restriction sites (in
bold) for cloning, and in frame V5 epitope tag (in orange). The synthetic sequence was
cloned into pCDNA3.1-V5/His-B at the EcoRI and PmeI sites.
GAATTCACCATGGAGCGGGTCACAATCGAGAACTTTTTCAATGGCACAATCC
CAATCAAGGTCACCGAAGATACTGTCAATCAGAAACGAGTCAGCGTGGCCCT
GGACAAGACTTACGGAGAGCAGCTGAAAGGGACCGTGGTCATCAAGGACAA
AGATGTGACCAACCAGCTGCCCTCAGTGAGCGATGTCGGCGAAAAGGTGGTC
AAAGCCCTGGACGTGGATTGGAACGCTTACTATGGATTCCCTAATGCCGCTG
CATTTTCTGCAAGCTCCCACGACGCCTATGAGTTCGATGTGGTCACCCACAAC
AACTTCATCGTGCATAAGCAGACAGACAACAATTGCTGGGTCAATGCCATTT
GTCTGGCTCTGCAGCGGCTGAAGCCCACATGGAAATTCCCTGGAGTGAAGAG
CCTGTGGGACGCATTCCTGACTCGCAAAACCGCCGGATTTGTGCACATGCTGT
ACCATATCTCCGGGCTGACTAAGGGCCAGCCAGGAGATGCTGAACTGACCCT
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GCACAAGCTGGTGGACCTGATGTCTAGTGATTCTGCCGTGACAGTCACTCATA
CCACAGCTTGCGACAAGTGTGCAAAAGTGGAGACCTTTACAGGACCAGTGGT
CGCAGCTCCACTGCTGGTGTGCGGGACAGATGAAATCTGCGTGCACGGCGTG
CATGTCAACGTGAAGGTCACTTCCATTCGAGGGACAGTGGCTATCACTTCTCT
GATTGGACCAGTGGTCGGCGACGTGATCGATGCAACCGGCTACATTTGCTAT
ACAGGCCTGAACAGTAGGGGACACTACACCTACTATGATAACAGAAATGGCC
TGATGGTGGACGCTGATAAGGCATATCATTTCGAGAAAAATCTGCTGCAAGT
GACTACCGCAATCGCCAGTAACTTTGTCGCTAATACACCTAAGAAAGAGATT
ATGCCAAAGACTCAGGCAAAAGAATCAAAAGCCAAAGAGTCAAACGGCAAG
CCTATTCCTAACCCCCTGCTGGGCCTGGATTCAACCTGAGTTTAAAC
8. SARS-CoV PLpro
SARS-CoV PLpro PLP2 sequence optimized for expression in human cells. The native
SARS-CoV PLpro sequence (from amino acids 1541 to 1855) was subjected to codon
optimization, removal of putative splice acceptor and splice donor sites, and addition of
restriction sites (in bold) for cloning, and in frame V5 epitope tag (in orange). The
synthetic sequence was cloned into pCDNA3.1-V5/His-B at the EcoRI and PmeI sites.
GAATTCACCATGGAGGTCAAGACAATCAAGGTGTTTACTACAGTGGACAATA
CAAATCTGCATACTCAGCTGGTCGATATGAGCATGACTTACGGCCAGCAGTT
CGGGCCAACCTACCTGGACGGCGCCGATGTGACAAAGATCAAACCCCACGTC
AACCATGAGGGGAAGACCTTCTTTGTGCTGCCTTCCGACGATACACTGCGGTC
TGAGGCTTTCGAATACTATCACACCCTGGACGAGAGCTTTCTGGGCCGCTACA
TGTCCGCACTGAATCATACAAAGAAATGGAAGTTTCCACAAGTGGGCGGACT
GACTAGTATCAAATGGGCAGATAACAATTGCTATCTGAGCTCCGTGCTGCTG
GCCCTGCAGCAGCTGGAGGTGAAGTTCAACGCACCCGCCCTGCAGGAAGCCT
ACTATAGGGCTAGAGCAGGAGACGCCGCTAACTTTTGTGCACTGATTCTGGC
CTATTCCAATAAGACAGTGGGAGAGCTGGGGGATGTCCGAGAAACCATGACA
CACCTGCTGCAGCATGCTAACCTGGAGTCTGCAAAAAGGGTGCTGAATGTGG
TCTGCAAGCACTGTGGACAGAAAACCACAACTCTGACCGGGGTGGAAGCCGT
CATGTACATGGGCACTCTGTCTTATGACAATCTGAAGACCGGAGTGAGTATTC
CTTGCGTCTGTGGGAGGGATGCTACACAGTACCTGGTGCAGCAGGAGTCTAG
TTTCGTCATGATGAGCGCCCCCCCTGCTGAATATAAGCTGCAGCAGGGCACA
TTTCTGTGCGCAAACGAGTACACTGGCAATTATCAGTGTGGACACTACACTCA
TATCACCGCCAAAGAAACTCTGTATAGAATTGACGGCGCTCACCTGACCAAG
ATGTCAGAGTACAAAGGACCCGTGACAGATGTCTTCTACAAGGAAACTAGCT
ATACCACAACTATCAAATGGAACAGTGCTGACATTCAGCATTCAGGGGGCCG
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GTCAAGCCTGGAGGGACCAAGCGGCAAGCCTATTCCTAACCCCCTGCTGGGA
CTGGACTCTACCTAAGTTTAAAC

APPENDIX II:
REVERSE GENETICS PROTOCOL
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Important notes before you start:
1. BHK-R cells are located in box B2 (liquid nitrogen tank). Those cells required
selection with G418 (media that contains .8 mg/mL G418 (8 uL stock [100 mg/mL] per 1
mL media used). Those cells look different than regular BKH21cells. The receptor
expression makes them look really funky with appendages all over the place. Also, most
of your cells will die upon thawing. Don’t get discouraged. Keep them under selection
and they will recover eventually. Then they will grow pretty fast. Split 1:10 every 2 days.
Media: DMEM 10% FCS.

2. It’s all about the fragments. If your fragments are ok everything else goes pretty
smoothly. Believe me
 If the plasm
a year sequence them to make sure they are ok, even if your digest pattern is ok. If your
digest pattern is not 100% correct, and you have any doubts, DO NOT PROCEED. Never
use glycerol stock to store or recover the plasmids.
3. Enzymes: use NEB enzymes, do not switch to Fermentas. I was able to generate wild
type virus using Fermentas cut fragments but the efficiency is much lower compared to
NEB cut fragments. Also, you save a lot of time using NEB for digest.
Bacterial Cell Culture
It is important to transform your DNA for growth for assembly into the correct E.coli cell
type. We have found that the A clone which is propagated in the Topo vector, grows best
in DH5 alpha cells. B, C, D, E, F and G (the pSMART vector clones, G is in pMH54
vector) grow best in Top Ten cells (Invitrogen Grow A on a Kanamycin plate; all the rest
are on Ampicillin plates.
If you are sure of the integrity of your clones (i.e., got them from the archive and didn’t
just make them yourself), you don’t have to screen transformants. BUT it’s better to
screen first. Do few mini preps and check digest pattern. Then when you are sure you can
start maxi scale in 150-200 mL of LB plus antibiotic. Let this grow at “~30oC” for at
least 24 hours. You get better yields the more you let them grow—30 hours is really
better. Patience pays off here.
DNA Purification
Note Alpha: Be advised: we have run into contamination of predicted attenuated virus
cultures with wild-type virus when wild-type DNA and mutant DNA are prepared in the
same sitting. The precise step of contamination is likely the gel box, but it can obviously
be anywhere there’s DNA. Because of this, we no longer construct a wild-type control.
If you absolutely must construct wild-type or are planning on constructing wild-type-like
mutants along with severely attenuated mutants, I advise prepping the DNA up to final
extract stage on different days, and cleaning the equipment thoroughly in between.
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Next do a maxiprep of your DNA using PureYield Maxiprep System Promega. Follow
the manufacturer instructions. Elute with water that is warmed up to 37OC.
Note from original protocol (never tested by myself): about prepping volumes—if you
don’t want to have so much DNA for the fragments you’re only going to use once (i.e., if
you’re making mutations in the first 5 kb, the A fragment), you can just prep a 20-40 mL
culture and do what amounts to 3-6 minipreps. You can do the lysate steps (everything
up to and including the high-speed spin where you get the white pellet after ten minutes)
in one centrifuge tube—scale up amounts for 3.5-7 minipreps, then divide the cleared
lysate at the end of the spin into 3-6 columns each separate fragment and proceed as
normal.
Note 1: It is important to test digest a small amount of your prepped DNA to make sure
its integrity is intact. A digest can go badly even from screened DNA, probably because
of something to do with the purification. I have had this occur with both F and G
fragments.
However you get your DNA, you need quite a lot for a round of virus production. The
actual amounts you need for each fragment depend on the size of the fragment, but if it’s
a backbone fragment (one that’s the same for all, not your mutant fragment) try to get 20
ug each backbone fragment per virus you are constructing. Example: you are making 4
viruses with mutations in A. You need 80 µg each of B, C, D, E, F, and G, and 20 ug
each of your mutant As. You hardly ever end up using all of your mutant fragments,
though.
Original protocol told you to IPA (isopropanol) precipitate your DNA at this point. You
don’t have to do this as long as you use Promega kit.
Digests
Again: learn from me and other people in our lab: use NEB enzymes. DO NOT SWITCH
TO FERMENTAS. If for some reason you want to or have to follow digestion procedures
in my hand-written notebook. It is possible to get wild type virus but again the efficiency
is lower than using NEB cut fragments (It took me a while to figure it out).
These are large-scale digests. I have provided the setups I do, but you can adjust
buffer/water amounts depending on what final volume you use. Other important notes:
1. When you set up the digest: do not exceed 5% of glycerol (present in your enzyme
tube) in your reaction as it will influence digest efficiency.
2. I usually cut at least 40ug of DNA (2 tubes of 20ug). This will give you about 3 rounds
for virus, depending on the fragment.
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3. I do not recommend doing all of them the same day. Divide into two days. Follow the
procedure all the way to gel purification the same day. Do not freeze gel fragments.
4. NEB double digests use different buffers so make sure you have the right one.
5. Digest must be done in PCR machine.
A Fragment
20ug DNA
x uL
Buffer 3
20 uL
Mlu I
x uL*
BsmB I
x uL*
to 200 uL
H2O
*x uL of enzyme is a function of how much DNA you have. I generally use 2 ul per 10
ug DNA, up to 10 ul enzyme, which works out to a 2-fold excess enzyme concentration
for most of these guys, allowing for a cut that can be anywhere between 1 hour (absolute
minimum, and I in fact never go below 1.5 h) and overnight if necessary. I do 3hr cut at
each temperature.
When I reach 2 hr of incubation I run a little of ample on agarose gel to make sure the cur
is correct, so I would be able to gel purify when the digests complete.
Note Beta: Wild-type A runs at 4.8 kb, and vector runs at 3.5 kb. This is a close cut in
the best of circumstances when you’re digesting a lot of DNA, and becomes problematic
if you’re doing deletions in the A fragment. To circumvent this, you can perform the
MluI cut first, then precipitate, and perform a BsmBI/SfiI cut in Buffer 2 + BSA, which
will cut the vector into two roughly equal-size pieces and get it out of your way.
Incubate at 37oC for 3 h, then move to 55oC and incubate for 3 h.
B and C Fragments
DNA 20ug
Buffer 3
Bgl I
BsmB I
H2O

x uL
20 uL
x uL*
x uL*
to 200 uL

Incubate at 37oC for 3 h, then move to 55oC and incubate for 3 h.
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D and E fragments
DNA 20ug
Buffer 4
Nci I
BsmB I
H2O

x uL
20 uL
x uL*
x uL*
to 200 uL

Incubate at 37oC for 3 h, then move to 55oC and incubate for 3 h.
F Fragment
DNA 20ug
Buffer 3
BsmB I
H2O

x uL
20 uL
x uL*
to 200 uL

Incubate at 55oC for 3 h.
G Fragment
DNA
Buffer 2
10X BSA
Sfi I
BsmB I
H2O

100 uL
20 uL
20 uL
x uL*
x uL*
to 200 uL

Incubate at 55oC for 3 h
Note 2: The original published protocol calls for breaking the A and G digests into two
stages—doing the Mlu/Sfi digest first, CIP treating, chloroform extracting and
precipitating DNA, then doing the BsmB I digest. This was implemented to prevent
concatomerization of MHV cDNA, but we have found the step is unnecessary if all other
steps are done carefully. If you are having difficulty having a particular mutant “take” or
anticipate it being severely attenuated (or if your DNA yield is low and you are digesting
<20 ug per virus) I would suggest putting the CIP treatment step back in. Basically, do
the Mlu/Sfi digest alone for 1.5-2 h, then add 4 uL CIP and incubate at 37oC for 1 hour,
chloroform extract (adjust salt concentration like in IPA precipitation, add 1 volume
chloroform, shake about a minute, spin two minutes, draw off DNA-containing top
aqueous phase, continue with IPA precipitation after salt step), then do the BsmB I
digest.
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While these digests are going on, I prepare the gels. We pour 75ml, .8 % Sea Plaque
agarose gels set with the 4-tooth combs (for old type agarose box). Use 1.5 uL EtBr per
gel. If your final digest volumes are 200 uL, you will use one gel per fragment.
Run your gels at 90-120 mA for however long it takes. C doesn’t separate from its vector
pieces very well (it’s 2 kb and the vector pieces are 1.2 and .8 kb but they consistently
run a little high), but if you run the DNA as far as it can go, you can tell which band to
cut. The advantage of running so much DNA is that it sops up EtBr like a sponge, and
you don’t have to worry about your DNA running out of the EtBr front. You can still see
it. Use the Dark Reader to cut. Try to minimize agarose as much as possible—you’re
going to have plenty as it is. If you ran 200 uL digests in four lanes per fragment, you
can cut one lane per tube.
N gene linearization
In our lab N gene is cloned into vector. All you have to do is to linearize the plasmid
using AdeI enzyme (in this case I used Fermentas and it worked fine). Then gel purify as
other fragments (see below).
Gel Extraction
We use the Promega Wizard Gel/PCR Purification kit. Columns in this kit have a
capacity of 40 ug bound DNA, so I use two per fragment. Follow the manufacturer’s
instructions, weighing your gel slices in tubes before adding the membrane-binding
buffer. If a tube weighs above 700 mg, you’ve got to split it into two tubes, because you
add the buffer to wt/vol and you won’t have room in the tube. Incubate gel/buffer in
tubes at 55oC for 10 minutes, shaking at 5 minutes. If at the end of 10 minutes you still
have some DNA chunks, incubate a little longer.
You may have to apply the melted gel slices to the columns in shifts. That’s okay. Just
follow the manufacturer’s protocol. When you elute from the column, elute the same
fragments into 1 tube and use water that has been heated to 65oC. Use 50uL/column of
nuclease free water to elute.
IMPORTANT STEP YOU SHOULD UNDER NO CIRCUMSTANCES SKIP: You
must chloroform extract your eluted DNA. Don’t add any salt—just squirt in a little less
than one volume of chloroform, shake for a minute, spin for 2 minutes, and draw off the
top DNA-containing aqueous layer, being very careful to avoid any white schmutz
(which may or may not be visible) at the interface. This is agarose that came through the
column with the DNA and will interfere severely with your seven-part ligation.
My protocol: I have 2 tubes so almost 100uL of eluted DNA. In 500uL tube I add 20uL
of water and 100uL of chloroform. Then vortex for 1 min and spin at 14K for 5 min.
Take the upper layer for further steps.
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Quantitation and Ligation of DNA
This is the most anal-retentive part of the whole process. If you cut corners here,
however, you will adversely affect the yield of virus you get out, and this could mean the
difference between seeing virus and not seeing it if your bug is attenuated. I have
successfully isolated and propagated viruses that popped up from ONE cell that took, but
be careful. Quantitate your DNA (at least your backbone pieces) by spectrophotometer.
Depending on how careful you’ve been and how much DNA you started with, expect
concentrations anywhere from 30 ng/uL to over 100 ng/uL for fragments.
Determining how much of a given fragment should go into the ligation is done by
determining rough molar ratios. To do this, you have to divide the concentration the spec
gives you (which does not take into account DNA size) by the size of the fragment. Then
you find your average molar ratio and determine load volume by a ratio of
average/experimental X average load volume (predetermined by elution amount and how
many viruses you are making that round). I have included one of my calculations to
demonstrate: (these were mutant A viruses, so A is not included)
Fragment
A
B
C
D
E
F
G

Concentration
(ng/uL)
52.9
53.2
48.4
42
191
86
74

L
(Conc./length)
11
12
24
28
67
12
8

Total
amount loaded (uL)
20
19.6
9.8
8.4
3.5
19.6
20

L is determined by dividing concentration by length of fragment: A=4.8; B=4.3; C=2.0;
D=1.5; E=2.8; F=7.0; G=8.7
Amount loaded is determined by finding the average of L (in this case, L/5-exclude E
because of very high concentration=11.8) and then determining average and maximum
load amounts based on how much DNA volume you have and how many viruses you
have to split it between. In this case, I had 4 viruses to make and 100 uL of backbone,
concentrations were very good, and variation in amounts between fragments was
minimal, so in this instance I set average load at 20 uL and max load at 25 uL. Amount
loaded is then determined by (Laverage/Lfragment) X (average load), not surpassing max
load. Example: for B, 11.8/12 X 20 = 19.6.
If you quantitate your mutant fragments, I don’t recommend figuring them into your load
equations, because you only need to make one of each mutant. You may need to stretch
your backbone fragments, though. Another thing to consider: if one or two
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concentrations of backbone lie well outside a narrow range defined by the other backbone
fragments, consider those outliers and don’t figure them into your calculations. Just add
your load maximum (or, if it’s superconcentrated DNA, a ballpark minimum) of DNA.
I set up the ligation as follows:
Fragments

100.9 (from above—will vary from round to round)

10X Ligase Buffer (NEB)

20 uL (1/10th a final ligation volume of 200 uL)

T4 DNA Ligase (NEB)

15 uL

H2O

to final volume of 200 uL

Mix well, and ligate overnight at 16oC. (water bath in the fridge set to 16OC.
Getting DBT cells ready
About 4-5 hours prior to electroporation I prepare DBT cells. You need to seed one T75
per virus being made with a 1:5 dilution of DBT cells, use DMEM 10% FCS media.
Because the virus coming off these flasks is going to be a stock virus, I try to use a
minimal volume of media, bringing the flask that’s being split up in 5 (T75) or 10 (T150)
and passing 1 mL into 4-5 mL media. Be careful: using 5 mL total or less in a T75
sometimes makes the cells settle thickly around the edges and sparsely in the middle.
This day is all about RNA, so take RNA precautions. Wear clean gloves and use plastics
and reagents set aside for RNA work. If you do something else in any interim, change
your gloves.
DNA Extraction
1. Add 1:5-1:10 volume NaOAc and 1:1 volume chloroform to DNA. I have usually
200uL ligation I use 30uL 3MNaOAc and 230ul chloroform.
2. Shake by hand for 1 minute
3. Spin at 14K rpm for 2 minutes
4. Transfer the aqueous fraction (top layer) to a new, labeled tube. Keep the nonpolar
fraction in case the pellet is lost.
5. Add 1:1 volume of isopropanol (usually I recover 170uL of liquid)
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6. Mix well and let sit 10 minutes at room temperature. Set a timer as a reminder to put
the tubes back in the centrifuge.
7. Spin at 14K rpm for 10 minutes
8. Remove supernatant and place in a labeled tube (in case the pellet is lost). For each of
the next few steps, a labeled tube with the supernatant should be kept to prevent loss of
the pellet.
9. Look for pellet (about the size of a ball point pen tip, you have to see it. Always make
sure pellet is there when you proceed). Decant the supernatant into another tube, leave a
small volume (~ 40 µl) so as to not disrupt the pellet.
10. Add 300 µl 70% ethanol and spin for 5 minutes. Decant the supernatant into another
tube, leave a small volume (~ 40 µl) so as to not disrupt the pellet.
11. Add 300 µl 95% ethanol and spin for 5 minutes. Extract very carefully all of the
supernatant possible.
NOTE: I extracted about 280 µl and spun several times to get all ethanol out
12. Let sit 10 minutes and add 10 µl nuclease free water.
13. Set up transcription reactions in same tube and label a tube for N-gene (use
mMessage mMaschine kit-Ambion). Add in order!

Ligated Fragments

N-gene (per virus)

GTP (3 mM-dilute the stock!)
NF H2O
2X NTP/Cap
DNA
10X Rxn Buffer
T7 RNA Pol Mix

7.5uL
-----25 uL
7.5 uL
5 uL
5 uL

-- uL
4 uL
12.5 uL
3.5 uL
2.5 uL
2.5uL

Total Volume

50 uL

25 uL / virus

14. Run in vitro reaction in PCR machine:
40.5oC 25 min
37.5oC 50 min
40.5oC 25 min
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Resuspending BHK-R cells from T150s (About 0.5 hr from transcription completion)
Towards the end of the transcription reaction, you need to get your BHK-R cells ready.
BHK-R cells were made from nonpermissive BHK cells by stably transfecting them with
the receptor CEACAM-1. To maintain the receptor expression, these cells must be
passaged in media that contains .8 mg/mL G418 (8 uL stock [100 mg/mL] per 1 mL
media used). However, after electroporation, these cells will be laid on a permissive seed
layer of DBTs, so selection in the mixed population flask doesn’t need to be maintained.
15. Wash flask with TC PBs (+CaCl2, MgCl2)
16. Add 3 ml trypsin and wait for cell monolayer to come off
17. Add 7 ml DMEM and resuspend
18. Add the 10 ml cell suspension to a 15 ml conical
19. Spin 750rpm for 5 min, remove media.
20. Add 10 ml cold PBS (no salts), resuspend cells
21. Spin conicals at 750rpm for 5 min
22. Aspirate out PBS and resuspend cells well in 10 ml cold PBS.
23. Take one 0.5 ml Eppendorf tubes and pipette 18 µl PBS
24. Put coverslip on hemocytometer
25. Take 2 µl cells and add to the 0.5 Eppendorf tube to make a 1:10 dilution
26. Pipette out 10 µl of diluted cells and load onto hemocytometer
27. Spin conicals at 750rpm for 5 min
28. Count cells in each of 4 squares (only along 2 of the sides)
Ex. 42 cells from 4 squares
42:4=10.5 x 105 x 10 (ml in PBS) = 1.05 x 107 cells
1.05 x 107 = 1.05 ml OptiMEM
1 x 107
NOTE: this is plenty b/c I only need 600 µl for each virus
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29. Aspirate out PBS and add calculated amount (1.05 ml) OptiMEM to cells
Electroporation of Cells
30. Bring RNA (ligated A-G, N) on ice, labeled 4 mm gap cuvettes (one for each virus),
IMPORTANT Keep cuvette in refrigerator prior to electroporation
31. In each cuvette to be electroporated, add, in order:
1) 22 µl N gene

2) 45 µl ligated RNA
3) 600 µl BHK-R cells
32. Pipette up and down several times to mix well
33. Tap cuvette on counter to ensure that the mixture is evenly distributed along the
inside gap
34. Wipe down cuvette (metal part) with a kimwipe and secure in place inside the pulse
pod
35. Use Dr. T. Gallagher lab gene pulser. Conditions 850V, 25uF. Your time constant
should be at least 0.6ms for each pulse.
36. Press button 3 times total, waiting a good 5 seconds between each press
NOTE: look for froth to ensure that cells were electroporated thoroughly
37. Keep the cuvettes in room temperature and until 10 minutes after the last
electroporation
38. Retrieve pre-prepared DBT-9s in T75s from 37

C incubator

39. Under hood, put as much of the electroporated cells as possible in the designated T75
by tipping cuvette while pipetting out. I also add some media to wash all of the contents
of the cuvette and add it to the flask.
40. Incubate at the appropriate temperature (37oC for garden-variety viruses, 33oC or
30oC for TS mutants).
41. Look for the virus the next day.
It takes at least 12 hours for anything to appear, I’ve noticed. The later in the day you
electroporate, the later the next day you should expect to see anything, unless you’re
shocking wild-type. Depending on the success of your ligation (which is amounts- and
proportions-dependent and a little lucky besides), the amount of raw material you started
with, the number of viruses you divided the backbone into, and the electroporation itself,
your flask(s) may produce anything from a robust response (starting from little 2-3 cell
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syncytia all over the place that are easy to pick out) to a sparse response (as little as ONE
plaque per flask, which I have had before, and which are difficult to catch until they
actually form multinucleate plaques of about 20 nuclei). You can sometimes see stuff
starting to happen if you hold the flask up to the light to contrast the monolayer. Plaques
appear as tiny holes.
If your virus is slow, you can expand the flask into a T150. Don’t put any selective
antibiotic onto the cells—I don’t trust the D9s to handle it and the BHK-Rs won’t lose
their receptor that quickly.
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